

William D. Chey, MD
Professor of Internal Medicine
Director, GI Physiology Laboratory
3912 Taubman Center, SPC 5362
Ann Arbor, MI 48109
734-936-4780
wchey@med.umich.edu

Title and Contents	Page 1
Education and Training	Page 2
Certification and Licensure	Page 2
Academic, Administrative, and Clinical Appointments	Page 2
Research Interests	Page 3
Grants/Patents	Page 3
Honors and Awards	Page 16
Memberships in Professional Societies	Page 18
Editorial Positions, Boards, and Peer-Review Service	Page 19
Teaching	Page 20
Committee, Organizational, and Volunteer Service	Page 21
Consulting Positions	Page 24
Visiting Professorships, Seminars, and Extramural Invited Presentations	Page 24
Bibliography	Page 51

Education and Training

09/1978-05/1982	University of Pennsylvania, Bachelor of Arts in Biology
09/1982-06/1986	Emory University School of Medicine, MD
07/1986-06/1989	Residency Training in Internal Medicine, Emory Affiliated Hospitals
07/1990-06/1993	Fellowship in Gastroenterology, University of Michigan

Certification and Licensure

Diplomat of NBME (7/87)

Licensed to Practice Medicine in the State of Michigan (#4301056884), Expire 07/05/2024

American Board of Internal Medicine Certification, 1989

American Board of Internal Medicine Subspecialty Certification in Gastroenterology, 1993,
Successful recertification 2003, 2013

Academic, Administrative, and Clinical Appointments

Academic

07/1989-06/1990	Senior Associate, Department of Internal Medicine, Emory University School of Medicine, Atlanta, Georgia
07/1993-08/1996	Lecturer in Internal Medicine, University of Michigan, Ann Arbor, Michigan
09/1996-08/2001	Assistant Professor, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
09/2001-08/2007	Associate Professor, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
09/2007-present	Professor, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
02/2015-present	Timothy T. Nostrant Collegiate Professorship in Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
07/2015- present	Professor, Department of Nutritional Sciences, University of Michigan, Ann Arbor, Michigan
04/2022 – present	Chief, Division of Gastroenterology, Michigan Medicine, Ann Arbor, Michigan

Clinical

07/1993-present	Director, GI Physiology Laboratory, University of Michigan Health System Ann Arbor, Michigan
01/2009-present	Co-Director, Michigan Bowel Control Program University of Michigan Health System

01/2015-present Ann Arbor, Michigan
Director, Digestive Diseases Nutrition & Behavioral Health
Program, Division of Gastroenterology, University of
Michigan Health System, Ann Arbor, Michigan
09/2018-present Director, University of Michigan Food for Life Kitchen

Private Sector Appointments

Co-Founder and Co-CMO My Total Health, Los Angeles, California
Senior Director, Nutrition & Behavioral Health Service GI on Demand

Research Interests

1. The pathophysiology and management of functional bowel disorders
2. The role of diet and nutrition in functional bowel and motility disorders
3. The emerging role of health information technology in medicine
4. Diagnosis and treatment of *Helicobacter pylori* and acid-peptic disorders

Active Research Funding:

Fecal Incontinence

Sponsor: National Institutes of Health – UO-1
Title: “Comparative Effectiveness of Biofeedback, Sacral Nerve Stimulation, and Injectable Bulking Agents for Treatment of Fecal Incontinence: The Fecal Incontinence Treatment (FIT) Study”
ClinicalTrials.gov NCT03811821
Principal Investigator: William Whitehead, PhD
Site Co-PIs: William D. Chey, MD, Stacy Menees, MD
Funding period: 6/1/20-TBA (\$432,380 to UM)

IBS

Sponsor: National Institutes of Health – RO-1
Title: “Home-based transcutaneous electrical acustimulation for abdominal pain”
Principal Investigator: Jiande Chen, PhD
Site Co-PIs: William D. Chey, MD, Chung Owyang, MD, Borko Nojkov, MD
Funding period: 7/1/20-6/30/25 (\$3,298,650)

Sponsor: Biomerica
Title: “An antibody guided dietary restriction trial using Biomerica InFoods 24G test in patients with Irritable Bowel Syndrome”
Principal Investigator: William D. Chey, MD
Funding period: 7/1/18-10/31/21 (\$181,015)

Sponsor: Commonwealth Diagnostics International
Title: “The role of breath testing in enriching the likelihood of response to rifaximin in patients with non-constipated IBS”
Principal Investigator: William D. Chey, MD

Co-investigator: Borko Nojkov, MD
Funding period: 9/10/19-10/31/21 (\$155,122)

Sponsor: QOL Medical
Title: "Sucrase-Isomaltase Deficiency in Irritable Bowel Syndrome and Diarrhea - Hiding in Plain Sight?"

Principal Investigator: Shanti Eswaran, MD
Project Mentor: William D. Chey, MD
Funding period: 4/1/19-3/30/22 (\$150,676)

Sponsor: ACG Institute
Title: "Low FODMAP plus PEG 3350 for the treatment of patients with Irritable Bowel Syndrome-Constipation"

Principal Investigator: Stacy Menees, MD
Project Mentor: William D. Chey, MD
Funding period: 7/1/18-3/30/22 (\$56,151)

Other:

Sponsor: Food and Drug Administration
Title: "Develop Patient-Focused Quality Standard or Specifications by Measuring In Vivo Drug Dissolution in Human GI Tract of Various MR Products for Validating In Vitro Dissolution Methods"

Principal Investigator: Duxin Sun, PhD
Co-investigators: William D. Chey, MD, Borko Nojkov, MD
Funding period: 7/1/21-6/30/23 (\$686,357)

Past

GCRC-CAP Award for "Visceral Afferent Dysfunction in Diabetic Constipation",
Principal Investigator: WD Chey
Funding period from 4/1/94 to 3/31/97 (\$196,400)

Glaxo Institute of Digestive Health Clinical Research Award for "Role of Hyperglycemia on Efferent Neural and Myogenic Function in the Human Colon",
Principal Investigator: WD Chey
Funding period from 7/1/94 to 6/30/95 (\$40,000)

Glaxo Institute of Digestive Health Clinical Research Award for "Visceral Afferent Neural Dysfunction in Diabetic Constipation",
Principal Investigator: WD Chey
Funding period from 7/1/95 to 6/30/96 (\$39,000)

Sandoz Pharma Ltd for "A randomized, double-blind, placebo-controlled, multicenter, dose ranging study to assess the safety and efficacy of SDZ HTF 919 at four dose levels in subjects with constipation-prone irritable bowel syndrome"

Principal Investigator: Chung Owyang, MD
Co-investigators: WD Chey, JL Barnett, G Elta, W Hasler, T Nostrant, J Scheiman, J Wiley.
Funding period from 4/95 to 2/96 (\$97,988)

Astra-Merck for "Prolonged effect of omeprazole on the ¹⁴C-urea breath test",
Principal Investigator: WD Chey
Funding period from 5/95 to 1/96 (\$4,200)

Chemtrak for "Accumeter *H. pylori* test: Cut-off verification, clinical performance, and reproducibility",
Principal Investigator: WD Chey.
Funding period from 8/95 to 2/96 (\$26,500)

Abbott Pharmaceuticals for "The efficacy of 2 different 7 day treatment programs for *Helicobacter pylori* infection",
Principal Investigator: WD Chey
Funding period from 9/95 to 10/96 (\$3000)

Solvay Pharmaceuticals for "Double-blind placebo-controlled, randomized, multicenter, parallel group dose finding study to investigate the efficacy of cilansetron in patients with irritable bowel syndrome and increased rectal visceral sensitivity"
Principal Investigator: Chung Owyang, MD
Co-investigators: WD Chey, MD
Funding period from 10/96 – 4/97

Chemtrak for "Accumeter *H. pylori* Test",
Principal Investigator: WD Chey.
Funding period from 9/96-2/97 (\$5,100)

GCRC Funding for "The effect of hyperglycemia on forebrain and brainstem activation resulting from rectal distention"
Principal Investigator: WD Chey
Funding period from 4/18/96-11/1/97 (\$24,000)

Pfizer Pharmaceuticals for "The efficacy of Ranitidine Bismuth Citrate, Azithromycin, and Amoxicillin for 7 versus 10 days to cure *H. pylori* infection"
Principal Investigator: WD Chey
Funding period from 3/1/97-3/31/98 (\$7,000)

Phase I SBIR award for "Non-invasive breath test for measuring gastric emptying"
Principal Investigator: KJ Goodman
Co-investigator: WD Chey
Funding period from 9/1/97-8/31/98 (\$61,782 total costs; \$32,552 subcontract to UMMC)

Phase II SBIR award for “Investigation of a blood test (EZ-HBT) for the diagnosis of *Helicobacter pylori* infection”

Principal Investigator: DA Wagner, PhD

Co-investigators: WD Chey, PA Toskes, AF Cutler

Funding period from 4/1/98-3/31/00 (\$15,600 from subcontract to UMMC)

John and Suzanne Munn endowed research fund of the University of Michigan Comprehensive Cancer Center for “Converting sigmoidoscopy to colonoscopy: a randomized, controlled trial to assess clinical and economic outcomes of a novel colorectal cancer screening strategy”

Principal Investigator: WD Chey, MD

Co-investigators: M Stern, AM Fendrick, R Mosely

5/14/98 to indefinite (\$7,200)

GCRC Funding for “Differential cortical activation in response to visceral and somatic stimulation in healthy volunteers and patients with noncardiac chest pain (#1575)”

Principal Investigator: WD Chey

Funding period from 8/13/98- 8/99 (\$24,600)

Phase II SBIR for “Non-invasive breath test for measuring gastric emptying”

Principal Investigator: KJ Goodman, PhD

Co-investigators: WD Chey, HP Parkman

Funding period from 7/1/99 to 6/30/01 (\$646,500 total award with \$117,546 from subcontract to UMMC)

Solvay Pharmaceuticals for “Double-blind, placebo-controlled, randomized, multicenter, parallel-group dose ranging study to investigate the efficacy and safety of Cilansetron in non-constipated patients with Irritable Bowel Syndrome”

Principal Investigator: WD Chey, MD

Co-Investigators: C Owyang, WL Hasler, J Barnett, J Wiley

Funding period from 3/99- (\$89,647)

Dia Sorin for “Appropriate test selection for patients undergoing the test and treat strategy for *H. pylori*”

Principal Investigator: AM Fendrick, MD

Co-Investigator: WD Chey

Funding period from 11/99-5/2000 (\$74,963)

Ballard Medical Products for “The effect of proton pump inhibitors on non-invasive testing for *H. pylori*”

Principal Investigator: WD Chey, MD

Funding from 9/99-8/2000 (\$5,000)

Solvay Pharmaceuticals for “Double-blind, placebo-controlled, long-term extension to evaluate the nine month safety profile of Cilansetron in non-constipated IBS patients”

Principal Investigator: WD Chey, MD

Co-Investigators: C Owyang, WL Hasler, J Barnett, J Wiley

Funding period from 7/1/99-6/30/2000 (\$71,725)

Glaxo-Wellcome for “A 24 week randomized, open label study of Health care resource use, quality of life and productivity with Alosetron 1 mg BID vs. traditional therapy in females with non-constipated IBS”

Principal Investigator: WD Chey, MD

Funding period from 2/1/2000-12/31/2000 (\$20,000)

Glaxo-Wellcome for “The effect of Alosetron on anal sphincter function in healthy volunteers and patients with fecal incontinence”

Principal Investigator: WD Chey, MD

Co-Investigator: WM Sun

Funding period from 7/1/2000-06/30/2001 (\$17,000)

Solvay for “A randomized, placebo controlled, multi-center study to investigate the safety and efficacy of 2mg cilansetron in non-constipated subjects with established irritable bowel syndrome”

Principal Investigator: WD Chey, MD

Co-Investigators: C Owyang, G Elta, J Barnett

Funding period from 1/1/2001-12/31/2001 (\$28,051)

Astra-Zeneca for “A comparative efficacy and safety study of Nexium (esomeprazole magnesium) delayed release capsules(40mg qd and 20mg qd) versus placebo for the prevention of gastric ulcers associated with daily NSAID use in patients at risk” Principal Investigator: James Scheiman,

Sub Investigators: William Chey, Grace Elta, Andrea Todisco, Michelle Anderson. Funding period: 2/01-12/02 (\$50,000)

Novartis for “A randomized, double-blind, placebo controlled multi-center study to assess the efficacy, safety, and tolerability of tegaserod 2 mg bid and 6 mg bid given orally vs. placebo in patients with chronic constipation”

Principal Investigator: WD Chey, MD

Co-Investigators: C Owyang, G Elta, J Barnett

Funding period from: 5/1/01-11/1/02 (\$49,675)

Astra-Zeneca for “Effect of functional bowel disease on outcome after surgical anti-reflux therapy”

Principal Investigator: WD Chey, MD

Co-Investigators: Lisa Colletti, David Axelrod, Michael Shaw, A. Mark Fendrick

Funding period from: 8/30/00-8/29/03 (\$67,042)

Phase II SBIR for “A breath test to detect bacterial overgrowth in the elderly”

Principal Investigator: D Wagner, PhD

Co-investigators: WD Chey, HP Parkman, P Toskes

Funding period from: 4/1/02-3/31/04 (\$74,972 from subcontract to UMMC)

Janssen Pharmaceuticals for “Nonerosive Reflux Disease: A study to understand etiology and predictors of response to PPI therapy”

Principal Investigator: WD Chey, MD

Co-investigators: M Cleary, M Shaw, J Inadomi

Funding period from: 2/1/02-1/31/04 (\$80,579)

Phase I SBIR for “A novel diagnostic test for irritable bowel syndrome”

Principal Investigator: D Wagner, PhD

Co-investigators: WD Chey

Funding period from: 3/1/03-2/28/04 (\$27,394)

Forest Laboratories for “Safety and efficacy of dexloxyglumide in female patients with constipation-predominant irritable bowel syndrome”

Principal Investigator: WD Chey, MD

Co-Investigators: C Owyang, G Elta

Funding period from: 2/1/02-3/31/03 (\$58,926)

Vela Pharmaceuticals for “A double-blind randomized, placebo-controlled study of R-Tofisopam in outpatients with Irritable Bowel Syndrome”

Principal Investigator: WD Chey, MD

Co-Investigators: C Owyang, WL Hasler, J Wiley

Funding period from: 9/9/2003-6/30/2004 (\$50,133)

Prometheus Laboratories for “The value of diagnostic testing in Irritable Bowel Syndrome”

Principal Investigator: WD Chey, MD

Co-Investigators: B Cash

Funding period from: 9/12/2003-12/30/2004 (\$31,265)

Janssen Pharmaceuticals for "Esophageal sensation in patients with heartburn:

Correlation of esophageal sensation with response to PPI"

Principal Investigator: WD Chey, MD

Co-investigators: J Rubenstein, B Nojkov

Funding period from: 9/30/03-10/1/04 (\$52,948)

Novartis Pharmaceuticals for "A 4-week, multicenter, double-blind, placebo-controlled, randomized, parallel-group, clinical study to evaluate the efficacy of tegaserod in relieving the symptoms of female patients with IBS, excluding those with predominant diarrhea IBS"

Principal Investigator: WD Chey, MD

Co-investigators: C Owyang, WL Hasler, J Wiley, L Fisher

Funding period from: 1/11/04-7/31/05 (\$30,517)

Novartis for “A 6 week randomized, double-blind, double-dummy placebo controlled, multicenter study to assess the effect of tegaserod 2mg TID on dyspeptic symptoms in diabetic patients with symptoms of diabetic gastropathy”

Principal Investigator: WD Chey, MD

Co-investigators: C Owyang, WL Hasler, J Wiley, L Fisher

Funding period from: 2/25/04-6/30/2005 (\$57,486)

Trine Pharmaceuticals for “A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of TRN-002 for the symptomatic treatment of diarrhea-predominant irritable bowel syndrome”

Principal Investigator: WD Chey, MD

Co-investigators: C Owyang, WL Hasler, J Wiley, L Fisher

Funding period from: 12/1/04-11/30/2005 (\$40,679)

Smart Pill Diagnostics for “Medical Utilization in patients with gastroparesis”

Principal Investigator: WL Hasler, MD

Co-investigators: John Wo, WD Chey

Funding period from: 11/1/04-10/31/2005 (\$25,389)

Rome Foundation for Disorders of GI Function for “Validation of the Rome III modular questionnaire”

Principal Investigator: WD Chey, MD

Co-investigators: R Saad, MD

Funding period from: 10/1/05-4/31/2006 (\$7,500)

Sucampo Pharmaceuticals for “An double-blind study of lubiprostone for constipation-predominant irritable bowel syndrome”

Principal Investigator: WD Chey, MD

Co-investigators: R Saad, MD

Date: 1/1/06-3/31/2007

Funding amount: \$52,614

Novartis for “The effects of tegaserod on orocecal transit in elderly patients with chronic constipation”

Principal Investigator: WD Chey, MD

Co-investigators: H Parkman, I Bottoli, D Joseph

Date: 7/1/06-6/30/07

Funding amount: \$750,000 for 3 sites - \$244,000 to UM

Salix for “A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 3 different doses of rifaximin bid for 2 or 4 weeks in the treatment of patients with IBS-D”

Principal Investigator: WD Chey, MD

Co-investigators: R Saad, MD

Date: 5/1/06-9/30/07

Funding amount: \$44,075

Trine Pharmaceuticals for “A randomized, double-blind placebo controlled study to assess the safety and efficacy of TRN-002 for the symptomatic treatment of diarrhea-predominant IBS in females”

Principal Investigator: WD Chey, MD

Co-investigators: R Saad MD, D Brenner MD
Funding period: 10/16/06-10/31/07 (\$33,064)

GCRC for “Pilot feasibility study of structure-function relationships in pediatric fecal incontinence”

Principal Investigator: Cheryl Gariepy, MD
Co-investigators: WD Chey, B Felt, P Strouse
Date: 11/01/05-4/30/07 (\$26,108)

Allergan Pharmaceuticals for “A multicenter, multiple-dose, double-blind, randomized, placebo controlled, parallel group study of the safety and efficacy of oral AGN 203818 given twice daily for 4 weeks for the relief of IBS pain”

Principal Investigator: WD Chey, MD
Co-investigators: R Saad, MD D Brenner MD
Date: 5/1/07- 5/08 (\$24,045)

Microbia, Inc. for “A randomized, multi-center, double-blind, placebo controlled dose-range-finding parallel-group, phase 2 trial of oral linaclotide acetate administered to patients with chronic constipation”

Principal Investigator: WD Chey, MD
Co-investigators: R Saad MD, D Brenner MD
Date: 5/1/07- 4/08 (\$26,628)

Microbia, Inc. “A randomized, multi-center, double-blind, placebo controlled dose-range-finding parallel-design, phase 2 trial of oral linaclotide acetate administered to patients with irritable bowel syndrome with constipation”

Principal Investigator: WD Chey, MD
Co-investigators: R Saad MD, D Brenner MD
Date: 7/30/07- 4/08 (\$36,040)

Alizyme “A phase III, multicenter, open label, extension study to evaluate the long-term safety of renzapride in women with constipation-predominant IBS”

Principal Investigator: WD Chey, MD
Co-investigators: R Saad, MD
Date: 5/1/06-6/30/08 (\$43,704)

Prometheus Laboratories, Inc. for “Procurement of blood samples for use in the development of a gastrointestinal disease test panel”

Principal Investigator: WD Chey, MD
Co-investigators: R Saad MD, D Brenner MD
Date: 9/1/07- 8/08 (\$ 35,950)

TAP Pharmaceuticals “Non-steroidal anti-inflammatory drug and aspirin utilization amongst US primary care physicians: A follow-up survey”

Principal Investigator: WD Chey, MD
Co-investigators: N Elnachef, JS Scheiman, AM Fendrick, CW Howden, MD

Date: 4/06-8/08 (\$18,649)

Pharmos Corporation “A double-blind, randomized, placebo-controlled phase 2b study of 100, 200, and 300 mg BID Dextofisopam in female outpatients with irritable bowel syndrome”

Principal Investigator: WD Chey, MD
Co-investigators: R Saad, MD D Brenner MD
Funding period: 9/1/07-3/31/09 (\$54,759)

Bill & Melinda Gates Foundation “A clinical trial of *H. pylori* eradication in Latin America”

Principal Investigator: Laurence Baker, DO
Study Executive Officer &
Steering Committee: William D. Chey, MD
Funding period: 7/24/08 – 7/24/10 (\$2,300,000 – 10% effort)

American College of Gastroenterology “Pilot study to determine the key characteristics which aid in the diagnosis of constipated patients with dyssynergic defecation”

Principal Investigator: Monthira Maneerattanaporn, MD
Project Mentor: William D. Chey, MD
Funding period: 7/1/10 – 6/30/11 (\$10,000 – 0% effort)

American Gastroenterological Association “The differences in physiologic mechanisms underlying chronic constipation in elderly versus younger adults with constipation”

Principal Investigator: Richard Saad, MD
Project Mentor: William D. Chey, MD
Funding period: 7/1/08 – 6/30/11 (\$225,000)

National Institutes of Health, “Development and Initial Validation of PROMIS GI Distress Scale”

Principle Investigator: Dinesh Khanna, MD, MS and Brennan Spiegel MD, MSHS
External Consultant: William D. Chey, M.D.
Funding Period: 9/1/09 – 7/31/13 (\$2,063,004 – 0% effort)

Coulter Translational Research Partnership Program, “Digital Manometry: A Disposable, Point-of-Service Device to Diagnose Dyssynergic Defecation”

Principle Investigator
(Clinician): William D. Chey, M.D.
Principle Investigator
(Bio-Medical Engineer): James Ashton-Miller, Ph.D.
Funding Period: 7/1/2012-12/31/2013 (\$99,734 – 5% effort)

Sponsor: Ironwood Pharmaceuticals
Title: “Development of My GI Health Consumer Portal”
PI: Brennan Spiegel, MD
Co-investigators: William D. Chey, MD, Roger Bolus, PhD
Funding Period: 7/1/2013- 12/31/14 (\$427,908, \$87,052 to UM – 10% effort)

Sponsor: Ironwood Pharmaceuticals
 Title: “My GI Health Educational Assets V1.5”
 PI: William D. Chey, MD
 Co-investigators: Lawrence An MD, Lin Chang MD
 Funding Period: 7/1/2013- 6/30/14 (\$242,620 – 0% effort)

Sponsor: VA Cooperative Studies Program #573
 Title: “A Randomized Trial of Medical and Surgical Treatments for Patients with GERD Symptoms that are Refractory to Proton Pump Inhibitors”
 Principal Investigator: Stuart Spechler MD
 Executive Committee: William D. Chey MD, Donald Castell MD, Douglas Drossman MD, Ronald Hinder MD
 Funding Period: 1/2012 – 1/2015 (\$11,066,620)

Sponsor: Coulter Translational Research Partnership Program
 Title: “Digital Manometry: A Disposable, Point-of-Service Device to Diagnose Functional Defecation Disorders: Year 2”
 Principle Investigator (Clinician): William D. Chey, MD
 Principle Investigator (Bio-Medical Engineer): James Ashton-Miller, Ph.D.
 Funding Period: 7/1/2013-2/28/2015 (\$107,806 – 5% effort)

Sponsor: Michigan Initiative for Innovation & Entrepreneurship
 Title: Digital Manometry: An inexpensive, disposable, point of service device to evaluate human anorectal function
 Principal Investigator: Jack Minor
 Co-investigators: William D. Chey MD, Thomas Marten, James Ashton-Miller PhD
 Funding Period: 7/1/14-6/30/15 (\$37,000 – 0% effort)

Sponsor: Michigan Nutrition & Obesity Research Center
 Title: “Low FODMAP diet vs. standard dietary recommendations for patients with irritable bowel syndrome with diarrhea (IBS-D): a randomized, controlled trial and gastrointestinal microbiome analysis”
 Principle Investigator : Shanti Eswaran, M.D.
 Project Mentor: William D. Chey, M.D.
 Funding Period: 7/1/2012-12/31/2015 (\$50,000 – 0% effort)

Sponsor: Prometheus Laboratories, Inc.
 Title: “Low FODMAP diet vs. standard dietary recommendations for patients with irritable bowel syndrome with diarrhea (IBS-D): a randomized, controlled trial and gastrointestinal microbiome analysis”
 Principle Investigator: Shanti Eswaran, M.D.

Project Mentor: William D. Chey, M.D.
Funding Period: 10/13/2013-12/31/2015 (\$25,000 – 0% effort)

Sponsor: Rome Foundation
Title: “Rome IV Clinical Validation Study”
PI: William D. Chey, MD
Co-investigators: Olaf Paulsson MD, William Whitehead PhD
Funding Period: 3/1/201- 9/15/15 (\$165,000, \$24.5K to UM, 2% effort)

Sponsor: Perrigo Company
Title: “Assessment of Gastroenterologists understanding of over-the-counter GI medications”
Principle Investigator : William D. Chey, M.D
Co-investigators: Stacy Menees, MD, Amanda Guenter, MD.
Funding Period: 4/1/2013-12/31/2015 (\$50,470 – 5% effort)
Sponsor: Vibrant
Title: “A multinational, multicenter, prospective double-blind, sham controlled, randomized study to assess the performance, efficacy and safety of Vibrating Capsule medical device in aiding relieving Constipated Individuals”
PI: William D. Chey, MD
Co-investigators: Shanti Eswaran MD, Richard Saad MD
Funding Period: 2/1/2015- 1/31/16 (\$83,786, 2.5% effort)
Sponsor: National Institutes of Health
Title: “Validation of GI PROMIS® Measures in Clinical Practice: A Pragmatic Trial Using a Novel e--Platform”
PI: Brennan Spiegel MD
Co-investigators: William D. Chey, MD Dinesh Khanna, MD
Funding Period: 7/1/13 -2/28/16 (\$200,000, \$50K to UM)

Sponsor: Ironwood Pharmaceuticals
Title: “Development and validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform”
Principal Investigators: William D. Chey, MD & Brennan Spiegel, MD
Funding period: 7/1/11 – 10/31/16 (\$1,920,170 total, \$1,028,267 UM – 20% effort)

Sponsor: Ironwood Pharmaceuticals
Title: “Creation and Validation of a Paired Survey Instrument to Study the Quality of Patient-Physician Relationships in Irritable Bowel Syndrome”
Principal Investigator: William D. Chey, MD
Co-investigators: Jacob Kurlander, MD, Douglas Drossman, MD
Funding period: 7/1/12 – 11/31/16 (\$114,637 – 5% effort)

Sponsor: GI Health Foundation
Title: GSID Patient Journey Screening and Survey
Principal Investigator: William D. Chey, MD

Funding period: 12/1/16-6/1/17 (\$17,100)

Sponsor: Ardelyx Pharmaceuticals
Title: “A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)/TEN-01-302”

Principal Investigator: William D. Chey, MD
Funding period: 10/18/2016 - 9/30/2018 (\$61,387)

Sponsor: MTRAC
Title: “Digital Manometry: A disposable, point of service diagnostic device for patients with fecal incontinence”

PI: William D. Chey, MD
Co-investigators: James Ashton-Miller, Ali Attari, Jason R. Baker
Funding Period: 2/1/2016 - 4/31/17 (\$104,802, 5% effort)

Sponsor: Rome Foundation.
Title: “Low FODMAP diet vs. psyllium for patients with fecal incontinence and loose stools: a randomized, controlled trial”

Principle Investigator: Stacy Menees, M.D.
Project Mentor: William D. Chey, M.D.
Funding Period: 6/1/2014-5/31/2017 (\$50,000 – 0% effort)

Sponsor: Nestle Health Sciences
Title: “My GI Health Virtual Dietician Platform”

PI: William D. Chey, MD
Co-investigators: Lawrence An MD, Brennan Spiegel MD
Funding Period: 1/1/2014- 12/31/17 (\$750,000, \$450K to UM, 10% effort)

Sponsor: UM Fast Forward GI Innovation Fund
Title: “Development of an office-based, disposable rectal expulsion device (RED) to screen for dyssynergic defecation in constipated patients”

Principal Investigator: William D. Chey, MD
Co-investigators: Jason Baker, Eric Shah, MD
Funding period: 6/15/17-6/14/18 (\$38,000)

Sponsor: Nestle Health Sciences
Title: “Creation of the My Nutrition Health Mobile App and a FODMAP Food Frequency Questionnaire”

Principal Investigator: William D. Chey, MD
Co-investigators: Brennan Spiegel MD, Chris Almario MD
Funding period: 4/1/17-4/1/18 (\$301,930)

Sponsor: MICHR Pilot Grant Program

Title: "Charting a course to a less restrictive diet for IBS patients"
Principal Investigator: Shanti Eswaran, MD
Project Mentor: William D. Chey, MD
Funding period: 1/1/17-1/1/18 (\$50,000)

Sponsor: MICHR Pilot Grant Program
Title: "Probe-based Confocal Laser Endomicroscopy to Detect Structural and Functional Duodenal Mucosal Abnormalities in Patients with Functional Dyspepsia"

Principal Investigator: Borko Nojkov, MD
Project Mentor: William D. Chey, MD
Funding period: 1/1/17-1/1/18 (\$50,000)

Sponsor: Nestle HealthCare Nutrition
Title: "Charting a course to a less restrictive diet for IBS patients"
Principal Investigator: Shanti Eswaran, MD
Project Mentor: William D. Chey, MD
Funding period: 11/4/17-9/30/19 (\$116,248)

Sponsor: MICHR Pilot Grant Program
Title: "Charting a course to a less restrictive diet for IBS patients"
Principal Investigator: Shanti Eswaran, MD
Project Mentor: William D. Chey, MD
Funding period: 1/1/17-1/1/18 (\$50,000)

Sponsor: UM Fast Forward GI Innovation Fund
Title: "Tier II – Development of an office-based, disposable rectal expulsion device to screen for dyssynergic defecation in constipated patients"
Principal Investigator: William D. Chey, MD
Project Mentor: Eric Shah, MD
Funding period: 7/1/18-6/30/19 (\$100,000)

Sponsor: Zespri
Title: "A randomized, controlled pilot study to compare the efficacy of Kiwifruit, prunes, or psyllium on abdominal and bowel symptoms in US patients with chronic constipation"
Principal Investigator: Shanti Eswaran, MD
Project Mentor: William D. Chey, MD
Funding period: 5/1/18-6/1/20 (\$176,844)

Sponsor: Vibrant
Title: "A Prospective, Randomized, Multi-center, Single-Blinded, Placebo-Controlled, 3-Arm Clinical Study to Assess the Efficacy and Safety of Vibrant Capsule for the Treatment of Chronic Idiopathic Constipation"
Principal Investigator: William D. Chey, MD

Co-investigators: Shanti Eswaran, Borko Nojkov
 Funding period: 1/22/19 – 9/30/19 (\$77,933)

Sponsor: Urovant
 Title: “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women with Irritable Bowel Syndrome”

Principal Investigator: William D. Chey, MD
 Funding period: 5/1/19-9/14/20 (\$106,314)

Sponsor: Craig H. Nelson Foundation
 Title: “The Wireless Motility Capsule for Neurogenic Bowel in Spinal Cord Injury”

Principal Investigator: Gianna Rodriguez, MD
 Co-investigators: William D. Chey, MD, Jason Baker, Richard Saad, MD
 Funding period: 7/31/17-7/30/20 (\$300,000)

Patents

Digital Manometry: a finger-mountable sensor device
 Serial Number: 13/714,728
 International Application Number: PCT/US2012/069680
 US Patent Application Filed 12/14/2012

Rectal Expulsion Device
 Invention Report 6563
 University of Michigan Office of Technology Transfer 2/9/15

Methods and kits for identifying food sensitivities and intolerances.
 Application No.: 15/323,857
 Docket No.: 065472-000492US00

Honors and Awards

1978-1981	Dean's List, University of Pennsylvania
1981	American Gastroenterological Association Student Research Award for "The Effect of CCK on Calcium Flux in Gut Smooth Muscle", WM Snape, Jr., MD, University of Pennsylvania
1981-1982	Alpha Epsilon Delta Pre-Medical Honor Society
1986-1987	Commendation for "Outstanding Performance" During the Internship Year
1994-1995	Glaxo Institute for Digestive Health Award for Clinical Research

1995-1996 Glaxo Institute for Digestive Health Award for Clinical Research

1995 Award for one of the top ten abstracts submitted to the Department of Internal Medicine's Research Day, University of Michigan Medical Center, April 29, 1995 for "Hyperglycemia blunts the perception of electrical rectal stimulation by effects on central processing of afferent input."

1995 Travel Scholarship Award to the Third International Symposium on Brain-Gut Interactions, Cambridge, UK

1996 Plenary Poster Session, Digestive Diseases Week, San Francisco, CA for "Hyperglycemia blunts rectal afferent transmission and increases rectal compliance in diabetic patients: A possible model of diabetic constipation"

1998 President's Plenary Poster, World Congress of Gastroenterology, Vienna, Austria for "Validation of the ¹³C-urea blood test for *H. pylori* infection: a US, multicenter trial"

2002 Honored as one of the "Best Doctors in Detroit", Hour Detroit Magazine, September

2003 Selected to the Rome III Committees on Functional GI Disorders –Design of Treatment Trials Committee and Bowel Function Committee

2003 Award for "Excellence in Teaching" from 2003 University of Michigan GI fellowship class

2003 Michigan Chapter American College of Physicians – "Governor's Award" for service to the MI Chapter

2004 Rewarded for teaching excellence – Department of Internal Medicine, University of Michigan Internal Medicine Residency Program

2005 Award for "Excellence in Mentorship" from 2005 University of Michigan GI fellowship class

2006 Named as one of "America's Top Physicians"

2007 Marquis Who's Who in America 2007-

2007 "Metro Detroit's Best Doctors" Hour Detroit Magazine, October

2007 ACG/Novartis Motility Award for "Prevalence and impact of co-morbid psychological distress on response to PPI therapy in patients with GERD", Annual Meeting of the American College of Gastroenterology October, 2007

2009 ACG/Salix Leadership Training Award – "Leadership Reflections and Insights" Harvard Business School, July 5-9, 2010

2010-3 Selected Co-editor-in-chief: American Journal of Gastroenterology

2010 “75 Best Gastroenterologists in America” Becker’s ASC Review (<http://www.beckersasc.com/gastroenterology-and-endoscopy/75-of-the-best-gastroenterologists-in-america.html>)

2012 “125 Best Gastroenterologists in America” Becker’s ASC Review

2012, 2013 Top 1% of US Gastroenterologists, US News and World Report (http://health.usnews.com/top-doctors/search?doctor=chey&specialist=Gastroenterologists&doctor_gender=&location=Ann+Arbor%2C+MI&distance=25&hospital=Hospital+Name&x=55&y=14)

2012 “Top Docs” in Metro Detroit, Hour Detroit Magazine

2013-6 Reappointed Co-editor-in-chief: American Journal of Gastroenterology

2014 *Academiae Laureati Medici* Clinical Excellence Society, Department of Internal Medicine, UMHS

2014 Dean’s Award for “Outstanding Clinician”, UMHS

2014 “160 Gastroenterologists to Know” Becker’s ASC Review (<http://www.beckersasc.com/160-gastroenterologists-to-know-2014/160-gastroenterologists-to-know-2014.html>)

2014 League of Research Excellence, University of Michigan Medical School

2015 Selected as inaugural Timothy T. Nostrant Collegiate Professor of Gastroenterology

2015-18 Elected President-elect (2015-16), President (2016-18), Clinical Excellence Society, Department of Internal Medicine, UMHS.

2015 League of Clinical Excellence, University of Michigan Medical School

2015 Distinguished Clinician Award, American Gastroenterological Association

2015 “190 Gastroenterologists to Know” Becker’s ASC Review (<http://www.beckersasc.com/lists/190-gastroenterologists-to-know-2015.html>)

2015 “David Sun Lecture: Food – the main course to GI wellness and disease” ACG Postgraduate Course, Honolulu, HI, October 17, 2015

2016 Alfred Hospital WTMS Visiting Professor Scholarship, Monash University, Melbourne, Australia, July 2016.

2016 Selected “Fulbright Specialist Roster”, Fullbright US Scholar Program, Washington, DC.

2016 “Healio Gastroenterology 200” Leading innovators in GI & Hepatology, Healio Gastroenterology, September 2016

2016, 2017 “Top Docs” in Metro Detroit, Hour Detroit Magazine

2019 “Healio 200” leaders and innovators in Gastroenterology, Healio Gastroenterology, May 2019.

2019	Healio Disruptive Innovators, Clinical Innovator Award October, 2019.
2019	Dean's Award for Innovation & Commercialization, University of Michigan Medical School
2019	"Clinical Innovation Disruptor Award", Healio Gastroenterology, October 2019
2020	Honorary Membership Award – Academy of Nutrition and Dietetics
2020	American College of Gastroenterology: Berk/Fise Award
2021	Appointed to Rome V Criteria Editorial Board
2021	Appointed Vice President, International Foundation of GI Disorders
2021	J. Edward Berk Distinguished Lecturer, Annual Meeting of the American College of Gastroenterology, October 2021
2021	Governor's Award for Research Excellence "Vonoprazan dual & triple therapies for <i>Helicobacter pylori</i> eradication" Annual Meeting of the American College of Gastroenterology, October 2021
2021	Secretary of the American College of Gastroenterology
2010-2021	"America's Top Doctors" Castle Connolly
2001-2021	"Best Doctors in America", Best Doctors, Inc, Aiken, SC

Memberships in Professional Societies

American Gastroenterological Association (AGA)
Fellow – American Gastroenterological Association (5/1/06)

American College of Physicians (ACP)
Fellow – American College of Physicians (7/1/99)
Council Member for the Michigan Chapter – ACP (2002-3)

American College of Gastroenterology (ACG)
Fellow - American College of Gastroenterology (6/98)

American Society of Gastrointestinal Endoscopy (ASGE), 1993-2020

Bockus International Society of Gastroenterology (inducted 2004)

Central Society for Clinical Research, 1993-present

Crohns and Colitis Foundation of America, 1998-2008

Detroit GI Society
Secretary (1999)
President Elect (2000)
President (2001)

International Foundation of Functional Gastrointestinal Disorders, 1993-present

Michigan Gut Peptide Center, 1993-present

Rome Foundation, 2004-present
Fellow (2013)

Southwest Oncology Group: A National Clinical Research Group, 2008-2016

Editorial Positions, Boards, and Peer-Review Service

Journals Refereed:	Alimentary Pharmacology & Therapeutics, 1994-present American Journal of Gastroenterology, 1994-present American Journal of Physiology, 1994-2000 Annals of Internal Medicine – recognized as a “best reviewer” (top 30% of reviewers) - 2008 Archives of Internal Medicine, 1996-present BMJ, 2018 Clinical Gastroenterology and Hepatology, 2000-present Gastroenterology, 1994-present Gut, 2000-present Helicobacter, 1996-present Journal of Clinical Gastroenterology, 1999 Journal of Neurogastroenterology & Motility, 2014-present Lancet, 2017-present Neurogastroenterology & Motility, 2010-present New England Journal of Medicine, 2017 World Journal of Gastroenterology, 2000
Editorial Boards	American Journal of Gastroenterology, 2004-present Clinical Endoscopy, 2011-2016 Clinical Gastroenterology and Hepatology, 2007-10 Digestive Health Matters, 2003-present Gastroenterology - Selected Summaries Staff, 2008-2011 Gastroenterology & Hepatology, 2005-present, Section Editor 2016-present Healio Gastroenterology, 2016-present Journal of Clinical Gastroenterology, Associate Editor, 2017-present Journal of Medicine, 2008-2012 Journal of Neurogastroenterology & Motility, Associate Editor, 2014-present Participate (International Foundation of Functional GI Disorders), 2000-3 Prevention Magazine, Medical Review Board, 2019-present Primary Care Special Edition, 2006-8 World Journal of Gastroenterology, 2007-11
Co-Editor in Chief	American Journal of Gastroenterology 2010-2015 Clinical & Translational Gastroenterology 2010-2014
Editor in Chief	Current Treatment Options in Gastroenterology 2020-present

Study Section Reviews

Data and Safety Monitoring Board for the NIH study, “Antidepressant therapy for Functional Dyspepsia” Primary Investigator: Nicholas Talley, MD, 2006-13

Planning Committee for Veteran’s Administration Cooperative Study #573: “A randomized trial of medical and surgical treatments for patients with GERD symptoms that are refractory to PPIs”. Principal Investigator: Stuart Spechler, MD, 2008-2017

Critical Path Institute Patient-reported Outcomes Consortium: IBS Working Group Advisory Board Member, Stephen Coons PhD, Director PRO consortium, 2010-present

Critical Path Institute Patient Reported Outcomes Consortium: Defining the symptoms of Functional Dyspepsia, Patrick Marquis, MD, MBA, Adelpia Values, 2012-2014

External Advisory Boards

University of North Carolina at Chapel Hill: Functional Bowel Disorders Center (2016-2018)

NHMRC Centre of Research Excellence in Digestive Health, PI: Nick Talley, University of Newcastle, Australia (2018-present)

Teaching

Housestaff Training

Rounding activities:

- 3rd and 4th year medical students and medical residents teaching during GI inpatient service or GI consult service rounds 6-8 weeks/year, 1993-2010, 3 weeks per year 2010-present

Clinic activities:

- 4th year medical student, medical resident, and/or GI fellow teaching 1.25 day/week in GI and IBS clinics, 1993-present, IBS clinic and Michigan Bowel Control Clinic one day per month, 2004-present
- Endoscopy activity:
 - GI fellow teaching, 1993-present
 - Therapeutic ERCP teaching 0.5 day/ week 1993-2005

Other Teaching/Media Activities

Spokesperson for the American College of Gastroenterology, American Gastroenterological Association and Division of Gastroenterology/Department of Public Relations at the University

of Michigan Health System (numerous radio, television, and print media interviews incl. Esquire, Family Circle, Ladies Home Journal, Men's Health, NY Times, Prevention, Self, USA Today, US News and World Report), 1995-present.

Featured expert for the Michigan Minute on the "Irritable Bowel Syndrome" 4/2007.

"Peptic ulcer disease" section for Online Teaching Resource **Recent Advances in Gastroenterology**, Temple University 2007.

Featured expert for the Michigan Health Minute on "Gastroesophageal Reflux Disease" 11/2006.
Editor – The Gastroenterology Fellow: Selected Reports from the 69th Annual Scientific Meeting of the American College of Gastroenterology. Spring 2005.

Participant in the REDUCE campaign of the AGA on NSAID-related GI disease 12/03.

Featured expert for the Michigan Health Minute on the "Irritable Bowel Syndrome" 11/2003.

Expert Commentator for Acid Related Disorders: A Medscape Special Report, www.medscape.com, 2003.

Faculty contributor to Irritable Bowel Syndrome: A comprehensive approach to effective management, Medcases, <http://www.ibscases.com/product/MedCasesFrame.asp>, 2003.

Motility and Irritable Bowel Syndrome, Clinical Advances in Gastroenterology tape series for the American College of Gastroenterology Vol 14, number 1, September 2002.

Morning report for senior internal medicine residents (1998-present).

Senior medical student Clinical Counselor (1997-present).

Author of the "Treatment section" of the *H. pylori* Foundation Web Page (1998-2000; www.helico.com).

Expert for the "Discussions section" of the *H. pylori* Foundation Web Page (1995-2000).

Expert for the "*H. pylori* forum", Physician's Online, 1997.

Program Chair: National Advisory Council on continuing medical education for *H. pylori* sponsored by Abbott Pharmaceuticals, 1995.

Contributor of questions to American Board of Internal Medicine recertification examination in Internal Medicine. Submitted January 1993 and September 1995.

Clinical conference preceptor 1-2 times/year, 1993-present.

Journal club presenter 1-2 times/year, 1993-present.

Fellow orientation lectures in Gastrointestinal Physiology, 1993-present.

Lectures in Gastrointestinal Physiology for fellows visiting the GI Physiology Laboratory, 1993-present.

Internal Medicine Resident's noon conference, once/year, 1994-present

Committee, Organizational, and Volunteer Service

Institutional

1993-	University of Michigan Medical Procedures Unit Interdisciplinary Committee
1995-	University of Michigan, Division of Gastroenterology, Fellow Evaluation Committee
1996-	Outpatient Follow-up Restructuring Committee, University of Michigan Medical Center
1996-	Clinical Operations Committee, Division of

1997- Gastroenterology, University of Michigan Medical Center
Clinical Research Committee, Division of Gastroenterology,
University of Michigan Medical Center
2014- Clinical Excellence Society, Department of Internal
Medicine, University of Michigan Health System
President-elect 2015-2016
President 2016-2018

National

AMERICAN COLLEGE OF GASTROENTEROLOGY

Secretary (2021-22)
Board of Trustees (2010-present)
ACG Institute, Board of Directors (2014-15)
ABIM recertification Committee (2004-7)
Educational Affairs Committee (2001-4)
ACG Annual Scientific Meeting Committee 2003, 2004
Practice Parameter Committee 2004-7, 2010-15
 Sub-chair: Upper Gut Section (2004-5)
 Chair: Upper Gut Section (2005-7)
 Liaison to the Board of Trustees (2012-15)
Course Co-director: ACG Midwest Regional Postgraduate Course in Gastroenterology,
 Chicago, IL, June 2007.
Chair, ACG *H. pylori* Clinical Management Guideline (2006-7)
IBS Task Force (2007-9, 2017)
Research Committee (2007-9)
Publications Committee (2010-15)
Public Relations Committee liaison (2016-2021)
Communications Council (2013-2015)
Chair, ACG *H. pylori* Clinical Management Guideline (2015-2017)
Co-Chair, Alternative Certification Bodies, MOC Review (2017)
Co-Chair, ACG Functional GI Health and Nutrition Circle (2018-present)
Course Co-director: ACG Pharmacology Course, Philadelphia, PA, October 2018
Co-Chair, Task Force to revise online IBS screener and treatment matrix
ACG IBS Clinical Management Guideline (2018-2020)
Course Co-director: ACG Pharmacology Course, San Antonio, TX, October 2019
Course Co-director: ACG FBD School, 2019-present
Director, Nutrition & Behavioral Health, Board of Directors, GI on Demand (2020-
present)
Course Co-director: ACG Pharmacology Course, Nashville, TN, October 2020
Co-chair, Joint ACG/AGA Chronic Constipation Clinical Practice Guideline 2021
Course Co-director: ACG Pharmacology Course, Las Vegas, NV, October 2021

AMERICAN GASTROENTEROLOGICAL ASSOCIATION:

AGA Council (2004-2008)
AGA Media Spokesperson (2004-2010)

Clinical Practice Section (1993- present)
 Nominating Committee - Clinical Practice Section (1995-2000)
 Chairman - Clinical Practice Section (1996-8)
 Outcomes research section abstract committee for Digestive Diseases Week (1997)
 GERD treatment abstract selection committee (2001)
 DDW Program Development Committee (2000, 2001, 2002)
 Committee Chairman - Clinical Practice Section (2003-4)
 Vice Chair – Clinical Practice Section (2004-2006)
 Chair – Clinical Practice Section (2006-8)

EGD Section (1997-present)
H. pylori diagnosis abstract selection committee for DDW (1998-2001),
 Committee Chairman (1999, 2000)
H. pylori resistance abstract selection committee for DDW (2002, 2003)
 Nominating Committee (2001-3)

Section on GI Motility and Nerve-Gut Interactions (1993- present)
 IBS pharmacotherapy abstract selection committee for DDW (2002, 2005-8, 2010)
 Nonulcer dyspepsia: Pathogenesis abstract selection committee for DDW (2003)

Scientific Advisory Board: Digestive Health Initiative Functional GI Disorders Campaign (1998-9)

Online Member Survey Panel (2001-2)

Foundation for Digestive Health and Nutrition
 Public Health Education Steering Committee (2001-4)

Scientific Advisory Board: Irritable Bowel Syndrome Educational Campaign (2004-5)

Course Co-director. Clinical Congress in Gastroenterology. Fort Lauderdale, FL, December 9-11, 2005

Course Co-director. Clinical Congress in Gastroenterology and Hepatology. Las Vegas, NV, January 23-25, 2009

Course Co-director. Freston Conference – “Food at the intersection of gut health and disease”. Chicago, IL, August, 2019

Clinical Practice Update: Role of diet in Irritable Bowel Syndrome, 2021.

AMERICAN NEUROGASTROENTEROLOGY & MOTILITY SOCIETY

ANMS Council (2016-2020)
 Site Director: Clinical Training Program for GI Fellows & Jr Faculty (2007-present)
 Educational Affairs Committee (2015-6)
 Meetings Committee (2017-2020)

AMERICAN SOCIETY OF GASTROINTESTINAL ENDOSCOPY:

Informatics Committee (2001-3)

FUNTIONAL BRAIN GUT RESEARCH GROUP

Elected to FBG council (2003-5)
 Co-chair: 4th Annual Young Investigator’s Conference (March 31, 2006)
 Chair: 5th Annual Young Investigator’s Conference (March 23, 2007)

Chair: Awards Committee (2007-10)

INTERNATIONAL FOUNDATION FOR FUNCTIONAL GI DISORDERS

Vice President (2021-present)

Board of Directors (2020-present)

Scientific Advisor (2017-present)

Advisory Board (2005-present)

Planning Committee – International Symposium on FGIDs (2001- 2012)

ROME FOUNDATION FOR FUNCTIONAL GI DISORDERS

Section on Clinical Trial Design for Rome III consensus guidelines (2004-6)

Section of Bowel Disorders for Rome III consensus guidelines (2004-6)

Rome III slide set Committees

Chair: Management and design of treatment trials (2006-7)

Outcomes/Endpoints in Clinical Trials on FBDs Working Team (2007-8)

Board of Directors (2010-2022)

Strategic Planning Committee (2010)

Rome IV Editorial Board (2011-6)

Chair, Rome IV Launch Committee, Chair (2015-present)

Multi-dimensional Clinical Profile Committee (2011-16)

Section of Bowel Disorders for Rome IV consensus guidelines (2013-16)

Co-chair, Working Group on the role of food in FGIDs (2012-3, 2021-present)

Co-chair, Visiting Professor & Visiting Lecturer Program (2015-2018)

Co-chair, Membership & Rome Fellows Committee (2014-2019)

Rome Foundation Research Institute, Co-director, Clinical Research Core (2018-present)

Rome V Editorial Board (2021-2026)

Section on luminal microenvironment and DGBI, Rome V

Executive Advisory Board: Functional Bowel and Motility Disorders Center, University of North Carolina at Chapel Hill, 2013-2016

Consulting Positions

Consultant

Allakos

Allergan/Abbvie

Alnylam

Arena

Bayer

Biomerica

Cosmo

Gemelli

Ironwood

Nestle

Orphomed

Phathom

Progenity

QoL Medical
Redhill
Ritter
Salix/Valeant Pharmaceuticals
Takeda Pharmaceuticals
Vibrant

Selected Visiting Professorships, Seminars, and Extramural Invited Presentations

Visiting Professorships

1. “Diagnostic strategies for *H. pylori* infection”, “The pathogenesis and management of nonulcer dyspepsia”, Visiting Professor, Hanoi Medical College, Bach Mai Hospital, Hanoi, Vietnam, November 12, 1997.
2. “Techniques to study brain-gut interactions”, Visiting Professor – Northwestern University, Chicago, IL, January 27, 2000.
3. “Brain-Gut Interactions: What we know and how we know it” Visiting Professor – University of North Carolina, Chapel Hill, NC, February 22, 2000.
4. “New insights into the Irritable Bowel Syndrome”, Visiting Professor – Bethesda Naval Hospital, June 14, 2001.
5. “Dyspepsia: A Discussion of Bugs and Drugs”, GI Grand Rounds and Visiting Professor – University of Alabama – Birmingham, September 6, 2001.
6. “Management of *H. pylori* infection”, Visiting Professor University of Arizona, Tucson, AZ. April 4, 2002.
7. “Appropriate diagnosis and treatment of *H. pylori* infection”, Visiting Professor, University of Arizona Medical Center, Tucson, AZ, January 30-31, 2003.
8. “Update on the management of IBS”, Visiting Professor, University of Kansas Medical Center, Kansas City, Kansas, April 22, 2003.
9. “Update on IBS”, Visiting Professor, Wake Forest Medical Center, Winston-Salem, NC, June 6, 2003.
10. “The diagnosis and treatment of IBS: What does the evidence say?” Visiting Professor, USC Medical Center, Los Angeles, CA, July 18, 2003.
11. “Update on the management of IBS”, GI Grand Rounds and Visiting Professor, Yale University, New Haven, CT, September 9, 2003.
12. “NSAIDs and the GI tract”, Emerging Diagnostic and Therapeutic Options in GI Disorders: An Update, Visiting Professor, Wake Forest University School of Medicine, Winston-Salem, NC, September 27, 2003.
13. “Irritable Bowel Syndrome: Emerging concepts and promising therapies”, Visiting Professor – Henry Ford Health System, Detroit, MI, May 13, 2004.
14. “Irritable Bowel Syndrome: Emerging concepts and promising therapies” Visiting Professor - Bethesda Naval Hospital, Bethesda, MD, June 3, 2004.
15. “Emerging therapies for functional dyspepsia”, Visiting Professor - Bayview Medical Center, Johns Hopkins University, Baltimore, MD, June 4, 2004.
16. “Evidence-based update on the irritable bowel syndrome”, Visiting Professor – Emory University School of Medicine, Atlanta, GA, June 28, 2004.

17. “Management of functional dyspepsia” GI Grand Rounds and “Evidence-based update on the irritable bowel syndrome” Internal Medicine Grand Rounds, Visiting Professor, University of Cincinnati, Cincinnati, OH, March 23, 2005.
18. “New insights into the evaluation and treatment of functional dyspepsia”, Visiting Professor – Division of Gastroenterology, University of Illinois, Chicago, IL, April 27, 2005.
19. “An evidence-based update on the management of chronic constipation”, Visiting Professor – Division of Gastroenterology, University of Indiana, Indianapolis, IN, May 9, 2005.
20. “Management of Functional Dyspepsia”, Visiting Professor – Division of Gastroenterology, University of Oklahoma, Oklahoma City, OK, June 8, 2005.
21. “GERD, Erosive Esophagitis, and NERD: the same or different diseases?” and Visiting Professor – Division of Gastroenterology, State University of New York at Buffalo, Buffalo, NY, June 23, 2005.
22. “Heartburn in 2005: Do findings at endoscopy really matter?” and Visiting Professor – Division of Gastroenterology, McMaster University, Hamilton, Ontario, September 21, 2005.
23. “Update on dyspepsia and functional dyspepsia” and Visiting Professor – Division of Gastroenterology, University of Alberta, Edmonton, Alberta, October 11, 2005.
24. “GERD, NERD and functional heartburn: Separate diseases or shades of gray?” and Visiting Professor – Division of Gastroenterology, University of Calgary, Calgary, October 12, 2005.
25. “Management of GERD for primary care physicians”, “The irritable bowel syndrome in 2006”, “Evidence based update on the management of Functional Dyspepsia”, Pinit Kullavanijaya Visiting Professor, Chulalongkorn University, Bangkok, Thailand, March 13-15, 2006.
26. “IBS: How new insights into pathogenesis are transforming treatment paradigms”, Visiting Professor, Baylor Hospital, Dallas, TX, March 28, 2006.
27. “Evidence based update on the diagnosis and treatment of the irritable bowel syndrome”, Visiting Professor, Metro Health Center, Cleveland, OH, April 20, 2006.
28. “The evolving management of functional dyspepsia”, Visiting Professor, Functional Frontiers Conference – Case Western Reserve, Cleveland, OH, April 20, 2006.
29. “Management of chronic constipation in 2006” Visiting Professor, Cleveland Clinic Foundation, Cleveland, OH, April 21, 2006.
30. “IBS: where we are and where we are going” Visiting Professor, Emory University School of Medicine, Atlanta, GA, May 14, 2007.
31. “IBS: what’s new in 2007” Visiting Professor, University of Colorado, Denver, CO, June 1, 2007.
32. “Management of IBS in 2008” Visiting Professor, University of Rochester, NY, August 11-12, 2008.
33. “GERD: New concepts and clinical practice” Gastroenterology Society of Taiwan, Taipei, Taiwan, March 15, 2009.
34. “Benefits and Harms of Acid Suppressive Therapy” Visiting Professor, Kaoshiung Medical University Hospital, Kaoshiung, Taiwan, March 16, 2009.
35. “Management of *H. pylori* infection in 2009” Visiting Professor, Medical University of South Carolina, Charleston, SC, June 22, 2009.

36. “Medical management of the Irritable Bowel Syndrome” Visiting Professor, Cleveland Clinic Foundation, Cleveland, OH, June 26, 2009.
37. “Evidence-based management of Chronic Constipation” Visiting Professor, Vanderbilt University Medical Center – Division of Gastroenterology, Nashville, TN, September 24, 2009.
38. “Diagnosis of IBS: Evolution of a work in progress” Visiting Professor, UCLA Medical Center – Division of Gastroenterology, Los Angeles, CA, October 15-16, 2009.
39. “Management of chronic constipation in 2009 and beyond” Visiting Professor, Medical College of Georgia, Athens, GA, November 18, 2009.
40. “Management of ERD and NERD, are they different?”, “Overlap between GERD and IBS” and “Management of Barrett’s Esophagus” Visiting Professor, Chulalongkorn University, Bangkok, Thailand, May 28-29, 2010.
41. “Peering into the crystal ball at the future of IBS” Visiting Scholars Program, Takeda Pharmaceuticals Headquarters, Chicago, IL, September 22, 2010.
42. “Erosive vs. Nonerosive GERD: The many faces of heartburn” Visiting Professor, Taipei Mackay Memorial University Hospital, Taipei, Taiwan, October 1, 2010.
43. “The benefits and risks of long-term PPI therapy” Visiting Professor, Chang Gung Memorial University Hospital, Linkou, Taiwan, October 2, 2010.
44. “Deciding who and who should not be treated with PPI therapy” Visiting Professor, Taipei Veterans General Hospital, Taipei, Taiwan, October 4, 2010.
45. “IBS in 2010 and beyond” Visiting Professor, Northwestern University, Chicago, IL, November 4, 2010.
46. “Food – the Forgotten Factor in IBS”, First Annual Lawrence Brandt Lecture, Montefiore Medical Center, Bronx, NY, April 14, 2011.
47. “Dyssynergic Defecation: An underappreciated cause of chronic constipation”, Visiting Professor, Montefiore Medical Center, Bronx, NY, April 14, 2011.
48. “Role of the Gut Microbiome and SIBO in IBS” Visiting Professor, Chinese PLA General Hospital, Beijing, China, May 16, 2011.
49. “Emerging treatment strategies for IBS”, Hugh Butt Visiting Professor, Mayo Clinic, Rochester, MN, October 7, 2011.
50. “Emerging medical therapies for the irritable bowel syndrome” Keio University Medical School, Tokyo, Japan, November 11, 2011
51. “Diet and IBS: Food for thought...” and “Evidence-based management of irritable bowel syndrome” H. Joyce Miller Visiting Professor, University of Iowa, Iowa City, IA, March 8, 2012.
52. “Food: the forgotten factor in IBS” Visiting Professor, University of Washington, Seattle, WA, May 31-June 1, 2012.
53. “Emerging role of food in the management of the Irritable Bowel Syndrome” Visiting Professor, Indiana University, Indianapolis, IN, August 27, 2012.
54. “The emerging role of the gut microbiome in the pathogenesis and treatment of IBS” Visiting Professor, Medical GI Grand Rounds. Mayo Clinic, Scottsdale, AZ, March 15, 2013.
55. “Dietary management of IBS: Food for thought” and “Medical Management of IBS” Visiting Professor, Baylor Medical College, Dallas, TX, April 8, 2014.
56. “Translating pathophysiologic insights to actionable management strategies for IBS” Sundar Mehta Visiting Professor, University of Colorado, Denver, CO, April 24-25, 2014.

57. “Diet, Bugs, and Drugs: The evolving management of IBS” Visiting Professor, University of Minnesota, Minneapolis, MN, August 14, 2014.
58. “The emerging role of diet in the pathogenesis and treatment of IBS” Visiting Professor, University of Kentucky, Lexington, KY, April 23-24, 2015.
59. “The role of the gut microbiome in the pathogenesis and treatment of IBS” David M. Bull Visiting Professor: Wayne State University, Detroit, MI, June 1, 2015.
60. “Diet or Deity – Is the Juice Worth the Squeeze for IBS?” and “How Health Information Technology will Change Clinical Medicine”, ACG Visiting Professor, McMaster University, Hamilton, Canada, June 24-25, 2015.
61. “Diet and IBS: Food for Thought” “Management of IBS in 2015”. Rome Foundation Visiting Professor, Cleveland Clinic, Cleveland, OH, September 10-11, 2015.
62. “Food – at the intersection of health and disease” Rome Foundation Visiting Professor, Brown University, November 12, 2015.
63. “The emerging role of food in the pathogenesis and treatment of IBS”. CAG Visiting Professor, Division of Gastroenterology, University of Calgary, Calgary, Canada, January 15, 2016.
64. “Food: at the intersection of disease and wellness” and “Update on the management of IBS” Advocate Lutheran General Health System, Park Ridge, IL, March 23, 2016.
65. “The emerging role of diet and lifestyle in the pathogenesis and treatment of IBS” Division of Gastroenterology, Thomas Jefferson Medical Center, Philadelphia, PA, April 20, 2016.
66. “How diet is changing the treatment paradigm for Irritable Bowel Syndrome”. University of Wisconsin, Madison, WI, June 7, 2016.
67. “Management of Irritable Bowel Syndrome”, “How health information technology will transform Gastroenterology”, “Diagnosis of IBS in the Rome IV era”, “The University of Michigan experience with the low FODAMP diet for IBS” Alfred Hospital WTMS Visiting Professor, Monash University, Melbourne, Australia, July 11-22, 2016.
68. “Food as Medicine: The changing face of GI Nutrition” Rome Foundation Visiting Professor: University of Alabama Birmingham, Birmingham, AL, September 26, 2016.
69. “Food: at the intersection of wellness and GI disease” Visiting Professor: University of Southern Alabama, Mobile, AL, September 28-29, 2016.
70. “The Emerging Role of Diet in the Pathogenesis and Management of IBS”, “Case presentations of patients with persistent *H. pylori* infection”, Rome Foundation Visiting Professor, Mayo Clinic, Jacksonville, FLA, January 6, 2017.
71. “Food – the main course to digestive health and disease”, “Update on the management of *H. pylori* infection”, Rome Foundation Visiting Professor, Medical College of Georgia, Augusta, GA, April 17, 2017.
72. “How do we apply Rome IV in everyday practice?”, “When should we stop studying a patient with IBS Utility of biomarker in IBS”, “State of the Art: Management of IBS”, “Interactive Clinical Case: Panel Discussion”. Auditorio Universidad Catolica Argentina, Puerto Madero, Argentina, April 20-21, 2017.
73. “The role of diet and nutrition in the pathogenesis and treatment of IBS”, Visiting Professor, St Louis University Medical Center, St. Louis, MO, September 8, 2017.
74. “Role of diet in the pathogenesis and treatment of IBS” Visiting Professor, University of Virginia, Charlottesville, April 6, 2018.
75. “Food for life – the role of diet in IBS” Visiting Professor, Division of Gastroenterology & Hepatology, Weill Cornell Medical Center, New York, NY, May 24, 2018.

76. “The evidence supporting diet therapies for IBS” Visiting Professor, Cook County Health and Hospitals System, Chicago, IL, June 15, 2018.
77. “Food – at the crossroads of GI wellness and illness” Visiting Professor, Mayo Clinic, Scottsdale, AZ, November 15, 2018.
78. “Nonpharmacological therapies for IBS” Visiting Professor, Brook Army Medical Center, San Antonio, TX, April 5, 2019.
79. “Integrated care model for IBS” Visiting Professor, University of Washington, Seattle, WA, April 12, 2019.
80. “Holistic management of IBS” Kirkendall Visiting Professor, University of Texas Houston, Houston, TX, April 18, 2019.
81. “Management of IBS: Thinking Outside of the Colon” Visiting Professor, Tulane University, New Orleans, LA, May 8, 2019.
82. “Management of IBS: Thinking Outside of the Colon” ACG Edgar Achkar Visiting Professor, University of Colorado, Denver, CO, June 7, 2019.
83. “Embracing Change: The key to a long, happy career in gastroenterology” Fellows Graduation Ceremony, Loyola University Medical Center, Chicago, IL, June 14, 2019.
84. “Small intestinal bacterial overgrowth”, “Exclusion diets for IBS”, “Patient-centered approach to IBS” Visiting Professor, University of Newcastle, Newcastle, AU, July 24-26, 2019.
85. “Difficult motility cases” Visiting Professor, Friendship Hospital, Beijing, China, November 5, 2019.
86. “Update on Irritable Bowel Syndrome” Visiting Professor, University of Arizona, Tucson, AZ, March 5-6, 2020.
87. “Medical therapies for Irritable Bowel Syndrome”, “Diet and Behavioral Therapies for IBS” Robert Fischer Visiting Professor, Temple University, Philadelphia, PA, March 11, 2020.
88. “Evidence-based update on managing *H. pylori* infection” and “Integrated care of IBS: Who, Why, How?” Medical University of South Carolina, Charleston, SC, November 3-4, 2021.
89. “Non-pharmacological therapies for IBS” Visiting Professor, University of Rochester, Rochester, NY, March 15-16, 2022.
90. “Integrated Care: The road to personalized healthcare” NYU Langone Medical Center, Visiting Professor, New York, NY, April 20, 2022.
91. “Why is integrated care a better way to manage IBS?” Visiting Professor, Marshall University Medical Center, Charleston, WV, June 13-14, 2022.

Selected Extramural Invited Presentations (since 2001)

1. “Management of the Irritable Bowel Syndrome” and “Review of Celiac Sprue” The Third Annual GI and Hepatology Update, University of Pennsylvania, Philadelphia, PA. September 20, 2001.
2. “Expressions of IBS: Psychosocial, visceral and other symptoms” Strategies in the treatment of IBS: From models to management. Annual Meeting of the American College of Gastroenterology, Las Vegas, NV. October 19, 2001.

3. “Non-erosive esophageal disorders: Acid reflux or altered visceral perception” Symposium on esophageal sensation. Satellite Meeting at the Annual Meeting of the American College of Gastroenterology, Las Vegas, NV. October 22, 2001.
4. “Ignore *H. pylori* status: treat with a PPI or other therapies” Weighing the Odds in Acid-related Disorders. Satellite Meeting at the Annual Meeting of the American College of Gastroenterology, Las Vegas, NV. October 23, 2001.
5. “Diagnosis of *H. pylori* infection” and “Management of Dyspepsia” GI Update, University of Cincinnati, Cincinnati, OH. November 9, 2001.
6. “Strategies to reduce the impact of NSAID-induced GI toxicity” American Society of Hospital Pharmacists Mid-year Clinical Meeting, New Orleans, LA December 5, 2001.
7. Planning committee for State Medical Society Meetings “Update on GERD and Dyspepsia” Beam Institute for Continuing Medical Education, New York, NY, 2002.
8. “GI Wrap-up 2001” Participant and **Course Co-director**, Captiva Island, FLA, February 8-10, 2002.
9. “Diagnosis of *H. pylori*: State of the Art Talk”, GI Grand Rounds, Henry Ford Health System, March 19, 2002.
10. “Strategies to reduce GI toxicity associated with NSAIDs and Aspirin”, Division of Rheumatology, University of Arizona, Tucson, AZ, April 5, 2002.
11. “Endoscopy-negative reflux disease is a functional disorder and should be treated appropriately” Satellite symposium at Digestive Diseases Week, San Francisco, CA, May 19, 2002.
12. “Meet the Professor – PUD” Digestive Diseases Week, San Francisco, CA, May 20, 2002.
13. Moderator, AGA clinical topic forum: “Management of the Irritable Bowel Syndrome” Digestive Diseases Week, San Francisco, CA, May 22, 2002.
14. “Strategies to reduce ‘Coxicity’ associated with NSAIDs and Aspirin”, Medical Grand Rounds, University of California - Davis, Sacramento, CA, May 23, 2002.
15. “Non-erosive esophageal disorders”, “NSAID-related mucosal injury”, “Current diagnosis of *H. pylori*” Update on Esophageal, Gastric and Swallowing Disorders for Primary Care. Orlando Regional Medical Center/University of South Florida, Orlando, CA, June 8, 2002.
16. Participant and **Course Co-director** for Update in Office Gastroenterology, Grand Traverse Resort, MI, August 18-21, 2002.
17. “Motility and IBS” Clinical Advances in Gastroenterology (Audio Tape series of the American College of Gastroenterology), August 2002.
18. Participant and **Course Co-director** for the Annual American College of Physicians - Michigan Chapter Scientific Meeting, Acme, MI, September 12-15, 2002.
19. “Management strategies for NSAID-associated peptic ulcer disease” Castle Medical Center, Honolulu, HI, September 26, 2002.
20. “Management of *H. pylori* infection” and “Controversies on COXicity” Gastroenterology Update, Queen’s Medical Center, Honolulu, HI, September 27-28, 2002.
21. Faculty participant “International clinical forum in gastroenterology and hepatology” Heidelberg, Germany, October 14, 2002.
22. “Current treatments of IBS and constipation” Clinical Case Challenges in Irritable Bowel Syndrome, Satellite symposium at the Meeting of the American College of Gastroenterology, Seattle, WA, October 22, 2002.
23. “Beyond fiber – where will IBS go in the next 10 years” Meeting of the American College of Gastroenterology, Seattle, WA, October 23, 2002.

24. **Program Co-director** – “Insights and Issues in the Management of Functional GI Disorders”, UM sponsored CME lecture series from October 26 to December 7, 2002.
25. “The long-term management of GERD: PPIs vs. Endoscopic therapies vs. Surgery” Pri-Med South, Broward County Convention Center, Ft. Lauderdale, Fla, February 14, 2003.
26. **Course Director** and Moderator for “First Annual Evening with the Experts 2003: New Frontiers in GERD: Are the new diagnostic tests and endoscopic therapies ready for prime time?” sponsored by the University of Michigan Medical School, Dearborn, MI, February 17, 2003.
27. “GI/Liver Wrap-up 2002” Participant and **Course Co-director**, Naples, FLA, February 28-March 2, 2003.
28. “Case studies and diagnostic strategies – upper GI” and planning committee: 5th International Symposium on Functional GI Disorders, Milwaukee, MI, April 4-6, 2003.
29. “IBS: Evidence-based approach to treatment” AGA Spring Postgraduate Course, Orlando, FL, May 18, 2003.
30. “What is our current understanding of the pathophysiology of IBS” **Program chair** and speaker at the Satellite symposium “Translating science into clinical outcomes: New paradigms in the management of the IBS patient” at Digestive Diseases Week, Orlando, May 18, 2003.
31. “Kill the Bug” in the Clinical Symposium “Dyspepsia management: Bugs, Drugs, or Padded Cells” Digestive Diseases Week, Orlando, FL, May 20, 2003.
32. Moderator, AGA clinical topic forum: “Controversies in *H. pylori*” Digestive Diseases Week, Orlando, FL, May 21, 2003.
33. “Management of Dyspepsia and NUD: the US Perspective” Transatlantic Dialogue: Dichotomies and directions in acid-related disorders, Orlando, FL, May 22-23, 2003.
34. “NSAID related GI toxicity: Does an aspirin a day keep the doctor away?” University of Colorado Medical Center, Denver, CO, July 17, 2003.
35. “NSAID-induced gastropathy” Florida Academy of Family Physicians, Orlando, FL, July 27, 2003.
36. “*H. pylori* for the primary care physician”, “Strategies to reduce NSAID associated GI toxicity”, “Update on the Irritable Bowel Syndrome”, Summer Internal Medicine Update, Mackinac Island, MI, August 1-3, 2003.
37. Participant and **Course co-director**, Update in Office Gastroenterology, University of Michigan, Bellaire, MI August 15-17, 2003.
38. Participant and **Course co-director**, Annual American College of Physicians - Michigan Chapter Scientific Meeting, Acme, MI, September 18-21, 2003.
39. “Evidence-based appraisal of the role of serotonergic agents in the treatment of IBS”, Breakfast symposium “Coping with the Complexities of IBS” at the meeting of the American College of Gastroenterology, Baltimore, MD, October 12, 2003.
40. “Alosetron”, Breakfast symposium “Irritable Bowel Syndrome – the world of new drugs” at the meeting of the American College of Gastroenterology, Baltimore, MD, October 14, 2003.
41. “Serotonergic modulation: IBS and beyond”, Satellite symposium “The Challenge of Irritable Bowel Syndrome in clinical practice: from science to solutions” at the meeting of the American College of Gastroenterology, Baltimore, MD, October 14, 2003.

42. "Diagnosis and management of IBS" and "Dyspepsia: Bugs or Drugs?" Meeting of the American College of Physicians: Southern California-Region III, Palm Springs, CA, October 25-26, 2003.
43. "Dyspepsia: Scopes, Bugs or Drugs?", Harvard CME GI Motility and IBS Symposium, Beth Israel Deaconess Medical Center, Boston, MA, October 31-November 1, 2003.
44. "Management of *H. pylori*: A clinician's guide", Advances in Gastroenterology, University of Tennessee, Chattanooga, TN, November 8, 2003.
45. "Non-erosive esophageal disorders", "*H. pylori* and peptic ulcer disease", "GI manifestations of NSAIDs", "Management of uninvestigated dyspepsia", Fifth Annual Update for Clinicians, University of South Florida, Orlando, FL, December 4-6, 2003.
46. "Traditional and emerging therapies for functional dyspepsia", New Frontiers in GERD and Dyspepsia, University of Arizona, Tempe, AZ, January 25-26, 2004.
47. Participant and **Course Director** for "*Helicobacter pylori*/PUD" GI/Liver Wrap-Up, University of Michigan, Naples, FL, February 27-29, 2004. Audio Digest Selection, volume 18, issue 12, 2004.
48. "Constipation: chronic disorder or irritable bowel?" Pri-Med Update, Rosemont, IL, March 11, 2004.
49. "Current and future management of uninvestigated and functional dyspepsia" Division of Gastroenterology, University of Montreal, Montreal, Canada, April 14, 2004.
50. "Evidence-based update on the management of the irritable bowel syndrome" Division of Gastroenterology, McGill University, Montreal, Canada, April 14, 2004.
51. "Nonerosive esophageal disorders: All that's heartburn isn't GERD" Arapahoe Gastroenterology Conference, Denver, CO, April 23, 2004.
52. "Treatment options for ENRD: PPIs vs other options" Satellite symposium "Building best practices in tough to treat patients" at Digestive Diseases Week 2004, New Orleans, LA, May 16, 2004.
53. "Emerging treatments for the Irritable Bowel Syndrome" as part of the AGA sponsored symposium: Progress in IBS Management: Translating Science into Clinical Practice. Digestive Diseases Week 2004, New Orleans, LA, May 17, 2004.
54. "Salvage therapies for *H. pylori* infection" as part of the Research Forum "*H. pylori* antimicrobial resistance and rescue" Digestive Diseases Week 2004, New Orleans, LA, May 18, 2004.
55. "Endoscopy negative reflux disease: definitions, epidemiology, and clinical impact" as part of the Clinical Symposium "Nonerosive esophageal disorders: all that's heartburn isn't GERD" Digestive Diseases Week 2004, New Orleans, LA, May 18, 2004.
56. "Dyspepsia: pH, Hp or alternative approaches?" Transatlantic Pacific Summit Meeting, New Orleans, LA, May 19-21, 2004.
57. "Approach to functional dyspepsia" Second annual solutions for common GI motility problems, University of Louisville, Louisville, KY, June 5, 2004.
58. "Irritable Bowel Syndrome: Emerging concepts and promising therapies" Medical Grand Rounds, Butterworth Hospital, Grand Rapids, MI, June 17, 2004.
59. Participant and **Course Director** for "*Peptic Ulcer Disease*" Northern Michigan DDW Wrap-Up, University of Michigan, Bay Harbor, MI, July 17-18, 2004.
60. "IBS case presentations" 13th Biennial American Motility Society Meeting, Mayo Clinic, Rochester, MN, September 9-12, 2004.

61. “Pharmacological advances in the management of functional GI disorders” Texas Society for Gastroenterology and Endoscopy and the American College of Gastroenterology: 29th Annual Texas Program, Dallas, TX, September 17-19, 2004.
62. “Current understanding and management of IBS” 1st Annual Michigan GI Society Symposium, Thompsonville, MI, October 1-3, 2004.
63. “Pharmacological therapy of functional bowel and GI motility disorders” American College of Gastroenterology Pharmacology Course, Orlando, FL, October 29, 2004.
64. Presenter at the American College of Gastroenterology ABIM Board Recertification Course, Orlando, FL, October 29, 2004.
65. “Pharmacological therapies for IBS and motility disorders: Now and the future” American College of Gastroenterology Annual Postgraduate Course, Orlando, FL, October 31, 2004.
66. Panelist for “Irritable Bowel Syndrome: Evolving perspectives and treatment strategies” Satellite Symposium at the Annual meeting of the American College of Gastroenterology, Orlando, FL, October 31, 2004.
67. Moderator for “Case challenges in functional bowel disease: What to do when standard treatment fails” Annual meeting of the American College of Gastroenterology, Orlando, FL, November 2, 2004.
68. “Emerging treatments for the Irritable Bowel Syndrome” as part of the AGA sponsored symposium: Progress in IBS Management: Translating Science into Clinical Practice, Los Angeles, CA, November 13, 2004.
69. “NSAID associated GI toxicity: Focus on aspirin and the COXIBs” Meeting of the Phoenix GI Society, Scottsdale, AZ, November 17, 2004.
70. “Update on the management of *H. pylori* infection for 2004” GI Grand Rounds – Mayo Clinic Scottsdale, Scottsdale, AZ, November 18, 2004.
71. “Clinical approach to chronic constipation” and “Irritable bowel syndrome” 11th Symposium on Neurogastroenterology, University of Iowa, Fort Myers, FL, February 4-6, 2005.
72. Participant and **Course Director** for “*Helicobacter pylori*/PUD” GI/Liver Wrap-Up, University of Michigan, Naples, FL, February 25-27, 2005.
73. “Obtaining industry-sponsored research funding” 3rd Annual Functional GI Disorders Young Investigator’s Forum. Functional Brain-Gut Research Group, Del Mar, CA, February 18-20, 2005.
74. “Traditional medical therapies for the irritable bowel syndrome” and Steering Committee for the 6th International Symposium on Functional GI Disorders, University of Wisconsin Medical School, Milwaukee, WI, April 8-10, 2005.
75. “Translating pathophysiology to novel therapies for the irritable bowel syndrome” Annual Spring Symposium of the Korean Society of Neurogastroenterology and Motility, Seoul, Korea, April 23, 2005.
76. “An evidence-based approach to dyspepsia” AGA 2005 Spring Postgraduate Course, Chicago, IL, May 14, 2005.
77. Participant in “GI Motility and Sensory Disorders...making sense in clinical practice” Satellite symposium at DDW 2005, May 15, 2005.
78. Chair for the Clinical Symposium “Controversies in the management of IBS”, Digestive Diseases Week 2005, May 15, 2005.
79. Co-chair for the “Distinguished Abstract Plenary Session” for the Clinical Practice Section of the AGA, Digestive Diseases Week 2005, May 16, 2005.

80. Co-chair for the Research Fora “Pharmacotherapeutics in Functional GI Disorders”, Digestive Diseases Week 2005, May 17, 2005.
81. “Functional Disease States” as part of the Clinical Symposium “Dyspepsia and its many causes” Digestive Diseases Week 2005, May 17, 2005.
82. “Diagnosis and treatment of chronic constipation” Medical Grand Rounds, Butterworth Hospital, Grand Rapids, MI, June 2, 2005.
83. “Management of chronic constipation”, “Peptic ulcer disease update”, “Uninvestigated dyspepsia: Bugs or Drugs” 41st Annual Northern Michigan Summer Conference: An update on common clinical concerns in primary care. Department of Family Medicine, University of Michigan, Bellaire, MI, June 15-16, 2005.
84. “New insights into functional dyspepsia”, “Salvage therapies for *H. pylori* infection”, “Emerging therapies for the irritable bowel syndrome” Clinical Gastroenterology and Videoendoscopy, University of South Florida Health Sciences Center, Edinburgh, Scotland, August 8-10, 2005.
85. Participant and **Course Director** for “*Peptic Ulcer Disease*” Northern Michigan DDW Wrap-Up, University of Michigan, Mackinac Island, MI, August 13-14, 2005.
86. “Update in the management of the irritable bowel syndrome” Florida GI Society and the American College of Gastroenterology, Naples, FL, September 11, 2005.
87. “NSAID-induced GI toxicity: Focus on aspirin and the COXIBs” Medical Grand Rounds – York Central Hospital, Toronto, Ontario, September 22, 2005.
88. “Evidence-based update on the management of chronic constipation” Edmonton GI Journal Club, Edmonton, Alberta, October 11, 2005.
89. Participant and **Course Director**, “Board Recertification Course for Gastroenterology” at the Annual Meeting of the American College of Gastroenterology, Honolulu, HI, October 28, 2005.
90. “Functional dyspepsia: looking beyond bugs and drugs” Postgraduate Course at the Annual Meeting of the American College of Gastroenterology, Honolulu, HI, October 29, 2005.
91. “Antidepressant therapy for functional dyspepsia?” Simultaneous Session at the Annual Meeting of the American College of Gastroenterology, Honolulu, HI, October 29, 2005.
92. “A case of irritable bowel syndrome” as part of the satellite symposium - Lessons from Cases: Clinical perspectives in GI motility and sensory disorders at the Annual Meeting of the American College of Gastroenterology, Honolulu, HI, November 1, 2005.
93. “Diagnosis of the Irritable Bowel Syndrome”, Moderator – Controversies in IBS section and **Course Co-Director**, Clinical Congress of Gastroenterology, American Gastroenterological Association, Ft. Lauderdale, FL, December 9-11, 2005.
94. Participant and **Course Director** for “*Helicobacter pylori*/PUD” GI/Liver Wrap-Up, University of Michigan, Naples, FL, February 24-26, 2006.
95. **Course Co-Director** and Participant, Functional Brain-Gut Research Group’s Young Investigator’s Forum, Miami, FL, March 31-April 2, 2006.
96. “Emerging therapies for IBS” as part of the Clinical Symposium “Emerging GI therapies” at Digestive Diseases Week, Los Angeles, CA, May 21, 2006.
97. Faculty Chair: Chronic Constipation: Translating novel mechanisms of action into innovative therapeutic interventions. Satellite Symposium at Digestive Diseases Week 06, Los Angeles, CA, May 21, 2006.
98. Program Moderator: Bacterial Overgrowth and IBS. Satellite Symposium at Digestive Diseases Week 06, Los Angeles, CA, May 21, 2006.

99. Co-chair for the Clinical Symposia, “Controversies in IBS”. Digestive Diseases Week 06, Los Angeles, CA, May 22, 2006.
100. Co-chair for the Distinguished Abstract Plenary of the Clinical Practice Section, AGA. Digestive Diseases Week 06, Los Angeles, CA, May 22, 2006.
101. “Medical management of functional dyspepsia” as part of the Satellite Symposium at Digestive Diseases Week 06 - Fast Track Solutions to GI Motility and Sensory Disorders, Los Angeles, CA, May 22, 2006.
102. “The irritable bowel syndrome” - DDW Review. University of Kansas, Kansas City, Kansas, June 7, 2006.
103. “Functional Dyspepsia: Moving beyond bugs and drugs”, GI Grand Rounds, Columbia University, New York City, NY, June 19, 2006.
104. Participant and **Course Director** for “*Peptic Ulcer Disease*” Northern Michigan DDW Wrap-Up, University of Michigan, Bay Harbor, MI, August 12-13, 2006.
105. “Update on the management of chronic constipation” Medical Grand Rounds, Akron General Hospital, Akron, OH, September 13, 2006.
106. “Current and emerging therapies for constipation” Satellite Symposium at the 2006 Joint International Neurogastroenterology and Motility Meeting, Boston, MA, September 16, 2006.
107. Faculty participant for the “Board Recertification Course for Gastroenterology” at the Annual Meeting of the American College of Gastroenterology, Las Vegas, NV, October 20, 2006.
108. “IBS: How new insights into pathogenesis are transforming treatment paradigms” Toledo Gut Club, Toledo, OH, November 9, 2006.
109. “Motility/Functional Bowel Disease Update” GI Grand Rounds, University of Michigan, November 21, 2006.
110. “Peptic ulcer disease update” GI Grand Rounds, University of Michigan, December 19, 2006.
111. Participant and **Course Director** for “*Motility and Functional Bowel Disorders*” GI/Liver Wrap-Up, University of Michigan, Captiva Island, FL, March 2-4, 2007.
112. “Design of treatment trials for functional bowel disorders” Scripps Clinic, La Jolla, CA, March 23, 2007.
113. **Course Director** and Participant, Functional Brain-Gut Research Group’s Young Investigator’s Forum, Del Mar, CA, March 23-25, 2007.
114. “Traditional therapies for IBS” and “Receptor acting agents for IBS”, Meeting of the International Foundation for the Functional GI Disorders, Milwaukee, WI, April 14-15, 2007.
115. “Evidence-based update on the management of IBS” Good Samaritan Hospital and Phoenix VA Medical Center, Phoenix, AZ, April 27, 2007.
116. “The global GERD epidemic” and “*H. pylori*: what are the new must-know points?” as part of the Satellite Symposium at DDW 07, “Expert insights in acid-related disorders” Washington DC, May 21, 2007.
117. Co-chair for the Late-breaking abstract research forum of the AGA. Digestive Diseases Week 07, Los Angeles, CA, May 22, 2007.
118. Co-chair for the Distinguished Abstract Plenary of the Clinical Practice Section, AGA. Digestive Diseases Week 07, Los Angeles, CA, May 22, 2007.

119. “Emerging medical therapies for chronic constipation” Digestive Diseases Week 2007, Washington, DC, May 22, 2007.
120. “Pharmacological Treatment of the Irritable Bowel Syndrome” for Clinical Advances in Gastroenterology, American College of Gastroenterology, Oakstone Publishing, June 2007.
121. **Course Co-director** and Participant for “Diagnosis and treatment of IBS”, Midwest Regional Postgraduate Course of the American College of Gastroenterology, Chicago, IL, June 29-July 1, 2007.
122. Participant and **Course Director** for “*Peptic Ulcer Disease*” Northern Michigan DDW Wrap-Up, University of Michigan, Mackinac Island, MI, July 27-29, 2007.
123. “Update on IBS for 2007” and “Evidence based approach to chronic constipation” Memorial Health University Medical Center, Savannah, GA, September 28, 2007.
124. “Management of Functional Dyspepsia in 2007” Georgia Gastroenterology and Endoscopy Society Meeting, Atlanta, GA, September 29, 2007.
125. “Management of the Irritable Bowel Syndrome” Pharmacology Course, Annual Meeting of the American College of Gastroenterology, Philadelphia, PA, October 12, 2007.
126. Moderator and Presenter “Board Recertification Course for Gastroenterology” at the Annual Meeting of the American College of Gastroenterology, Philadelphia, PA, October 12, 2007.
127. “Developing Therapy for Chronic Constipation” Postgraduate Course at the Annual Meeting of the American College of Gastroenterology, Philadelphia, PA, October 14, 2007.
128. “Best of DDW 07: Upper GI Disorders” United European Gastroenterology Week, Paris, France, October 30, 2007.
129. “Functional Dyspepsia: Diagnosis and treatment”, “The IBS patient in the Office” La Semana Nacional De Gastroenterologia, Asociacion Mexicana De Gastroenterologia, Leon, Guanajuato, November 19, 2007.
130. “The diagnosis and treatment of IBS in 2008”, Clark GI Society, Washington DC, February 7, 2008.
131. Participant and **Course Director** for “*Peptic ulcer disease and upper GI bleeding*” GI/Liver Wrap-Up, University of Michigan, Captiva Island, FL, February 22-24, 2008.
132. “Irritable Bowel Syndrome: Creative Offerings” 12th Annual Common Problems in Office Practice, Department of Internal Medicine, University of Michigan Health System, Plymouth, MI, March 15, 2008
133. “Update on Functional Dyspepsia” Northwest GI Society, Seattle, WA, March 20, 2008.
134. “IBS: Translating recent scientific advances to management solutions” University of Washington, Seattle, WA, March 21, 2008.
135. “The American College of Gastroenterology’s *H. pylori* guideline” for Clinical Advances in Gastroenterology, American College of Gastroenterology, Oakstone Publishing, April 2008.
136. “Functional Dyspepsia” Luncheon Learning Session, AGA Postgraduate Course, San Diego, CA, May 17-18, 2008.
137. “Irritable Bowel Syndrome” Clinical Challenge Session, AGA Postgraduate Course, San Diego, CA, May 17-18, 2008.
138. “Emerging therapies for functional bowel disorders”, Digestive Diseases Week, San Diego, CA, May 19, 2008.
139. Co-chair for the Late-breaking abstract research forum of the AGA. Digestive Diseases Week 08, Los Angeles, CA, May 20, 2008.

140. Co-chair for the Distinguished Abstract Plenary of the Clinical Practice Section, AGA. Digestive Diseases Week 08, Los Angeles, CA, May 20, 2008.
141. “Management of IBS in 2008” International Meeting of Motility and Neurogastroenterology, Wuhan, China, June 21, 2008.
142. “Gastric Disorders” as part of *Highlights of Digestive Diseases Week 2008*, Northwestern University, Chicago, IL, June 28, 2008.
143. Participant and **Course Director** for “*Peptic Ulcer Disease and Upper GI Bleeding*” Northern Michigan DDW Wrap-Up, University of Michigan, Bay Harbor, MI, July 18-20, 2008.
144. “Update on *H. pylori* infection: What are the remaining issues in 2008?” Meeting of the San Diego GI Society, San Diego, CA, August 20, 2008.
145. “Management of IBS in 2008” Medical Grand Rounds, East Virginia Medical Center, Norfolk, VA, September 24, 2008.
146. “Dyspepsia and vomiting” ACG Postgraduate Course, Orlando, FL, October 4, 2008.
147. “The new IBS guidelines: What the practitioner needs to know” ACG Allied Health Professionals Symposium. Orlando, FL, October 5, 2008.
148. “Utility of diagnostic tests” as part of the symposium “ACG guidelines: An evidence based approach to IBS. Annual Meeting of the American College of Gastroenterology, Orlando, FL, October 6, 2008.
149. “Functional Dyspepsia” Neurogastroenterology and Motility: Joint International Meeting 2008, Lucerne, Switzerland, November 8, 2008.
150. “Advancing best practices in IBS-C” Drexel University College of Medicine, Philadelphia, PA, November 20, 2008.
151. “All about *H. pylori*: Update for 2009”, “Update on the irritable bowel syndrome”, and “Constipation: New treatment options for a chronic condition” Tenth Annual Disorders of the Esophagus and GI tract. Orlando, FL, December 5-6, 2008.
152. “Management issues in Chronic Constipation” Beth Israel Medical Center, New York, NY, December 10, 2008.
153. Course Co-director and Speaker for the American Gastroenterological Association’s Clinical Congress of GI and Hepatology, Las Vegas, NV, January 22-25, 2009.
154. Participant and **Course Director** for “*Peptic ulcer disease and upper GI bleeding*” GI/Liver Wrap-Up, University of Michigan, Captiva Island, FL, February 27-March 1, 2009.
155. Course planning committee, speaker, and moderator – Meeting of the International Foundation of Functional GI Disorders, Milwaukee, WI, April 17-19, 2009.
156. “Management of the Irritable Bowel Syndrome: Translating novel insights into actionable treatment strategies” University of Louisville, Louisville, KY, April 23, 2009.
157. “Traditional treatments of the Irritable Bowel Syndrome” “The use of antibiotics, probiotics, and prebiotics for IBS” IBS Summit 2009. Puerto Vallarta, Mexico, April 24-26, 2009.
158. “Evidence-based management of chronic constipation” University of California at Fresno, Fresno, CA, May 14, 2009.
159. “Clinical Challenge Session: Difficult cases in functional bowel disorders” AGA Postgraduate Course, Digestive Diseases Week 2009, Chicago, IL, May 30-31, 2009.

160. "The role of colonic transit testing in patients with constipation" Clinical Symposium: Motility Controversies in FGIDs. Digestive Diseases Week 2009, Chicago, IL, May 31, 2009.
161. "Evidence-based diagnosis of IBS" AGA sponsored satellite symposium, Digestive Diseases Week 2009, Chicago, IL, May 31, 2009.
162. "Functional dyspepsia" Meet the Professor: Digestive Diseases Week 2009, Chicago, IL, June 1, 2009.
163. "Medical treatments for GERD" Clinical Advances in Gastroenterology, American College of Gastroenterology, Sanibel Island, FL, July 11, 2009.
164. Participant and **Course Director** for "*Novel insights into the Irritable Bowel Syndrome*" Northern Michigan DDW Wrap-Up, University of Michigan, Mackinac Island, MI, July 17-19, 2009.
165. "Irritable Bowel Syndrome: Translating the latest science to practical management solutions" Medical Grand Rounds, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, August 7, 2009.
166. "Current controversies in the management of the irritable bowel syndrome" GI Grand Rounds, New York University, New York, NY, August 18, 2009.
167. "Evidence-based management of Functional Dyspepsia" American College of Gastroenterology Midwest Regional Postgraduate Course, Kansas City, MO, August 29, 2009.
168. "Recertification preparation and update course" Faculty Member, Annual Meeting of the American College of Gastroenterology, San Diego, CA, October 23, 2009.
169. Moderator – "The upper gut" Postgraduate Course, Annual Meeting of the American College of Gastroenterology, San Diego, CA, October 24, 2009.
170. "*H. pylori* in 2009: When to test, how to test and how to treat", Postgraduate Course, Annual Meeting of the American College of Gastroenterology, San Diego, CA, October 24, 2009.
171. "Managing the sensitive gut: The NERD/GERD/IBS interface" Satellite Symposium at the Annual Meeting of the American College of Gastroenterology, San Diego, CA, October 25, 2009.
172. Faculty member in the Satellite Symposium: "Trial by Jury: Examining the ACG Position Statement on the Management of IBS" San Diego, CA, October 26, 2009.
173. "Treatment options: Food, bugs or drugs?" as part of the simultaneous symposium: Is IBS another IBD? Annual Meeting of the American College of Gastroenterology, San Diego, CA, October 27, 2009.
174. "Evidence-based treatment of IBS" as part of the Symposium: "The Dark Side of IBS" at United European Gastroenterology Week, London, UK, November 24, 2009.
175. "Functional Dyspepsia: How to manage in clinical practice" and "Breath Tests, Antibiotics, Probiotics in IBS: When and who to test and treat" American Gastroenterological Association Clinical Congress, Las Vegas, NV, January 15-16, 2010.
176. "Salvage therapy for *H. pylori*" and "IBS Update: Review of practice guidelines and practical tips" ACG Governors/ASGE Best Practices Course, Las Vegas, NV, January 29-31, 2010.
177. Participant and **Course Director**, GI-Liver Wrap Up, University of Michigan Medical Center, Sarasota, FLA, February 19-21, 2010. Audio Digest Selection: IBS and celiac disease: separating the wheat from the chaff. 2010;24:22.

178. “Newer concepts in the diagnosis and treatment of Irritable Bowel Syndrome” American College of Gastroenterology Regional Postgraduate Course, New Orleans, LA, March 5-6, 2010.
179. “*H. pylori*: Handling recurrent and refractory cases” and “Evolving diagnosis and therapy of functional dyspepsia” American College of Gastroenterology Regional Postgraduate Course, New York, NY, March 20-21, 2010.
180. “Small Intestinal Bacterial Overgrowth” Michigan Bowel Control Program Grand Rounds, University of Michigan Health System, Ann Arbor, MI, April 14, 2010.
181. “Handling the Complicated Functional Bowel Disease Patient” AGA Postgraduate Course Clinical Challenge Session. Digestive Diseases Week, New Orleans, LA, May 1-2, 2010.
182. “What’s up With Bacterial Overgrowth? IBS & Beyond” AGA Postgraduate Course General Session. Digestive Diseases Week, New Orleans, LA, May 2, 2010.
183. “Emerging Therapies for Functional Bowel Disease” AGA Clinical Symposium. Digestive Diseases Week, New Orleans, LA, May 2, 2010.
184. “Probiotics – What Works for IBS?” AGA Clinical Symposium. Digestive Diseases Week, New Orleans, LA, May 4, 2010.
185. “Emerging Diagnostic and Therapeutic Strategies for Functional Bowel Disorders: Insights from DDW 2010” GI Grand Rounds. University of Michigan Health System, June 8, 2010.
186. “Diagnosis and Treatment of Small Intestinal Bacterial Overgrowth” GI Grand Rounds, University of Michigan Health System, Ann Arbor, MI, June 8, 2010.
187. “Small Intestinal Bacterial Overgrowth” Difficult Clinical Problems in Gastroenterology, University of Manitoba, Winnipeg, Canada, June 11, 2010.
188. Participant and **Course Director**, Northern MI DDW Wrap-Up, University of Michigan Medical Center, Mackinac Island, MI, July 16-18, 2010.
189. “Perianal Inspection and Digital Rectal Examination” GI Fellows Teaching Series, University of Michigan Health System, Ann Arbor, MI, August 24, 2010.
190. “Meet the Professor” ANMS 5th Biennial Postgraduate Course on GI Motility & Neurogastroenterology in Clinical Practice, Boston, MA, August 26, 2010.
191. “Workshop: Testing for Bacterial Overgrowth, IBS and Carbohydrate Malabsorption” ANMS 5th Biennial Postgraduate Course on GI Motility & Neurogastroenterology in Clinical Practice, Boston, MA, August 26, 2010.
192. Moderator: Plenary Session: IBS-IBD Overlap, International Neurogastroenterology & Motility Meeting, Boston, MA, August 28, 2010.
193. “Diagnosis and Treatment of GERD” GI Fellows Teaching Series, University of Michigan Health System, Ann Arbor, MI, September 29, 2010.
194. “Plenary Presentation: Erosive vs. Nonerosive GERD: The many faces of heartburn” Annual Meeting of the Gastroenterological Society of Taiwan, Taipei, Taiwan, October 3, 2010.
195. “Recertification preparation and update course” Faculty Member, Annual Meeting of the American College of Gastroenterology, San Antonio, TX, October 15, 2010.
196. “Treatment of IBS” Learning Luncheon, Postgraduate Course, Annual Meeting of the American College of Gastroenterology, San Antonio, TX, October 16, 2010.
197. “Celiac disease and IBS: How far should you go?” Annual Meeting of the American College of Gastroenterology, San Antonio, TX, October 18, 2010.

198. Moderator: Plenary Session: Functional GI Disorders/Inflammatory Bowel Disease, Annual Meeting of the American College of Gastroenterology, San Antonio, TX, October 20, 2010.
199. “Management of chronic constipation” Balloon Training, Manual Techniques and Exercises for Bowel Dysfunction sponsored by the Department of Physical Therapy, University of Michigan Health System, Ann Arbor, MI, November 6, 2010.
200. “Critical review and rationale for the use of prokinetics for GERD” as part of the symposium “GERD & dyspepsia share motility disorders that affect diagnosis & treatment” at 2010 Gastroenterology Mexican Week, Acapulco, Mexico, November 16, 2010.
201. “Manipulation of intestinal microbiota in the treatment of IBS”, 2010 Gastroenterology Mexican Week, Acapulco, Mexico, November 16, 2010.
202. “Overlap between IBS and celiac disease” Michigan Bowel Control Program Grand Rounds, Ann Arbor, MI, December 8, 2010.
203. “PPI safety: What are the concerns” and “Evidence-based management of IBS” AGA Clinical Congress of Gastroenterology & Hepatology, Miami, FL, January 14-15, 2011.
204. “Management of the difficult IBS patient” ACG Western Region Postgraduate Course, Las Vegas, January 28-30, 2011.
205. “Management of IBS”, Update on GERD & Motility Disorders, Emory University School of Medicine, Atlanta, GA, March 19, 2011.
206. “New and emerging treatments of the gut”. 9th International Symposium on Functional GI Disorders, Milwaukee, WI, April 8, 2011.
Audio-Digest Gastroenterology, Volume 25, Issue 16, August 21, 2011.
207. “Challenging cases at the referral center”. 9th International Symposium on Functional GI Disorders, Milwaukee, WI, April 9, 2011.
208. “Role of small intestinal bacterial overgrowth in the Irritable Bowel Syndrome” Digestive Diseases Week, Chicago, IL, May 8, 2011.
Audio-Digest Gastroenterology, Volume 25, Issue 20, October 21, 2011.
209. “Management of the patient with IBS-C” Satellite Symposium – GI Health Foundation, Digestive Diseases Week, Chicago, IL, May 8, 2011.
210. “First-line and salvage treatments for *H. pylori* infection” First Beijing *Helicobacter pylori* Summit Symposium. Beijing, China, May 15, 2011.
211. “Management of Gastroesophageal Reflux Disease in 2011”. Shanghai, China, May 17, 2011.
212. “Management of Acute Peptic Ulcer Bleeding” Medan, Indonesia, May 19, 2011.
213. Participant and **Course Director**, Northern MI DDW Wrap-Up, University of Michigan Medical Center, Mackinac Island, MI, August 19-21, 2011.
214. “Functional Disorders and IBS – New Therapies” ACG/Virginia GI Society Regional Postgraduate Course, Williamsburg, VA, September 10, 2011.
215. “Testing of colonic function: Wireless Motility Capsule” and “Meet the Professor” ANMS 6th Biennial Postgraduate Course on GI Motility & Neurogastroenterology in Clinical Practice, St Louis, MO, September 16, 2011.
216. “The role of food in functional GI disorders” Dr. Timothy T. Nostrant Retirement CME Program, University of Michigan Health System, Ann Arbor, MI, September 23, 2011.
217. “Emerging therapies for IBS and Chronic Constipation” Chicago Gut Club, Oakbrook, IL, September 27, 2011.

218. “IBS: Evidence-based diagnosis and management”, “Learning Luncheon: Refractory Abdominal Pain: Management Considerations”, ACG Postgraduate Course, Washington, DC, October 30, 2011.
219. “Strategies for effective management of IBS-C and Chronic Constipation: Expert Perspectives” CME Satellite Symposium: Annual Meeting of the American College of Gastroenterology 2011, Washington, DC, October 30, 2011.
220. “Current Management of *H. pylori* Infection” Annual Meeting of the American College of Gastroenterology 2011, Washington, DC, November 1, 2011.
221. “The role of food in the irritable bowel syndrome” 5th Annual Japan & US Collaboration in Gastroenterology, Tokyo, Japan, November 10, 2011
222. “Evidence-based management strategies for IBS” and “Role of probiotics for IBS and IBD” Clinical Congress of Gastroenterology & Hepatology, Miami, FL, January 20-21, 2012.
223. “Evidence-based management of the patient with dyspepsia” and “Management of *H. pylori* infection”, Best Practices in Gastroenterology & Hepatology, Huntington Beach, CA, January 27-28, 2012.
224. “Emerging therapies for IBS-C and Chronic Constipation” and “Star articles from the GI journals” Canadian Digestive Diseases Week, Montreal, CA, February 27, 2012.
225. “Management of IBS in 2012” University of Michigan Health Service CME Lecture Series. Ann Arbor, MI, March 29, 2012.
226. “Dietary strategies for patients with IBS” Advocate Christ Medical Center, Oak Lawn, IL, May 3, 2012.
227. “Management of *H. pylori* infection” Fellow’s Conference, Division of Gastroenterology, University of Michigan Health System, May 9, 2012.
228. “Clinical Challenge Session: Managing the Difficult IBS Patient” AGA Postgraduate Course, Digestive Diseases Week 2012, San Diego, May 19, 2012.
229. “Microbiome and Irritable Bowel Syndrome” AGA Postgraduate Course. Digestive Diseases Week 2012, San Diego, May 20, 2012.
230. “Clinical Symposium: Everything You Need to Know about IBS Treatment” Digestive Diseases Week 2012, San Diego, May 19, 2012.
231. “Clinical Symposium: Celiac disease or gluten sensitivity: What's the difference and how to evaluate and treat?” Digestive Diseases Week 2012, San Diego, May 21, 2012.
232. “Committee Sponsored Symposium: Diets and Irritable Bowel Syndrome” Digestive Diseases Week 2012, San Diego, May 21, 2012.
233. “Evidence-based treatment strategies for IBS-C and Chronic Constipation” Pacific Northwest GI Society, Seattle, WA, May 31, 2012.
234. “Diagnostic evaluation of IBS” and “Treatments directed at the bowel for IBS”, Small group and facilitated role play moderator. Rome Foundation/AGA Workshop: Improving the Medical Interview and the Physician Patient Relationship with Patients Having Functional GI Disorders, Chapel Hill, NC, June 8-9, 2012.
http://theromefoundation.org/meetings_events/communication_workshop_agenda.cfm
235. “Slow colon transit: Why it matters and how to treat it” and “Diet and IBS: Food for thought” UNC Patient Symposium, Chapel Hill, NC, June 23-24, 2012.
236. Participant and **Course Director**, Northern MI GI-Liver Wrap-Up, University of Michigan Medical Center, Mackinac Island, MI, July 20-22, 2012.

237. “Cases in colorectal disorders”, “Meet the Professor”, “Evaluation and Treatment of Constipation”. ANMS 7th Annual Postgraduate Course on GI Motility & Neurogastroenterology in Clinical Practice, Chicago, IL, July 28-30, 2012.
238. “Moderator: Functional Bowel Disorders” and “Constipation and Pelvic Floor Disorders” ACG Midwest Region Postgraduate Course, Indianapolis, IN, August 25-26, 2012.
239. “Discussant: Large Bowel: Clinical Session”, “Functional Constipation”, “Chair: Pharmacotherapy, pharmacology and alternative therapies” Joint International Neurogastroenterology & Motility Meeting, Bologna, Italy, September 6-8, 2012.
240. “New developments in the management of IBS” North California Society of Gastroenterology, San Francisco, CA, September 20, 2012.
241. “Management of chronic constipation.” Sanya Festival of Gastroenterology and Endoscopy, Hainan Island, China, October 10, 2012,
242. ACG Postgraduate Course Learning Luncheon "Current treatment of *H. pylori*", Las Vegas, NV, October 20, 2012.
243. ACG Postgraduate Course - Moderator – “Motility and FGIDs”, speaker: “Management of Chronic Constipation”, Las Vegas, NV, October 21, 2012.
244. Moderator: “Food and GI Diseases: Where's the Beef?”, speaker: “Food: The Forgotten Factor in IBS”, Annual Meeting of the American College of Gastroenterology, Las Vegas, NV, October 23, 2012.
245. Rome Foundation Symposium: “The role of diet in IBS”, Pan American Congress of Gastroenterology, Panama City, Panama, November 10, 2012.
246. “Are Functional Constipation and IBS-C distinct conditions: Considerations for Rome IV”, the role of the gut microbiota in IBS”, “Understanding the pathophysiology of bloating”, Mexican Gastroenterology Week, Merida, Mexico, November 21, 2012.
247. “Rational management of GERD”, “Meet the Experts – How to publish in Western Medical Journals”, Asian Pacific Digestive Week, Bangkok, Thailand, December 7, 2012.
248. “Up and Down the GI Tract: GERD, Celiac Disease, Fecal Incontinence” **National Course Co-Director**, Regional Pri-Med CME Series, 2013
249. “Therapeutic challenges in the Functional GI Disorders” 9th Annual Meeting of the Japanese Gastroenterology Association. Tokyo, Japan, January 25, 2013.
250. “Management of Chronic Constipation” Spring Conference for the MSGNA. Ypsilanti, MI, February 9, 2013.
251. “Transforming the way that Patients and Doctors interact: *My GI Health*” Michigan Bowel Control Program Education Hour. University of Michigan Health System, Ann Arbor, MI, February 13, 2013.
252. “Morbidity and Mortality – Expert GI Commentator”, Internal Medicine Grand Rounds, University of Michigan Health System, Ann Arbor, MI, February 22, 2013.
253. “The future of therapies for functional GI disorders” Through the Glass Darkly Symposium, McMaster University, Hamilton, ON, February 23, 2013.
254. Biannual Meeting of the International Foundation of Functional GI Disorders: “Mini Symposium: The Rome Working Group, Food & Functional Gastrointestinal Disorders: Dietary Factors and Lower GI Symptoms”; “Workshop: Clinical Pearls for the Clinician: Diagnostic Pearls”; “General Plenary Session: New and Emerging Treatments of the Gut”. Milwaukee, WI, April 12-14, 2013.
Audio Digest Gastroenterology, Volume 27, Issue 20, October 21, 2013.

255. “The essentials to managing IBS” Department of Internal Medicine Spring Review: University of Michigan, Ann Arbor, MI, May 10, 2013.
Audio-Digest Internal Medicine Volume 61, Issue 02, January 14, 2014, ISSN 0271-1303
256. “The role of food in the functional GI disorders: Report from a Rome Foundation Working Group” Rome IV Orientation Meeting, Orlando, FL, May 16, 2013.
257. “The transformative role of patient portals in clinical practice” AGA Postgraduate Course, Digestive Diseases Week 2013, Orlando, FL, May 19, 2013.
258. “Finding and Eradicating H. Pylori in 2013” AGA Postgraduate Course Luncheon Breakout Session, Digestive Diseases Week 2013, Orlando, FL, May 19, 2013.
259. “State of the Art: Foods, Fads and FODMAPs” Research Forum, Digestive Diseases Week 2013, Orlando, FL, May 19, 2013.
260. “Research Forum: Irritable Bowel Syndrome” Moderator, Digestive Diseases Week 2013, Orlando, FL, May 20, 2013.
261. “Clinical Conversations: Getting Patients with CC and IBS-C Back on Track” Satellite Symposium, Digestive Diseases Week 2013, Orlando, FL, May 19, 2013.
262. “Management of GERD”, “Diagnosis and Treatment of H. pylori infection”, Evidence-based management of chronic constipation”, “Dietary and lifestyle strategies for IBS”, “Medical and complementary treatments for IBS”, Michigan Academy of Family Practice Meeting 2013, Bellaire, MI, June 19-21, 2013.
Audio-Digest Family Practice, Volume 61, Issue 41, November 7, 2013, ISSN 0271-1362
Audio-Digest Family Practice, Volume 61, Issue 45, December 7, 2013, ISSN 0271-1362
263. “DDW 2013 Review: Motility and Functional GI disorders” GI & Liver Association of the Americas – First Annual Conference. Austin, TX, June 21, 2013.
264. “Evidence-based treatment of IBS”, Management strategies for chronic constipation” 21st Annual Primary Care Conference, Kiawah Island, SC, July 4-6, 2013.
265. “Diet & lifestyle interventions for IBS” University of Florida: 7th Annual GI/Liver Meeting, Clearwater, FL, July 27, 2013.
266. “Evidence-based approach to IBS”, “What’s new in Celiac Disease and non-celiac Wheat Intolerance” ACG 2013 Midwest Regional Postgraduate Course, St. Louis, MO, August 24-25, 2013.
267. “Current and emerging therapies for IBS-C and chronic constipation” ANMS Clinical Course, Huntington Beach, CA, September 20, 2013.
268. “Diet as a primary treatment strategy for IBS” Rome Foundation Symposium, ANMS Scientific Meeting, Huntington Beach, CA, September 20, 2013.
269. “Bloating: Blowing up old myths” and “The changing face of *Helicobacter pylori*” American College of Gastroenterology Postgraduate Course, San Diego, CA, October 13, 2013.
270. “Traditional medical treatments for IBS” and course moderator, UNC Center for Functional GI and Motility Disorders. Chapel Hill, NC, November 2, 2013.
271. “Management of constipation” and **course planning committee**, Practical Solutions to Common GI Problems. Division of Gastroenterology, University of Michigan Health System, Plymouth, MI, November 16, 2013.
272. “Clinical approach to the patient with dyspepsia” and “Complementary and Alternative Medicine for GI Disorders” American College of Gastroenterology Governor’s Course, Las Vegas, NV, January 24, 2014.
273. “Update on the Functional GI Disorders” ACG Lecturer, Meeting of the Japanese Gastroenterological Association, Fukushima, Japan, February 14-15, 2014.

274. "Primary and Salvage Treatments for *H. pylori* infection" GI Pow-Wow, Denver, CO, April 12, 2014.
275. "Incontinence: the scope of the problem and treatment options" AGA Postgraduate Course, Chicago, IL, May 3, 2014.
276. "The overlap between inflammatory bowel diseases, microscopic colitis and IBS" Digestive Diseases Week, Chicago, IL, May 6, 2014.
277. "Management of IBS – What's New?" American College of Gastroenterology East Regional Course, Washington, DC, June 7, 2014.
278. "Update on Celiac Disease" & "Patient Portals – How to use them in your practice" Michigan Association of Family Practice Annual Meeting, Bellaire, MI, June 18-19, 2014.
279. Expert Panel Discussant. Young Investigator's Forum. American Neurogastroenterology & Motility Society. Baltimore, MD, July 25, 2014.
280. "Medical therapies for IBS" & "Dietary recommendations for patients with FGIDs" ANMS Post-graduate Course, Baltimore, MD, July 26-27, 2014.
281. "Evidence-based treatment strategies for IBS" & "Management of chronic constipation" 5th Annual Essentials in Primary Care Conference, Big Island, HI, July 31, 2014.
282. "Update on irritable bowel syndrome" ACG Virginia GI Society Meeting, Williamsburg, VA, September 6-7, 2014.
283. "Treatment approach to the patient with IBS" & "Best of DDW 2014: FGID & Motility" Gastroenterology International Frontier, Beijing, China, September. 26, 2014.
284. "Treatment approach to the patient with IBS" 1st AGA Professional Conference in China, 9th SRRSH International Academic Week, 7th Zhejiang Digestive Disease Academic Conference, Hangzhou, China, September. 27, 2014.
285. "The role of food in functional GI disorders" Rome Symposium, Latin American Digestive Diseases Week, Buenos Aires, Argentina, October 8, 2014.
286. "Management of *H. pylori* infection" ACG Postgraduate Course, Philadelphia, PA, October 19, 2014.
287. "The role of inflammation in IBS" Annual Meeting of the ACG, Philadelphia, PA, October 20, 2014.
288. "Anorectal dysfunction: definitions, clinical presentation, features on defecography and anorectal function testing" & "IBS-C and chronic constipation: Differences in clinical presentation, pathophysiological mechanisms" Rome Foundation Symposium: Recent Advances in FGIDs. Dubai, UAE, October 31-November 1, 2014.
289. "The role of food in FGIDs", "Manipulating gut microbiome in FGIDs: probiotics, antibiotics and fecal transplant". Clinical Practice in Neurogastroenterology & Motility, Cancun, Mexico, November 15-16, 2014.
290. "Dyspepsia – Don't test, just treat" AGA Clinical Congress in Gastroenterology & Hepatology, Miami, FL, January 23-24, 2015.
<http://www.hcplive.com/conferences/aga-2015/Debating-Testing-or-Treatment-for-Gastroparesis>
291. "Diet as a primary treatment strategy for irritable bowel syndrome". University of Toronto City Wide Rounds, Toronto, Canada, March 11, 2015.
292. "New advances in the treatment of GERD" Changhua Christian Hospital, Changhua, Taiwan, March 30, 2015.
293. "Manipulating the gut microbiome: Emerging treatment strategies for IBS" Kaohsiung Medical University, Kaohsiung, Taiwan, March 31, 2015.

294. “Manipulating the microbiome to treat IBS” Arapahoe POW WOW, Denver, CO, April 18, 2015.
295. “Management of IBS in 2015” Bluegrass Gut Club, Lexington, KY, April 23, 2015.
296. “Current management options for patients with IBS and diarrhea” McGill Grand Rounds, Montreal General Hospital, Montreal, CN, May 6, 2015.
297. “The emerging role of bile acids in the pathogenesis and treatment of IBS with diarrhea” Medical Grand Rounds, Toronto General Hospital, Toronto, CN, May 7, 2015.
298. “Emerging diagnostic and treatment strategies for IBS with diarrhea” McMaster University, St. Joseph’s Hospital-Charlton Campus, Hamilton, May 8, 2015.
299. “Learning Luncheon: *Helicobacter pylori* in the Modern Age: How to Find, How to Treat” AGA Postgraduate Course, Washington DC, May 16, 2015.
300. “2015 Rome Foundation Symposium: Use of Health Information Technology in Clinical Practice” Digestive Diseases Week 2015, Washington DC, May 17, 2015.
301. “Breakfast with the expert: Antibiotic-Resistant *H. pylori* Infections: What to Do When Standard Therapy Fails” Digestive Diseases Week 2015, Washington DC, May 18, 2015.
302. “Management of GERD in 2015” and “The emerging role of diet and lifestyle in IBS” 6th Annual Essentials in Primary Care Conference, Kiawah Island, SC, July 3-6, 2015.
303. “Targeting the microbiome” and moderator – “Luminal factors affecting epithelial function and symptoms in IBS” 2015 AGA James Freston Conference, Chicago, IL, August 29-30, 2015.
304. “Emerging therapeutic options for chronic constipation/anorectal disorders” ANMS 10th Postgraduate Course, Chicago, IL, August 28, 2015.
305. “Food – at the intersection of GI wellness and illness” Georgia GI Society Annual Meeting, Atlanta, GA, September 12, 2015.
306. “Emerging role of lifestyle and diet for IBS” and “Evidence-based medical management of IBS” Oregon Gut Club, Portland, OR, September 19, 2015.
307. “Advances in the management of functional GI disorders” University of Washington, Seattle, WA, September 21, 2015.
308. “FGID Update” Chicago Gut Club, Chicago, IL September 24, 2015.
309. “First and second line therapies for *H. pylori* infection” Gastroenterology Update: A case-based approach to common GI problems. UMHS, Dearborn, MI, October 2, 2015.
310. “David Sun Lecture: Food – the main course to GI wellness and disease” ACG Postgraduate Course, Honolulu, HI, October 17, 2015.
311. “Evolving concepts in the treatment of IBS” “Diet- what should you choose for IBS?” Annual Meeting of the American College of Gastroenterology, Honolulu, HI, October 20, 2015.
312. “Hotspot Clinical Trial Discussion: Naloxegol”, “Bridging guidelines into practice: Pharmacological agents for IBS”, “Expert roundtable discussion on chronic diarrhea: Bile acid diarrhea”, “Managing the GI side effects of opioids”, United European Gastroenterology Week, Barcelona, Spain, October 26-28, 2015.
313. “Keynote Address: The emergence of diet as a therapy for irritable bowel syndrome” Prato International FODMAP Congress, Monash University, Prato, Italy, November 2-3, 2015.
314. “The emerging role of diet in human health and gastrointestinal diseases” School of Public Health, University of Michigan, Ann Arbor, MI, November 11, 2015.
315. “The emerging role of Diet & Lifestyle in IBS” Ob-Gyn Grand Rounds, University of Michigan Health System, Ann Arbor, MI, January 7, 2016.

316. "Management of IBS-D in 2016" Edmonton Citywide Gut Club, Edmonton, Canada, January 12, 2016.
317. "The emerging role of the gut microenvironment in the pathogenesis of IBS" University of British Columbia Gut Club, Vancouver, Canada, January 13, 2016.
318. "Do bile acids play a role in the pathogenesis and treatment of IBS?" University of Calgary GI faculty dinner conference, January 14, 2016.
319. "The role of the gut microbiome on functional bowel symptoms" 2016 ACG Board of Governors Postgraduate Course, Scottsdale, AZ, January 30, 2016.
320. "My GI Health" Pelvic Floor Research Group Day, University of Michigan Health System, February 3, 2016.
321. "Food – the main course to wellness and disease" FODMAPs, SIBO, and the gut microbiome, Boston, MA, February 26, 2016.
322. "Prebiotics, Probiotics, Synbiotics, and Antibiotics -- Role in IBS" & "Management of visceral pain" ACG/Florida GI Society Regional Postgraduate Course, Bonita Springs, FL, March 18-20, 2016.
323. "Rome III Criteria for Functional Gastrointestinal Disorders: Is There a Need for Better Definition?" & "How Best to Publish in Scientific Journals" 6th Asian Postgraduate Course on Neurogastroenterology & Motility, Seoul, Korea, April 2-4, 2016.
324. "State of the Art Lecture: Microbiota, FODMAP Diet & IBS" Digestive Diseases Week 2016, San Diego, CA. May 22, 2016.
325. "Treatment of functional GI disorders: Current challenges, future opportunities" NIH Functional Bowel Disorders Workshop, June 24, 2016.
326. "The new way to diagnose FGIDs: Rome IV", "The new drug revolution for IBS", "Why does food cause GI symptoms?" The Multidisciplinary Treatment of IBS. Alfred Hospital. Melbourne, Australia, July 16, 2016.
327. "The probiotic scene for IBS in the US" PRO-GUT Meeting, Melbourne, Australia, July 17, 2016.
328. "Food: the main course to GI wellness and illness" Annual Meeting of the Florida Academy of Nutrition & Dietetics. Tampa, FL, July 24, 2016.
329. "The emerging role of diet in the pathogenesis and treatment of IBS", "Diagnosis of IBS in the Rome IV era" Brazilian Congress of Functional Diseases of the Digestive System. Gramado, Brazil, July 29-31, 2016.
330. **Course Co-Director:** Food: the main course to GI Health – Nutrition Management for GI Diseases. Ann Arbor, MI, August 20-24, 2016.
331. "Dietary management of the lower gut" American Neurogastroenterology & Motility Society. San Francisco, CA, August 25-26, 2016.
332. "Management of functional dyspepsia" ACG Midwest Regional Course, Minneapolis, MN, August 27-28, 2016.
333. "Food in GI Health & Disease", Case Western Reserve Cleveland IDEAS Symposium 2016, Cleveland, OH, September 9, 2016.
334. "The Low-FODMAP diet - what is it and who is it for?" Ohio Gastroenterology Society, Columbus, OH, September 17, 2016.
335. "Therapeutic nutrition: Food for thought" Division of Gastroenterology & Hepatology, University of Michigan Health System. Ann Arbor, September 22-23, 2016.
336. Moderator: Esophagus and Stomach, Postgraduate Course, Annual Meeting of the American College of Gastroenterology, Las Vegas, NV, October 16, 2016.

337. “Resistant *Helicobacter pylori* infection – what now?” Postgraduate Course, Annual Meeting of the American College of Gastroenterology, Las Vegas, NV, October 16, 2016.
338. Moderator: Rome IV symposium, Speaker: “Bowel Disorders”, Annual Meeting of the American College of Gastroenterology, Las Vegas, NV, October 18, 2016.
339. Moderator: Colon Controversies, Speaker: “New tricks for an old problem: Opioid induced constipation” Annual Meeting of the American College of Gastroenterology, Las Vegas, NV, October 17, 2016.
340. “Microbiome-based treatment strategies for IBS.” Canadian Digestive Health Foundation Discover the World Within Symposium, Toronto, ON, November 7, 2016.
341. “The emerging role of food in the management of IBS” University Health Service, UMHS, Ann Arbor, MI, November 10, 2017.
342. “Treatment of *H. pylori* infection in 2017” Loma Linda University Medical Center, Loma Linda, CA, December 16, 2016.
343. “Rome IV criteria for IBS: Notable Changes” 2017 ACG/LGS Regional Postgraduate Course, New Orleans, March 4, 2017.
344. “Management of *H. pylori* infection: ACG Practice Guidelines” GI Grand Rounds, Division of Gastroenterology, Michigan Medicine, March 7, 2017.
345. “Evaluation of chronic constipation”, “The future of Gastroenterology in 2017” 2017 ACG Western Regional Postgraduate Course, Las Vegas, NV, March 11-12, 2017.
346. “Gut microbiota in chronic constipation” “Rome IV criteria: Bowel Disorders” APNM-JSNM joint meeting 2017, Osaka, Japan, March 22-24, 2017.
347. “Keynote address: You are what you eat – the role of food in gut health and disease”, “Update on Celiac disease”, 2017 ACG Eastern Regional Postgraduate Course. Washington, DC, April 8, 2017.
348. “Update on the Rome IV criteria for the diagnosis of functional GI disorders” GI Grand Rounds, Division of Gastroenterology, Michigan Medicine, April 11, 2017.
349. “Rome IV criteria for IBS: Notable Changes”, “Utility of biomarkers in the diagnosis of IBS”, “State of the art management of IBS” SAGE Autumn Symposium, Buenos Aires, Argentina, April 20-21, 2017.
350. Planning Committee and speaker: Falk Symposium “Mucosal Microbiome and Mucosal or Systemic Dysfunction: Mechanisms, Clinical Manifestations and Interventions” Brisbane, AU, May 19-20, 2017.
351. “Current Diagnosis of IBS-D” and “Salvage therapy for *Helicobacter pylori* infection” Digestive Diseases Week, Chicago, IL, May 6-9, 2017.
352. “New diagnostic and therapeutic approaches to IBS” 37th Annual Advances in Gastroenterology Conference, Thomas Jefferson University, Atlantic City, NJ, June 17, 2017.
353. “Update on functional GI disorders for primary care physicians” and “Celiac disease” 25th Annual Primary Care Summer Conference Session, Kiawah Island, SC, June 30 to July 3, 2017.
354. “Pain assessment in clinical trials: Pelvic pain and IBS”. IMMPACT Meeting. Washington DC, July 13, 2017.
355. “Novel therapies for IBS” and “Functional dyspepsia” AGA NP PA GI Course, Chicago, IL, August 11, 2017.
356. “Bloating and Distention: The Role of Diet and the Microbiome” ACG Midwest Regional CME Course. St. Louis, MO, August 25, 2017.

357. "Updates in the treatment of IBS" Mastering concepts in IBD and IBS: St Louis University. St Louis, MO, September 9, 2017.
358. "Microbiome-Gut-Brain Interactions" Chinese GI Association Annual Meeting, Xian, China, September 16, 2017.
359. Course Director and Speaker, **Food: the main course to digestive health**. Michigan Medicine, Ann Arbor, MI, September 22-24, 2017.
360. "Update on the management of *H. pylori* infection" Third Annual GI Update, Michigan Medicine, Dearborn, MI, September 29, 2017.
361. "Learning luncheon: *H. pylori*: Who to treat and how" ACG Postgraduate Course. Orlando, Fla, October 15, 2017.
362. "Diagnostic challenges in *H. pylori*" and "Rome IV vs. Biomarkers: How accurate are our diagnostic tools?" Annual Meeting of the ACG/WCOG. Orlando, FL, October 16-17, 2017.
363. "Should dietary trials have different rules to drug trials?" and "Sucrase-isomaltase deficiency: Hiding in plain sight". Gastrodiet 2017. Monash University. November 3-5, 2017.
364. "Fecal incontinence: How to fix it" and "Efficacious care of the functional bowel disorders" 43rd Annual Topics in GI and Hepatobiliary Update, Johns Hopkins University, Baltimore, MD, November 10, 2017.
365. Panel participant. AGA Regional Practice Skills Workshop, UCLA, Los Angeles, CA, December 9, 2017.
366. "Upper GI Disorders" Rome Foundation Webcast, New York, NY, January 19, 2018.
367. "Managing the bloated patient: role of diet, probiotics, antibiotics" ACG/ASGE Best Practices Course. Las Vegas, NV, January 27-28, 2018.
368. "Irritable bowel syndrome" Canadian Digestive Diseases Week 2018. Toronto, Ontario, February 9-10, 2018.
369. "Dietary therapies for IBS" and "Update on the management of *H. pylori* infection" Annual Educational Meeting in Gastroenterology, Cedars Sinai, Los Angeles, CA, March 2-3, 2018.
370. "Small intestinal bacterial overgrowth" and "New options for the medical management of IBS" ACG/Florida Gastroenterology Society Annual Spring Postgraduate Course. Bonita Springs, FL, March 17-18, 2018.
371. "Functional dyspepsia". Annual Arapahoe GI course. Denver, CO, April 14-15, 2018.
372. "Update on the management of IBS-D" Kansas City Live Course and Update in Gastroenterology. Kansas University, Kansas City, April 20-21, 2018.
373. AGA Postgraduate Course – "Case-based sessions - Breath testing: Role in Diagnosis and Prediction of Treatment Response", Washington, DC, June 2, 2018.
374. AGA Postgraduate Course – "Irritable Bowel Syndrome – What's new?" Washington, DC, June 3, 2018.
375. "How to get your functional GI patient functioning again". Digestive Diseases Week 2018, Washington, DC, June 3, 2018.
376. "Meet the Professor: Dietary interventions for IBS" Digestive Diseases Week 2018, Washington, DC, June 4, 2018.
377. Moderator: "Chronic Diarrhea and Irritable Bowel Syndrome: Current Knowledge and Update on Management Strategies" Digestive Diseases Week 2018, Washington, DC, June 5, 2018.

378. “Efficacy and Safety of Tenapanor in Patients with Constipation Predominant Irritable Bowel Syndrome: A 6-month, Double-Blind, Placebo-Controlled Phase 3 Trial (T3MPO-2)” Digestive Diseases Week 2018, Washington, DC, June 5, 2018.
379. “Dietary modifications for lower GI disorders” ANMS Clinical Postgraduate Course, Milwaukee, WI, July 26, 2018.
380. “Getting CIC patients to effective therapy through phenotype and specialized care” ANMS Clinical Postgraduate Course, Milwaukee, WI, July 26, 2018.
381. Session Chair: “Therapeutic advances in FGIDs” Functional Neurogastroenterology Motility Meeting, Amsterdam, NE, August 31, 2018.
382. “FODMAPs” Functional Neurogastroenterology Motility Meeting, Amsterdam, NE, August 31, 2018.
383. “Management of ulcer disease in the upper GI tract” VGS/ACG Regional Postgraduate Course, Williamsburg, VA, September 8, 2018.
384. “Management of IBS in 2018” Chicago Gut Club, Oakbrook, IL, September 12, 2018.
385. “Chronic idiopathic constipation and opioid-induced constipation: The same but different...” GI GALA, San Diego, CA, September 21, 2018.
386. Course Director and Speaker, **Food: the main course to digestive health**. Michigan Medicine, Ann Arbor, MI, September 28-30, 2018.
387. Course Co-Director and Speaker, ACG Pharmacology Course, Annual Meeting of the American College of Gastroenterology, Philadelphia, PA, October 5, 2018.
388. “Non-pharmacologic therapies for IBS” ACG Postgraduate Course, Philadelphia, PA, October 6, 2018.
389. “Presidential Plenary: A Low FODMAP Diet May Reduce Symptoms in Patients with Fecal Incontinence” Best FBD Research Award, Annual Meeting of the American College of Gastroenterology, Philadelphia, PA, October 8, 2018.
390. “Non-celiac gluten sensitivity” Annual Meeting of the American College of Gastroenterology, Philadelphia, PA, October 9, 2018.
391. “Plenary Session: Avoidant/Restrictive Food Intake Disorder in the Adult Gastroenterology Population: An Under-Recognized Diagnosis?” Annual Meeting of the American College of Gastroenterology, Philadelphia, PA, October 10, 2018.
392. “Functional esophageal disorders” and “Functional gastroduodenal disorders” Rome Foundation CME course. Santa Fe, NM, October 13-14, 2018.
393. “Role of the gut microbiome in IBS”, Diagnosis of IBS and functional constipation in the Rome IV era”, “Diet therapies for IBS”. Peking University Medical Center Hospital Symposium of FGIDs and Psychological Disorders. Beijing, China, October 26-27, 2018.
394. “Chronic Constipation” Colorado Society for Parenteral & Enteral Nutrition, Denver, CO, November 9, 2018.
395. “Management of *H. pylori* infection” Phoenix GI Society, Scottsdale, AZ, November 15, 2018.
396. “What are the key differences between Rome III and Rome IV” Rome Foundation- Thai GI Thought Leader Summit, Chiang Mail, Thailand, December 6, 2018.
397. “Management of visceral pain” ACG/FGS Postgraduate Course, Naples, FL, March 3, 2019.
398. “Manipulation of the gut microbiota in IBS and other GI conditions” ACG/LGS Postgraduate Course, New Orleans, LA, March 9, 2019.
399. “Management of IBS in 2019” GI GALA Conference, Dallas, TX, March 29, 2019.

400. "Practical diagnosis and management of IBS" Focus on GI Motility and IBD. Brooke Army Medical Center, San Antonio, April 6, 2019.
401. "Is it IBS, SIBO or both?" 2019 Integrative SIBO Conference, Seattle, WA, April 13, 2019.
402. "Evidence-based treatment of *H. pylori*" Evening with the expert, Baltimore, MD, May 2, 2019.
403. "Food and IBS" Clinical Symposium, Digestive Diseases Week 2019, San Diego, CA, May 18, 2019.
404. "SIBO: fact or fiction" AGA Postgraduate Course, Digestive Diseases Week 2019, San Diego, CA, May 18, 2019.
405. "Keeping to time and keeping the patient happy" Clinical Symposium, Digestive Diseases Week 2019, San Diego, CA, May 19, 2019.
406. "Overlap between food intolerances and IBS" Clinical Symposium, Digestive Diseases Week 2019, San Diego, CA, May 21, 2019.
407. "Emerging role of the microbiome in IBS" Newcastle Gut Club, Newcastle, AU, July 25, 2019.
408. "Evidence-Based Diet Therapies for IBS: Which Ones for Which Patients?" AGA Freston Conference: *Food at the intersection of gut health and disease*. **Course Co-Director**, Chicago, IL, August 8, 2019.
409. "Emerging capsule technologies for functional gastrointestinal and motility disorders: The future is now!", "Diet therapies for IBS: Where are we going?" **Course Co-director**, ANMS Post-Graduate Course. Chicago, IL, August 16-17, 2019.
410. "IBS and small intestinal bacterial overgrowth" *ANMS Annual Patient Education Conference*, Chicago, IL, August 18, 2019.
411. "Non-medical therapies for IBS: Soup to nuts", "Microbiome-based therapies for IBS", "The inspired digital rectal examination". *ACG Functional GI Disorders School*. **Course Co-Director**, Williamsburg, VA, September 6, 2019.
412. "Functional dyspepsia: Getting to the right diagnosis and treatment" *ACG/VGS Regional Postgraduate Course*, Williamsburg, VA, September 7-8, 2019.
413. "Microbiome-based treatments for IBS" *Food, the Main Course to Gut Health*, **Course Co-director**, Michigan Medicine, Ypsilanti, MI, September 20-22, 2019.
414. "Primary and salvage treatment for *H. pylori* infection" ACG What's New in GI Pharmacology, **Course Co-Director**, San Antonio, TX, October 25, 2019.
415. "Non-celiac Wheat Intolerance" ACG Annual Postgraduate Course, San Antonio, TX, October 26, 2019.
416. "Presidential Plenary: Avoidant restrictive food intake disorder amongst GI behavioral health patients: comparison of ARFID vs non-ARFID patients" Best FBD Research Award, Annual Meeting of the American College of Gastroenterology, San Antonio, TX, October 27, 2019.
417. "Update on the management of IBS" San Diego Gut Club, San Diego, CA, November 14, 2019.
418. "Is IBS a diagnosis of exclusion", "Management strategies for chronic constipation", "Exclusion diets for IBS" Mexican Digestive Diseases Week, Cancun, Mexico, November 17-20, 2019.

419. “Keynote Address: Understanding the overlap between IBS and IBD” AIBD Meeting, Orlando, FL, December 12, 2019.
420. “IBS Masqueraders: Focus on sucrose-isomaltase deficiency” NYSGE Meeting, New York, NY, December 20, 2019.
421. “IBS as a gut microbiome disorder”, “Non-pharmacological therapies for IBS”, “The inspired digital rectal exam”. ACG Functional Bowel Disorders School, **Course Co-director**, San Diego, CA, January 10, 2020.
422. “Tips for Writing a Manuscript That Editors Want to Publish” ACG Bridging the Leadership Gap. San Diego, CA, January 11, 2020.
423. “How do we help the patient with chronic bloating” ACG Governor’s Course, Las Vegas, NV, January 26, 2020.
424. “Role of food in the pathogenesis and treatment of IBS” NUTR 688, School of Public Health, University of Michigan, January 29, 2020.
425. “Refractory constipation”, “Treatment of *H. pylori*” University of Michigan Winter GI and Hepatology Update. Bonita Springs, FL, February 7-9, 2020.
426. “Dietary therapies for IBS”, “Panel Discussion” 8th Annual UCLA Melinkoff GI & Hepatology Symposium, Los Angeles, CA, March 7, 2020.
427. “Small intestinal bacterial overgrowth: Challenges in diagnosis and management” Inaugural ACG Virtual Grand Rounds, March 26, 2020.
428. Moderator: “Celiac disease: 10 things every clinician should know” Amy Oxentenko, ACG Virtual Grand Rounds, April 30, 2020.
429. “Dietary therapies for IBS” Today’s Dietitian Virtual Symposium, May 17, 2020.
430. “Diet therapies for Irritable Bowel Syndrome” ACG Eastern Regional Course, June 6, 2020.
431. “Joint ACG/ANMS Webinar - Restarting Your Motility Practice: Breath Testing” June 15, 2020.
432. Speaker and Course Co-director, “IBS/IBD Crossfire” PER Medical Education, June 27, 2020.
433. “Supplements for IBS: What is the evidence?” IFFGD Virtual Hill Day, July 26, 2020.
434. “The ins and outs of Chronic Constipation in 2020” Department of Internal Medicine Virtual Grand Rounds, Michigan Medicine, July 31, 2020.
435. “Dietary modulation of IBS”, “Modulation of gut microbiome: FMT and beyond”. Asian Pacific Neurogastroenterology & Motility Meeting. Seoul, Korea, August 14-16, 2020.
436. “Functional Dyspepsia”, Diet Therapies for Irritable Bowel Syndrome, Taiwan Digestive Diseases Week, August 25-26, 2020.
437. “Novel food intolerance testing and personalizing diet interventions for IBS patients” 2020 Food & Nutrition Conference & Expo, October 18, 2020.
438. Course Co-director and Speaker “ACG: What’s new in GI Pharmacology Course” “Dissaccharidase deficiency: A primer for gastroenterologists”, October 23, 2020.
439. Course Director: “Congenital sucrose-isomaltase deficiency: Hiding in plain sight” ACG Annual Meeting Satellite Symposium, October 24, 2020.
440. “Dietary and CAM Approaches for Management of IBS” ACG Post-graduate Course, October 25, 2020.

441. "A comparative effectiveness study of kiwifruit, prunes, or psyllium for US patients with chronic constipation" ACG Annual Meeting Presidential Plenary, October 26, 2020.
442. "GI on Demand: Making virtual integrated care for GI disorders a reality" ACG Annual Meeting, October 28, 2020.
443. "Non-medical therapies for IBS: Soup to nuts", "Microbiome-based therapies for IBS", "The inspired digital rectal examination". *ACG Functional GI Disorders School. Course Co-Director*, Virtual Program, December 5, 2020.
444. "NIH Fecal incontinence treatment trial review" MBCP Education Hour, Virtual Program, December 9, 2020.
445. "Management of Small intestinal bacterial overgrowth" Michigan Medicine GI Fellows Conference, Virtual Program, February 3, 2021.
446. "Small intestinal bacterial overgrowth: Fact of fiction." Northwell Lenox Hill Medical Center Grand Rounds, Virtual Program, February 18, 2021.
447. "SIBO: Challenges in diagnosis and treatment" FGS/ACG Annual Spring Symposium, February 27, 2021
448. "Evidence-based update on Irritable Bowel Syndrome" University Health Service Grand Rounds, Michigan Medicine, March 11, 2021.
449. Moderator for ACG Virtual Grand Rounds: "How to be an integrative gastroenterologist" Elena Ivanina, March 11, 2021.
450. "State of the art diagnosis and treatment of Irritable Bowel Syndrome" General Medicine Grand Rounds, Michigan Medicine, March 23, 2021.
451. "Non-medical therapies for IBS: Soup to nuts", "Microbiome-based therapies for IBS", "The inspired digital rectal examination". *ACG Functional GI Disorders School. Course Co-Director*, April 9, 2021.
452. "Recognizing potential masqueraders of IBS" Henry Ford Health System GI Grand Rounds, April 29, 2021.
453. "Clinical Challenges in GI: Answers from the experts" "Integrated care for IBS", DDW 2021, May 21, 2021.
454. "State of the Art Treatment of *H. pylori* Infection", DDW 21 satellite symposium, May 21, 2021.
455. "The Spectrum of congenital sucrose-isomaltase deficiency" DDW 21 satellite symposium, May 22, 2021.
456. "The Changing Landscape in EGIDs Beyond the Esophagus" DDW 21 satellite symposium, May 23, 2021.
457. "Carbohydrate digestion & absorption, SID pathophysiology, symptoms, and epidemiology", CSID Leadership Summit, June 17, 2021.
458. "Update on diet therapies for IBS" GI Connect CME Conference, June 19, 2021.
459. "Recognizing Potential Masqueraders for IBS" Michigan GI Society, June 24, 2021.
460. "Non-medical therapies for IBS: Soup to nuts", "Microbiome-based therapies for IBS", "The inspired digital rectal examination". *ACG Functional GI Disorders School. Course Co-Director*, August 13, 2021.
461. "Management of *H. pylori* in 2021" ACG Virtual Grand Rounds, September 2, 2021.
462. "Evidence-based Management of IBS" Nestle Nutrition Institute, September 2, 2021.
463. "The role of food in integrated care for IBS" School of Public Health, University of Michigan, September 22, 2021.

464. "Treatment of Irritable Bowel Syndrome" Keynote Address, GI & Hepatology Symposium: Practice Pearls and Novel Therapeutics. Emory University. Braselton, GA, September 11, 2021.
465. "Management of *H. pylori* Infection in 2021" GI Pow Wow, Denver, CO, October 2, 2021.
466. **Course Co-director** and Speaker "ACG: What's new in GI Pharmacology Course" "Evidence-based treatment of *H. pylori* in 2021", October 22, 2021.
467. "Dietary therapies for IBS: a recipe for success" ACG Postgraduate Course, Las Vegas, NV, October 24, 2021.
468. "Small intestinal bacterial overgrowth" Learning Luncheon, ACG Postgraduate Course, Las Vegas, NV, October 24, 2021.
469. "The end of the beginning: Megatrends in GI". Jack Berk Memorial Lecture, Annual Meeting of the ACG, October 26, 2021.
470. **Course Co-director** and Speaker "International Foundation of GI Disorders 30th Anniversary Norton Education Symposium", Charleston, SC, November 5-6, 2021.
471. "Role of diet in the pathogenesis and treatment of IBS" Harvard Interhospital GI Motility Conference, November 11, 2021.
472. "*H. pylori* infection: Something old, something new" Baptist Hospital GI Symposium, November 13, 2021.
473. "UM Division of Gastroenterology & Liver Diseases Vision Talk: Where we are, where we want to go, and how we get there" University of Michigan, Ann Arbor, MI, December 10, 2021.
474. "The role of diet in the pathogenesis and management of IBS" ACG Second Year Fellow Course, Washington DC, January 15, 2021.
475. "Is IBS a microbiome-based disorder", "Diet therapies for IBS: Is food really medicine?" ACG Functional GI & Motility Disorders School. Las Vegas, NV, January 28, 2022.
476. Course Co-director & Speaker "Evidence-based *H. pylori* Update" University of Michigan Winter GI Symposium, Coconut Point, FL, February 11-12, 2022.
477. "Irritable Bowel Syndrome", "Chronic Constipation". Idaho Gut Club Meeting, Sun Valley, ID, March 11-12, 2022.
478. "*H. pylori*: The refractory cases" LGS/ACG Regional Course, New Orleans, LA, March 20, 2022.

Bibliography

Peer-Reviewed Publications

1. **Chey WD**, Hasler WL, and Bockenstedt P. Angiodysplasia and vonWillebrand's Disease type IIB treated with Estrogen/Progesterone therapy. *Am J Hematology* 1992; 41:276-79.
2. **Chey WD**, Kochman ML, Traber PG, and Gumucio JJ. Nizatidine-induced subfulminant hepatic failure: Report of a case and review of the literature. *J Clin Gastroenterol* 1995; 20:164-7.

3. Sims M, Hasler W, **Chey WD**, Kim M, and Owyang C. Acute hyperglycemia inhibits gastrocolonic and colonic peristaltic reflexes measured by an electronic barostat in healthy humans. *Gastroenterol* 1995; 108:350-9.
4. Hasler WL, Kim MS, **Chey WD**, Stevenson V, Stein B, Owyang C. Central cholinergic and alpha-adrenergic mediation of gastric slow wave dysrhythmias evoked during motion sickness. *Am J Physiol* 1995; 268: G539-G547.
5. **Chey WD**, Kim ML, Hasler WL, Owyang C. Acute hyperglycemia alters perception of rectal distention and blunts the rectoanal inhibitory reflex in healthy volunteers. *Gastroenterol* 1995; 108:1700-8.
6. **Chey WD**, Beydoun A, Roberts D, Hasler W, and Owyang C. Somatostatin analog educes perception of rectal electrical stimulation by spinal afferent pathway inhibition. *Am J Physiol* 1995; 269 (Gastrointest. Liver Physiol. 32): G821-6.
7. **Chey WD**, Carpenter S, Spybrook M, Nostrant T, Elta G, Scheiman J. Prolonged effect of omeprazole on the ¹⁴C-urea breath test. *Am J Gastroenterol* 1996; 91:89-92.
8. Kohagen KR, Kim MS, McDonnell M, **Chey WD**, Owyang C, Hasler WL. Nicotine effects on prostaglandin-dependent gastric slow wave rhythmicity and antral motility in non-smokers and smokers. *Gastroenterol* 1996; 110:3-11.
9. Scheiman JM, **Chey WD**, Behler EM, Crause I, Elta GH. One-week therapy for *H. pylori*: A randomized trial of two treatment regimens. *J Clin Gastroenterol* 1996; 23:170-3.
10. **Chey WD**, Fey D, Woods M, Scheiman J, Del Valle J, Nostrant T. Lansoprazole and ranitidine effect the accuracy of the ¹⁴C-urea breath test by a pH dependent mechanism. *Am J Gastroenterol* 1997; 92:446-50.
11. Kim MS, **Chey WD**, Owyang C, Hasler WL. Role of plasma vasopressin as a mediator of nausea and gastric slow wave dysrhythmias in motion sickness. *Am J Physiol* 1997; 272(4 Pt 1): G853-62.
12. Marinella MA, **Chey WD**. The syndrome of inappropriate antidiuretic hormone secretion in a patient with Whipple's disease. *Am J Med Sci* 1997; 313:247-8.
13. **Chey WD**, Fisher L, Elta GH, Barnett J, Nostrant T, Del Valle J, Scheiman J. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for *H. pylori* infection: a randomized trial. *Am J Gastroenterol* 1997; 92:1483-6.
14. Elta GH, Barnett JL, Wille RT, Brown KA, **Chey WD**, Scheiman JM. Pure cut electrocautery current for sphincterotomy causes less post-procedure pancreatitis than blended current. *Gastrointest Endosc* 1998; 47:149-53.
15. **Chey WD**, Murthy U, Linscheer W, Barish C, Riff R, Rubin H, Safdi M, Schwartz H, Shah H, Wruble L, El-Zamaity, HMT. The ChemTrak Hp Chek™ fingerstick, whole blood serology test for the detection of *H. pylori* infection. *Am J Gastroenterol* 1998; 93:16-19.
16. Fendrick AM, **Chey WD**. Approach to the patient with *Helicobacter pylori*-associated epigastric pain. *J Clin Outcomes Med* 1998; 5:41-8.
17. Bjornsson ES, **Chey WD**, Ladabaum U, Hooper FG, Woods ML, Owyang C, Hasler WL. Differential 5-HT₃ mediation of the human gastrocolonic response and colonic peristaltic reflex. *Am J Physiol* 1998; 275: G498-505.
18. Gorelick AB, Koshy SS, Hooper FG, Bennett TC, **Chey WD**, Hasler WL. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy volunteers. *Am J Physiol* 1998; 275: G460-6.

19. **Chey WD**, Fisher L, Barnett J, Delvalle J, Elta GH, Nostrant T, Palaniappan J, Scheiman J. Triple therapy with low versus high dose azithromycin to treat *H. pylori* infection. *Aliment Pharm Ther* 1998; 12:1263-7.
20. Fendrick AM, **Chey WD**, Fennerty MB. Estimating the demand for *H. pylori* confirmatory testing after eradication treatment. *Am J Med* 1999; 107:133-6.
21. **Chey WD**, Murthy U, Shaw S, Zawadski A, Linscheer W, Laine L. A comparison of 3 fingerstick, whole blood antibody tests for *H. pylori* infection: a US multi-center trial. *Am J Gastroenterol* 1999; 94:1512-5.
22. **Chey WD**, Murthy U, Toskes P, Carpenter S, Laine L. The ¹³C-urea blood test accurately detects active *H. pylori* infection: a US, multicenter trial. *Am J Gastroenterol* 1999; 94:1522-4.
23. Pop-Busui, R, **Chey W**, Stevens MJ. Severe Hypertension Induced by the Long-Acting Somatostatin Analogue Sandostatin LAR in a Patient with Diabetic Autonomic Neuropathy. *Journal of Clinical Endocrinology & Metabolism* 2000; 85:943-946.
24. Mao HV, Lak BV, Long T, Chung NQ, Thang DM, Hop TV, Chien NN, Hoan PQ, Henley KS, Connor BA, Stone CD, **Chey WD**. Omeprazole or ranitidine bismuth citrate with clarithromycin and amoxicillin for 10 days to treat *H. pylori* infection: A randomized, controlled trial in Vietnamese patients with duodenal ulcer. *Aliment Pharmacol Ther* 2000; 14:97-101.
25. **Chey WD**, Metz DC, Shaw S, Kearney D, Montague J, Murthy U. Appropriate timing of the ¹⁴C-urea breath test to establish eradication of *H. pylori* infection. *Am J Gastroenterol* 2000; 95:1171-4.
26. Wille RT, Barnett JL, **Chey WD**, Scheiman JM, Elta GH. Routine droperidol pre-medication improves sedation for ERCP. *Gastrointest Endosc* 2000; 52:362-6.
27. Stern MA, Fendrick AM, McDonnell WM, Gunaratnam N, Moseley RH, **Chey WD**. A randomized, controlled trial to assess a novel colorectal cancer screening strategy: the conversion strategy. *Am J Gastroenterol* 2000; 95:2074-9.
28. Hirsh G, **Chey WD**. Case of the Month: ruptured pseudoaneurysm. *Am J Med* 2000; 109:65.
29. Stern MA, **Chey WD**. Pneumatosis coli and colonic intussusception. *N Engl J Med* 2001; 345:964.
30. Ladabaum U, Minoshima S, Hasler WL, Cross D, **Chey WD**, Owyang C. Localization of human cortical and subcortical responses to gastric distention using positron emission tomography. *Gastroenterol* 2001; 120:369-76.
31. **Chey WD**, Shapiro B, Zawadski A, Goodman K. Gastric emptying characteristics of a novel ¹³C-octanoate-labelled muffin meal. *J Clin Gastroenterol* 2001; 32:394-99.
32. **Chey WD**, Chathadi K, Montague J, Ahmed F, Murthy U. Intra-gastric acidification reduces the occurrence of false negative urea breath test results in patients taking a proton pump inhibitor. *Am J Gastroenterol* 2001; 96:1028-32.
33. **Chey WD**, Fendrick M. Non-invasive *H. pylori* testing for the test and treat strategy: a decision analysis to assess the impact of past infection on test choice. *Arch Intern Med* 2001; 161:2129-32.
34. **Chey WD**. Diagnosis of *Helicobacter pylori*. *Practic Gastroenterol* 2001; 25:28-41.
35. Scheiman JM, Carlos R, Barnett JL, Elta GH, Nostrant TT, **Chey WD**, Francis I, Nandi P. Can endoscopic ultrasound or magnetic resonance cholangiopancreatography replace ERCP in patients with suspected biliary disease? *Am J Gastroenterol* 2001; 96:2900-4.

36. Quallich LG, Stern MA, Rich M, **Chey WD**, Barnett JL, Elta GH. Bile duct crystals do not contribute to post-cholecystectomy syndrome. *Gastrointestinal Endoscopy* 2002; 55:163-6.
37. Lake J, **Chey WD**. Diagnosis of *H. pylori* in the clinical setting. *Frontiers in Bioscience* 2001; 6: e129-e136.
38. Gonlachanvit S, **Chey WD**, Goodman KJ, Parkman HP. Effect of meal size and test duration on gastric emptying and gastric myoelectrical activity as determined with simultaneous EGG and ¹³C-octanoate breath test in normal subjects using a muffin meal. *Dig Dis Sci* 2001; 46:2643-50.
39. Bjornsson E, **Chey WD**, Hooper F, Woods M, Owyang C, Hasler W. Impaired gastrocolonic response and peristaltic reflex in slow transit constipation: Role of 5-HT₃ pathway. *Am J Physiol* 2002; 283: (Gastrointest Liver Physiol) G400-G407.
40. Gorelick A, Cannon M, Barnett J, **Chey W**, Scheiman J, Elta G. First cut, then blend: an electrocautery technique affecting bleeding at sphincterotomy. *Endoscopy* 2001; 33:976-80.
41. Ladabaum U, **Chey WD**, Scheiman J, Fendrick M. Empiric therapy may be cost-effective compared to *H. pylori* testing and treatment in some populations with uninvestigated dyspepsia. *Aliment Pharmacol Ther* 2002; 16:1491-1501.
42. **Chey WD**, Olden K, Carter E, Boyle J, Drossman D, Chang L. Utility of the Rome I and Rome II criteria for IBS in US women. *Am J Gastroenterol* 2002; 97:2803-11.
43. Cash BD, **Chey WD**. Diagnosis of the Irritable Bowel Syndrome. *Practical Gastroenterol* 2002; 26:24-38.
44. Cash BD, **Chey WD**. Irritable Bowel Syndrome: Diagnosis and Management. *J Clin Outcomes Med* 2002; 9:409-18.
45. Cash BD, Schoenfeld P, **Chey WD**. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. *Am J Gastroenterol* 2002; 97:2812-19.
46. Brown WH, **Chey WD**, Elta GH. Number of Responses on a Review of Systems Questionnaire Predicts the Diagnosis of Functional GI Disorders. *J Clin Gastroenterol* 2003; 36:222-27.
47. Koshy SS, Bansal R, Scheiman J, Barnett J, **Chey WD**, Nostrant TT. Intrasphincteric botulinum toxin versus Witzel pneumatic balloon dilatation for treatment of primary achalasia. *J Clin Gastroenterol* 2003; 36:209-214.
48. **Chey WD**, Huang B, Lukasik N, Jackson RL. Lansoprazole vs. Esomeprazole in symptomatic gastro-esophageal reflux disease: A double-blind, randomized, multicentre trial in 3000 patients confirms comparable symptom relief. *Clin Drug Invest* 2003; 23:69-84.
49. Hasler WL, **Chey WD**. Clinical management of nausea and vomiting. *Gastroenterol* 2003; 125:1860-7.
50. Schoenfeld P, **Chey WD**. An evidence based approach to clinical practice guidelines – diagnosis and treatment of Irritable Bowel Syndrome. *Clin Gastroenterol Hepatol* 2003; 1:322-7.
51. Cash BD, **Chey WD**. Irritable Bowel Syndrome: An evidence based approach to diagnosis. *Aliment Pharmacol Ther* 2004; 19:1235-45.
52. Gorelick A, Barnett J, **Chey W**, Anderson M, Elta G. Botulinum toxin injection after biliary sphincterotomy. *Endoscopy* 2004; 36(2):170-3.

53. Cash BD, **Chey WD**. Irritable Bowel Syndrome: A systematic review. *Fam Med Clin N Am* 2004; 6:647-70.
54. Rubenstein J, Sherif A, Appelman H, **Chey WD**. Ulcerative colitis associated enteritis. *J Clin Gastroenterol* 2004; 38:46-51.
55. **Chey WD**, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ. Long-term efficacy and safety of Alosetron in women with severe diarrhea-predominant Irritable Bowel Syndrome. *Am J Gastroenterol* 2004; 99:2195-2203.
56. Fischer R, Thistle J, Lembo A, Novick J, O’Kane P, **Chey WD**, Beglinger C, Rueegg P, Shi V, Dogra A, Luo D, Earnest D. Tegaserod does not alter fasting or meal-induced biliary tract motility. *Am J Gastroenterol* 2004; 99:1342-9.
57. **Chey WD**. Erosive esophagitis and NERD: Can we really classify patients with heartburn using endoscopic findings? *Clin Gastroenterol Hepatol*, 2004; 2:654-5.
58. Evans LT, **Chey WD**. Clostridial aortitis and colon cancer. *Gastrointest Endosc* 2004; 60:803.
59. Johanson JF, Wald A, Tougas G, **Chey WD**, Novick J, Lembo A, Fordham F, Guella M, Nault B. Tegaserod is effective and well tolerated in patients with chronic constipation: Findings from a randomized, double-blind, placebo-controlled trial. *Clin Gastroenterol Hepatol* 2004; 2:796-805.
60. Saad R, **Chey WD**. A clinician’s guide to the diagnosis and treatment of *H. pylori*. *Clin J Med* 2005; 72:109-126.
61. Gonlachanvit S, Rhee J, Sun WM, **Chey WD**. Effect of acute acoustic stress on anorectal function and sensation in healthy humans. *Neurogastroenterol Motil* 2005; 17:222-8.
62. **Chey WD**, Inadomi JM, Booher A, Sharma VK, Fendrick AM, Howden CW. Primary care physicians perceptions and practices on the management of GERD: Results of a national survey, *Am J Gastroenterol* 2005; 100:1243-50.
63. **Chey WD**, Cash BD. Cilansetron: A new serotonergic agent for the irritable bowel syndrome and diarrhea. *Expert Opinions on Investigational Drugs*, 14:185-93; 2005.
64. Talley NJ, Vakil N, **Practice Parameters Committee of the ACG**. Guidelines for the management of dyspepsia. *Am J Gastroenterol* 2005; 100:2324-37.
65. Schmeidl-Ren P, Kesisoglou F, Mapili JA, Sabek ME, **Chey WD**, Roessler B, Zimmermann EM. Increased transduction of human intestinal epithelial cells by adenoviral vectors in inflammatory bowel disease. *Inflamm Bowel Dis* 2005; 11:464-72.
66. Cash BD, **Chey WD**. Role of serotonergic agents in the treatment of patients with primary chronic constipation. *Aliment Pharmacol Ther* 2005; 22:1047-60.
67. Ahmed F, **Chey WD**, Murthy U. Evaluation of the Ez-HBT *Helicobacter* blood test to establish *Helicobacter pylori* eradication, *Aliment Pharm Ther* 2005; 22:875-80.
68. Dickman R, Green C, **Chey WD**, Jones MP, Eisen GM, Ramirez F, Briseno M, Garewal HS, Fass R. Clinical predictors of Barrett’s esophagus length. *Gastrointest Endosc* 2005; 62:675-81.
69. Saad R, **Chey WD**. What is the most effective treatment for patients with dyspepsia who are negative for *Helicobacter pylori* infection? *Nat Clin Pract Gastroenterol Hepatol* 2006; 3:20-21.
70. **Chey WD**, Eswaran S, Howden CW, Inadomi J, Fendrick AM, Scheiman J. Primary care physicians perceptions of NSAID and aspirin-associated toxicity: Results of a national survey. *Aliment Pharm Ther* 2006; 23:655-68.

71. Saad R, **Chey WD**. Tegaserod in the treatment of irritable bowel syndrome with constipation. *Women's Health* 2006; 2:29-42.
72. Saad R, Schoenfeld P, **Chey WD**. Levofloxacin triple or PPI quadruple salvage therapy for persistent *Helicobacter pylori* infection: Results of a meta-analysis. *Am J Gastroenterol* 2006; 101:488-96.
73. Chang L, **Chey WD**, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. *Am J Gastroenterol* 2006; 101:1-11.
74. Longstreth G, Thompson WG, **Chey WD**, Houghton L, Mearin F, Spiller R. Rome III: Functional Bowel Disorders. *Gastroenterol* 2006; 130:1480-91.
75. Irvine EJ, Whitehead W, **Chey WD**, Matsueda K, Shaw M, Talley NJ, Veldehuyzen van Zanten S. Rome III: Design of treatment trials. *Gastroenterol* 2006; 130:1538-51.
76. Saad R, **Chey WD**. Current and emerging therapies for functional dyspepsia. *Aliment Pharmacol Ther* 2006; 24:475-92.
77. Saad R, **Chey WD**. Treatment of *H. pylori* infection in 2006. *Gastroenterol Hepatol Annual Review* 2006; 1:30-35.
78. **Chey WD**, Wong B. American College of Gastroenterology Practice Guidelines: Management of *Helicobacter pylori* infection. *Am J Gastroenterol* 2007; 102:1808-25.
79. Elnachef N, McMorris M, **Chey WD**. Successful treatment of Common Variable Immunodeficiency Disorder Associated Diarrhea with Budesonide: A Case Report. *Am J Gastroenterol* 2007; 102:1322-25.
80. Rubenstein JH, Nojkov B, Korsnes S, Adlis SA, Shaw MJ, Inadomi JM, **Chey WD**. Esophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. *Aliment Pharmacol Ther* 2007; 26:443-52.
81. Saad R, **Chey WD**. The role of breath tests in clinical GI practice. *Gastroenterol* 2007; 133:1763-6.
82. Portlock CS, Hamlin P, Noy A, **Chey WD** (4/12) Markowitz A. Infectious disease associations in advanced stage, indolent lymphoma (Follicular and Non-Follicular): Developing a lymphoma prevention strategy. *Ann Oncology* 2008; 19:254-258. [I contributed by helping with the study design, providing breath testing analysis and interpretation and reviewing and revising the manuscript]
83. Portlock CS, Hamlin P, Noy A, **Chey WD** (4/12) Markowitz A. Infectious disease associations in advanced stage, indolent lymphoma (Follicular and Non-Follicular): Developing a lymphoma prevention strategy. *Ann Oncology* 2008; 19:254-258. [I contributed by helping with the study design, providing breath testing analysis and interpretation and reviewing and revising the manuscript]
84. Kuo B, McCallum RW, Koch KL...**Chey WD** (6/12)...Parkman HP. Comparison of gastric emptying of a non-digestible capsule to a radiolabeled meal in healthy and gastroparetic subjects. *Aliment Pharmacol Ther* 2008; 27:186-96. [I contributed by helping to design the study, interpret the data and by reviewing and revising the manuscript]
85. Saad R, **Chey WD**. Recent developments in the treatment of the irritable bowel syndrome. *Expert Opinion Invest Drugs* 2008; 17:117-30.

86. Nojkov B, Saad R, Adlis S, Shaw M, **Chey WD**. Predictors of response to PPI therapy in patients with GERD: the influence of co-morbid IBS and psychological disease. *Aliment Pharmacol Ther* 2008; 27:473-82.
87. **Chey WD**, Paré P, Viegas A, Ligozio G, Shetzline MA. Tegaserod for females suffering from IBS with mixed bowel habits or constipation: A randomized controlled trial. *Am J Gastroenterol* 2008; 103:1217-25.
88. Saad R, **Chey WD**. Treatment of persistent *H. pylori* infection. *Clin Gastroenterol Hepatol* 2008; 6(10):1086-1090.
89. Saad R, **Chey WD**. Lubiprostone in the treatment of chronic idiopathic constipation and irritable bowel syndrome and constipation. *Exp Rev Gastroenterol Hepatol* 2008; 2(4):497-508.
90. Vakil N, Laine L, Talley NJ...**Chey WD** (6/10), Cohard-Radice M. Tegaserod treatment for dysmotility-like functional dyspepsia: Results of two randomized, controlled trials. *Am J Gastroenterol* 2008 103(8):1906-19. [contributed by helping to design the study, interpret the data and by reviewing and revising the manuscript]
91. Elnachef N, Scheiman JS, Fendrick M, Howden C, **Chey WD**. Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers. *Aliment Pharmacol Ther* 2008; 28:1249-58.
92. Lewicky-Gaupp C, Morgan D, **Chey WD** (3/6), Fenner DE. Does physical therapy for constipation related to puborectalis dyssynergia improve symptom severity and quality of life? *Dis Colon Rectum* 2008; 51:1686-91.
93. Lacy B, **Chey WD**. Lubiprostone: Chronic constipation and irritable bowel syndrome with constipation. *Expert Opinion Pharmacol* 2009; 10:143-52.
94. Drossman D, **Chey WD**, Johanson JF, Fass R, Panas R, Ueno R. Lubiprostone in patients with constipation-associated irritable bowel syndrome: results of two randomized, placebo-controlled trials. *Aliment Pharmacol Ther* 2009; 29:329-41. [contributed by helping to design the study, interpret the data and by reviewing and revising the manuscript]
95. Maneerattanaporn M, **Chey WD**. Sleep and functional gastrointestinal disorders: The chicken or the egg? *Neurogastroenterol Motil* 2009; 2:97-99.
96. Brenner D, Moeller MJ, **Chey WD**, Schoenfeld P. The role of probiotics in the treatment of irritable bowel syndrome: a systematic review. *Am J Gastroenterol* 2009; 104:1033-49. [contributed by helping to design the study and by writing, reviewing and revising the manuscript]
97. Ford AC, **Chey WD**, Talley NJ, Malhotra A, Spiegel BMR, Moayyedi P. Utility of diagnostic tests for celiac disease in Irritable Bowel Syndrome: Systematic review and meta-analysis. *Arch Int Med* 2009; 169:651-8.
98. **ACG IBS Task Force**. An evidence-based review of the management of irritable bowel syndrome. *Am J Gastroenterol* 2009; 104 (supplement 1): S1-S35. [contributed by interpreting the data used to make management recommendations and by writing, reviewing and revising the manuscript]
99. Sharma P, **Chey WD**, Hunt R, Laine L, Malferheiner P, Wani S. Endoscopy of the esophagus in gastroesophageal reflux disease – Are we losing sight of symptoms? Another perspective. *Dis Esophagus* 2009; 22:461-6. [contributed by helping to write, review and revise the manuscript]

100. Rao SSC, Kuo B, McCallum RW, **Chey WD**, DiBaise JK, Hasler WL, Koch KL, Lackner JL, Miller C, Saad R, Semler JR, Sitrin, MD, Wilding GE, Parkman HP. Investigation of Wireless Manometry Capsule for Colonic and Whole Gut Transit: A Comparative Study with Radiopaque Markers in Health and Constipation. *Clin Gastroenterol Hepatol* 2009; 7:537-44. [contributed by helping to design the study, interpret the data and by reviewing and revising the manuscript]
101. Spiegel B, Harris L, Lucak S, Mayer E, Naliboff B, Bolus R, Estrailian E, **Chey WD**, Lembo A, Karsan H, Tillisch K, Dulai G, Tally J, Chang L. Developing valid and reliable health utilities in IBS: Results from the IBS Proof Cohort. *Am J Gastroenterol* 2009; 104:1984-91.
102. Ford AC, Brandt LJ, Young C, **Chey WD**, Foxx-Orenstein A, Moayyedi P. Efficacy of 5-HT₃ Antagonists and 5-HT₄ Agonists in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. *Am J Gastroenterol* 2009; 104:1831-43.
103. Fass R, **Chey WD**, Zakko SF, Andhivarothai N, Palmer RN, Perez MC, Atkinson SN. The effects of the proton pump inhibitor TAK 390MR on daytime and nighttime heartburn in patients with nonerosive gastroesophageal reflux disease: A double-blind, randomized, placebo-controlled trial. *Aliment Pharmacol Ther* 2009; 29:1261-72.
104. **Chey WD**, Mody RR, Wu EQ, Chen L, Kothari S, Persson B, Beaulieu N. Treatment patterns and symptom control in patients with gastroesophageal reflux disease – A US Community-based Survey. *Curr Medical Res Opin* 2009; 8:1869-78.
105. Hasler WL, Saad RJ, Rao SS, Wilding GE, Parkman HP, Koch KL, McCallum RW, Kuo B, Sarosiek I, Sitrin MD, Semler JR, **Chey WD**. Heightened colon motor activity measured by wireless capsule in patients with constipation: relation to colon transit and IBS. *Am J Physiol – GI and Liver Physiology* 297: 2009; G1107-14.
106. Spiegel B, Camilleri M, Bolus R, Andresen V, **Chey WD**, Fehnel S, Mangel A, Talley NJ, Whitehead WE. Psychometric evaluation of endpoints in IBS randomized controlled trials: A Rome Foundation Working Group Report. *Gastroenterol* 2009; 137:1944-53.
107. Spiegel B, Bolus R, Harris LA, Lucak S, Mayer E, Naliboff B, Esrailian E, **Chey WD**, Lembo A, Karsan H, Tillisch K, Talley J, Chang L. Measuring IBS Patient Reported Outcomes with an Abdominal Pain Numeric Rating Scale: Results from the PROOF Cohort. *Aliment Pharmacol Ther* 2009; 30:1159-70.
108. Sarosiek I, Selover KH, Katz LA, Semler JR, Wildings GE, Lackner JM, Sitrin MD, Kuo B, **Chey WD**, Hasler WL, Koch KL, Parkman H, Sarosiek J, McCallum R. Assessment of Regional Gut Transit Times in Healthy Controls and Patients with Gastroparesis using Wireless Motility Technology. *Aliment Pharmacol Ther* 2010; 31:313-22.
109. Luther J, Higgins P, Moayyedi P, Vakil N, **Chey WD**. Clarithromycin-based triple therapy vs. Bismuth-based quadruple therapy for *H. pylori* infection: A meta-analysis. *Am J Gastroenterol* 2010; 105:65-73.
110. Saad R, Rao S; Hasler WL; Katz LA; Koch K; Kuo B; Lackner JM; Parkman HP; McCallum R; Miller C; Sarosiak I; Semler J; Sitrin MD; Wilding GE; **Chey WD**. How well do stool form or stool frequency correlate with colonic transit: Results from a multi-center study using the SmartPill Wireless pH/Pressure Capsule & radio-opaque Sitzmarker test in healthy controls and constipated patients. *Am J Gastroenterol* 2010; 105:403-11.
111. **Chey WD**, Howden CW, Tack J, Ligozio G, Earnest D. Long-Term Tegaserod Treatment for Dysmotility-like Functional Dyspepsia: Results of Two Identical 1-year

- Cohort Studies. *Dig Dis Sci* 2010; 55:684-97.
112. **Chey WD**, Mody RR, Izat E. Patient and Physician Satisfaction with Proton Pump Inhibitors: Are There Opportunities for Improvement? *Dig Dis Sci* 2010; 55:3415-22.
 113. **Chey WD**, Nojkov B, Cash BD. The yield of colonoscopy in patients with nonconstipated IBS: Results from a prospective, controlled US multicenter trial. *Am J Gastroenterol* 2010; 105:859-65.
 114. Nojkov B, Rubenstein J, **Chey WD**, Hoogerwerf W. The effect of shift work on the prevalence and clinical impact of Functional Bowel Disorders in nurses. *Am J Gastroenterol* 2010; 105:842-7.
 115. Kloetzer L, **Chey WD**, McCallum RW, Koch KL, Wo JM, Sitrin M, Katz LA, Lackner JM, Parkman HP, Wilding GE, Semler JR, Hasler WL, Kuo B. Motility of the antroduodenum in healthy and gastroparetics characterized by wireless motility capsule. *Neurogastroenterol Motil* 2010; 22:527-e117.
 116. Spiegel B, Bolus R, Harris LA, Lucak S, Mayer E, Naliboff B, Esrailian E, **Chey WD**, Lembo A, Karsan H, Tillisch K, Talley J, Chang L. Characterizing Abdominal Pain in IBS: Guidance for Study Inclusion Criteria, Outcome Measurement, and Clinical Practice. *Aliment Pharmacol Ther* 2010; 32:1192-1202.
 117. Spiegel B, Bolus R, Agarwal N, Harris LA, Lucak S, Esrailian E, **Chey WD**, Lembo A, Karsan H, Tillisch K, Talley J, Sayuk G, Chang L. Measuring Symptoms in Irritable Bowel Syndrome: Development of a Framework for Clinical Trials. *Aliment Pharmacol Ther* 2010; 32:1275-91.
 118. Mullady DK, Yadav D, Amann ST, O'Connell MR, Barmada MM, Elta GH, Scheiman JM, Wamsteker EJ, **Chey WD**, Korneffel M, Weinman BM, Slivka A, Sherman S, Hawes RH, Brand RE, Burton FR, Lewis MD, Gardner TB, Gelrud A, DiSario JA, Baillie J, Banks PA, Whitcomb DC, Anderson MA. Type of pain, pain-associated complications, quality of life, disability and resource utilization in chronic pancreatitis: a prospective cohort study. *Gut* 2011; 60:77-84.
 119. Pimentel M, Lembo A, **Chey WD**, Zakko S, Ringel Y, Yu J, Mareya S, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. *New Engl J Med* 2011; 364:22-32.
 120. **Chey WD**, Maneerattanaporn M, Saad R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. *Gut Liver* 2011; 5:253-66.
 121. **Chey WD**, Camilleri M, Chang L, Rikner L, Graffner H. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. *Am J Gastroenterol* 2011; 106:1803-12.
 122. Greenberg ER, Anderson GL, Morgan DR, Torres J, **Chey WD**, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce E, Meza-Montenegro MM, Peña R, Peña EM, Salazar-Martinez E, Correa P, Martinez ME, Valdivieso M, Goodman GE, Crowley JJ, Baker LM. 14-day triple, 5-day concomitant, and 10-day sequential therapies for *Helicobacter pylori* infection in seven Latin American sites: a randomized trial. *Lancet* 2011; 378:507-14.
 123. Cash BD, Rubenstein JH, Young PE, Gentry A, Nojkov B, Lee D, Andrews AH, Dobhan R, **Chey WD**. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. *Gastroenterol* 2011; 141:1187-93.
 124. Kuo B, Maneerattanaporn M, Lee AA, Baker JR, Weiner SM, **Chey WD**, Wilding GE, Hasler WL. Generalized transit delay on wireless motility capsule testing in patients with

- clinical suspicion of gastroparesis, small intestinal dysmotility, or slow transit constipation. *Dig Dis Sci* 2011; 56:2928-38.
125. Menees SB, Maneerattanaporn M, Kim HM, **Chey WD**. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. *Am J Gastroenterol* 2012; 107:28-35. PMID 22045120
 126. **Chey WD**, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with Irritable Bowel Syndrome with Constipation. *Aliment Pharmacol Ther* 2012; 35(5):587-99. PMID 22251419
 127. Tack J, Camilleri M, Chang L, **Chey WD**, Galligan JJ, Lacy BE, Muller-Lissner S, Quigley EMM, Schuurkes J, DeMaeyer JH, Stanghellini V. Systematic Review: Cardiovascular safety profile of 5-HT4 agonists developed for GI disorders. *Aliment Pharmacol Ther* 2012; 35:745-67. PMID 22356640
 128. **Chey WD**, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA, Baird MJ, Schneier HA, Johnston JM. Linaclotide for Irritable Bowel Syndrome with Constipation: A 26-week, Randomized, Double-blind, Placebo-controlled Trial to Evaluate Efficacy and Safety. *Am J Gastroenterol* 2012; 107(11):1702-12. PMID 22986437
 129. Menees S, Saad R, **Chey WD**. Agents that act luminally to change diarrhea and constipation. *Nature Rev Gastroenterol Hepatol* 2012, 9:661-74. PMID 22945441
 130. Quigley EM, Tack J, **Chey WD**, Rao SS, Fortea J, Falques M, Diaz C, Shif SJ, Currie MG, Johnston JM. Randomised clinical trials: linaclotide phase 3 studies in IBS-C – a prespecified further analysis based on European Medicines Agency-specified endpoints. *Aliment Pharmacol Ther* 2013; 37:49-61. PMID 23116208
 131. Smith TM, Menees SB, Xu X, Saad RJ, **Chey WD**, Fenner DE. Factors associated with quality of life among women with fecal incontinence. *Int Urogynecol J* 2013; 24:493-9. PMID 22806489
 132. Greenberg ER, **Chey WD**. Defining the role of sequential therapy for *H. pylori* infection. *Lancet* 2013; 381:180-2. PMID: 23158881
 133. Menees SB, Smith TM, Xu X, **Chey WD**, Saad RJ, Fenner DE. Factors associated with symptom severity in women presenting with fecal incontinence. *Dis Colon Rectum*. 2013; 56(1):97-102. PMID: 23222286
 134. Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martinez E, Greenberg ER, Bravo LE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC, Meza-Montenegro MM, Pena EM, Pena R, Correa P, Martinez ME, **Chey WD**, Valdivieso M, Anderson GL, Goodman GE, Crowley JJ, Baker LH. Risk of recurrent *Helicobacter pylori* infection 1 year after initial eradication therapy in 7 Latin American communities. *JAMA* 2013; 309:578-86. PMID 23403682
 135. Eswaran S, Goel A, **Chey WD**. What role does wheat play in the symptoms of Irritable Bowel Syndrome? *Gastroenterol Hepatol* 2013; 9:85-91. PMID 23983652
 136. **Chey WD**. The role of food in the functional gastrointestinal disorders: introduction to a manuscript series. *Am J Gastroenterol* 2013; 108:694-7. PMID 23545712
 137. Eswaran S, Muir J, **Chey WD**. Fiber and functional gastrointestinal disorders. *Am J Gastroenterol* 2013; 108:718-27. PMID 23545709
 138. Khanna D, Nagaraja V, Gladue H, **Chey W**, Pimentel M, Frech T. Measuring response in the gastrointestinal tract in systemic sclerosis. *Curr Opin Rheumatol* 2013; 25:700-706. PMID 24047604

139. Rubenstein JH, Morgenstern H, **Chey WD**, Murray J, Scheiman JM, Schoenfeld P, Appelman HD, McMahon L, Metko V, Kellenberg J, Kalish T, Baker J, Inadomi JM. Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett's esophagus. *Gut* 2013 Mar 5 [Epub ahead of print]. PMID 23461896
140. Saad R, **Chey WD**. Breath testing for small intestinal bacterial overgrowth: maximizing test accuracy. *Clin Gastroenterol Hepatol* 2014;12(12):1964-1972. PMID 24095975
141. Jones MP, **Chey WD**, Singh S, Gong H, Shringarpure R, Hoe N, Chuang E, Talley NJ. A biomarker panel and psychological morbidity differentiate the irritable bowel syndrome from health and provide novel pathophysiological leads. *Aliment Pharmacol Ther* 2014; 39:426-437.
142. **Chey WD**, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for Opioid-induced Constipation in Patients with Noncancer Pain. *N Engl J Med* 2014;25: 2387-2396. PMID: 24896818
143. Schoenfeld P, Pimentel M, Chang L, Lembo A, **Chey WD**, Yu J, Paterson C, Bortey E, Forbes WP. Safety and tolerability of rifaximin for the treatment of IBS with diarrhea; a pooled analysis of randomized, placebo-controlled trials. *Aliment Pharmacol Ther* 2014; 39:1161-8.
144. Webster L, **Chey WD**, Tack J, et al. Randomised clinical trial: long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. *Aliment Pharmacol Ther* 2014; 40:771-9.
145. Almario C, **Chey WD**, Kuang A, et al. Computer Algorithm Vs Physician-Documented History of Presenting Illness (HPI): Results of a Blinded Comparison. *Am J Gastroenterol* 2015; 110:170–179. PMID: 25461620
146. Menees S, Powell C, Kurlander J, Goel A, **Chey WD**. A Meta-analysis of the Utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in Adults with IBS. *Am J Gastroenterol* 2015; 110:1243-44. PMID: 25732419
147. **Chey WD**, Eswaran S, Kurlander J. Management of Irritable Bowel Syndrome. *JAMA* 2015; 313(9):949-958. PMID: 25734736
148. Heidelbaugh JJ, Stelwag MA, Miller SA, Shea EP, **Chey WD**. The Spectrum of Constipation-Predominant Irritable Bowel Syndrome and Chronic Idiopathic Constipation: US Survey Assessing Symptoms, Care Seeking, and Disease Burden. *Am J Gastroenterol* 2015; 110:580-7. PMID: 25781368
149. Baker JR, Eswaran S, Saad R, Menees S, Fenner D, **Chey WD**. Improvement in Abdominal Symptoms After Biofeedback Therapy in Patients with Dyssynergic Defecation. *Clin Translational Gastroenterol* 2015; 6: e105. PMID: 26225863
150. Menees S, Guentner A, Chey SW, Saad R, **Chey WD**. How Do US Gastroenterologists use Over-the-Counter and Prescription Medications in Patients with Gastroesophageal Reflux and Chronic Constipation? *Am J Gastroenterol* 2015; 110:1516-25. PMID: 26054623
151. Almario CV, **Chey WD**, Iriana S, Dailey F, Robbins K, Patel AV, Reid M, Whitman C, Fuller G, Bolus R, Dennis B, Encarnacion R, Martinez B, Soares J, Modi R, Agarwal N, Lee A, Kubomoto S, Sharma G, Bolus S, Chang L, Spiegel BMR. Computer versus physician identification of gastrointestinal alarm features. *Int J Med Inform* 2015; 84:1111-17. PMID: 26254875
152. Kulkarni HS, **Chey WD**, Mookherjee S, Saint S, Bump GM. Taking the detour. *J Hosp*

- Med 2015; 10:686-90. PMID: 26178589
153. Mearin F, Lacy B, Chang L, **Chey WD**, Lembo A, Simren M, Spiller R. Rome IV: The Functional Bowel Disorders. *Gastroenterol* 2016; 150:1393-1407.
 154. Palsson OS, Whitehead WE, van Tilburg MAL, Chang L, **Chey WD**, Crowell MD, Keefer L, Lembo AJ, Parkman HP, Rao SSC, Sperber A, Spiegel B, Tack J, Vanner S, Walker LS, Whorwell P, Yang Y. Development and validation of the Rome IV diagnostic questionnaire for adults. *Gastroenterol* 2016; 150:1481-91.
 155. Almario C, **Chey WD**, Spiegel BS. Impact of National Institutes of Health Gastrointestinal PROMIS® Measures in Clinical Practice: Results of a Multicenter Controlled Trial. *Am J Gastroenterol* 2016; 111:1546-56. PMID: 27481311
 156. Eswaran S, **Chey WD**, Han-Markey T, Ball K, Jackson K. US, randomized, controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in adults with IBS-D. *Am J Gastroenterol* 2016; 111:1824-32. PMID: 27725652
 157. Chang L, **Chey WD**, Drossman D, Losch-Beridon T, Wang M, Lichtlen P, Mareya S. Effects of Baseline Abdominal Pain and Bloating on Response to Lubiprostone in Patients with Irritable Bowel Syndrome with Constipation. *Aliment Pharmacol Ther* 2016; 44:1114-22. PMID: 27669680
 158. McRorie J, **Chey WD**. Fermented Fiber Supplements Are No Better Than Placebo for a Laxative Effect. *Dig Dis Sci* 2016; 61:3140-46. PMID: 27680987
 159. **Chey WD**, Leontiadis G, Howden C, Moss S. American College of Gastroenterology Practice Guideline: Management of *Helicobacter pylori* infection. *Am J Gastroenterol* 2017; 112:211-38.
 160. Ford AC, **Chey WD**. Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis. *Am J Gastroenterol* 2017; 112:65-76. PMID: 27753436
 161. Chey WY, Chang V, Hoellrich CM, Lubkin M, Corcoran D, Chang TM, **Chey WD**. Mega-cecum: An unrecognized cause of symptoms in some female patients with urogynecological symptoms and severe slow-transit constipation. *Dig Dis Sci* 2017; 62:217-23. PMID: 27913997
 162. **Chey WD**, Lembo AJ, Phillips JA, Rosenbaum DP. Tenapanor Treatment of Patients with Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial. *Am J Gastroenterol* 2017; 112:763-74. PMID: 28244495
 163. Lacy BE, **Chey WD**, Cash BD, et al. Eluxadolone efficacy in IBS-D patients who report prior loperamide use. *Am J Gastroenterol* 2017; 112:924-32. PMID: 28417992
 164. Eswaran S, **Chey WD**, Jackson K, Pilai S, Chey SW, Han-Markey T. A Low FODMAP Diet improves quality of life, reduces activity impairment, and improves sleep quality in patients with Irritable Bowel Syndrome and Diarrhea: Results from a US Randomized Controlled trial. *Clin Gastroenterol Hepatol* 2017; 15:1890-9. PMID: 28668539
 165. **Chey WD**, Dove LS, Andrae A, Covington PS. Early response predicts a sustained response to eluxadolone in patients with irritable bowel syndrome with diarrhea in two Phase 3 studies. *Aliment Pharmacol Ther* 2017; 45:1319-28. PMID: 28326568
 166. Lenhart A, **Chey WD**. A Systematic Review of the Effects of Polyols in Gastrointestinal Health and Irritable Bowel Syndrome. *Adv Nutrition* 2017; 8:587-96. PMID: 28710145
 167. Guivatchian T, Koeppe ES, Baker JR, Moisa C, Demerath M, Foor-Passin C, **Chey WD**, Eswaran SL, Kolars JC, Menees SB. Family history in colonoscopy patients: feasibility

- and performance of electronic and paper-based surveys for colorectal cancer risk assessment in the outpatient setting. *Gastrointest Endoscopy* 2017; 86:684-91. PMID: 28174125
168. Kurlander J, **Chey WD**, Morris C, Drossman D, et al. Development and Validation of the Patient-Physician Relationship Scale (PPRS) among Patients with Irritable Bowel Syndrome. *Neurogastroenterol Motil* 2017; 28: e13106. PMID: 28544094
 169. Chey SW, **Chey WD**, Saini SD, Weissman A, Harris L, Menees S. US Primary Care Providers use of Over-the-Counter Medications for Gastroesophageal Reflux Disease and Chronic Constipation. *Am J Pharm Ben* 2017; 9:116-21.
 170. Cryer B, Drossman DA, **Chey WD**, Webster L, Habibi S, Wang M. Analysis of nausea in clinical studies of lubiprostone for the treatment of constipation disorders. *Dig Dis Sci* 2017; 62:3568–3578. PMID: 28849329
 171. Camilleri M, Ford AC, Mawe G, Dinning PG, Rao S, **Chey WD**, Lembo A, Fadok T, Chang L. Chronic Constipation. *Nat Rev Dis Primers* 2017; 3: article number 17095. PMID: 29239347
 172. Eswaran S, Farida J, Green J, Miller JD, **Chey WD**. Nutrition in the management of GI diseases and disorders: the evidence for the low FODMAP diet. *Curr Op Pharmacol* 2017; 37:151-7.
 173. Schoenfeld P, Lacy BE, **Chey WD**, Lembo AJ, Kurtz CB, et al. Low dose (72 mcg) Linaclotide for Chronic Idiopathic Constipation: A 12 week randomized, double-blind, placebo-controlled trial. *Am J Gastroenterol* 2018; 113:105-14. PMID: 29091082
 174. Lenhart A, Ferch C, Shaw M, **Chey WD**. Use of Dietary Management in Irritable Bowel Syndrome: Results of a Survey of over 1500 U.S. Gastroenterologists. *J Neurogastroenterol Motil* 2018; 24:437-51. PMID: 29886578
 175. Shah E, Almario CV, Spiegel BMR, **Chey WD**. Lower and upper gastrointestinal symptoms differ between individuals with IBS with constipation or chronic idiopathic constipation. *J Neurogastroenterol Motil* 2018; 24:299-306. PMID: 29605985
 176. Menees S, Almario CV, Spiegel BMR, **Chey WD**. Prevalence and Predictors of Bowel Incontinence: Results from a Population-Based Survey of Over 71,000 Americans. *Gastroenterol* 2018; 154:1672-81. PMID: 29408460
 177. Garcia-Etxebarria K, Zheng T, Bongfiglio F, **Chey WD**, et al. Increased prevalence of rare sucrase-isomaltase (*SI*) pathogenic variants in irritable bowel syndrome patients. *Clin Gastroenterol Hepatol* 2018; 16:1673-6. PMID: 29408290
 178. Ford AC, Moayyedi P, **Chey WD**, Harris LA, Lacy BE, Saito YA, Quigley EMM. American College of Gastroenterology Monograph on the Management of IBS. *Am J Gastroenterol* 2018; 113:1-18. PMID: 29950604
 179. Dionne J, Ford AC, Yuan Y, **Chey WD**, Lacy BE, Quigley EMM, Moayyedi P. A systematic review and meta-analysis evaluating the efficacy of a gluten free diet and a low FODMAP diet in treating symptoms of IBS. *Am J Gastroenterol* 2018; 113:1290-1300. PMID: 30046155
 180. Brenner D, Dove LS, Andrae DA, Covington PS, Gutman C, **Chey WD**. Radar plots: a novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea. *Neurogastroenterol Motil* 2018; 30: e13331. PMID: 29575372
 181. Auesomwang C, Maneerattanaporn, M, **Chey WD**, Kiratisin P, Leelakusolwong S. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for

- Helicobacter pylori* eradication. J Gastroenterol Hepatol 2018; 33:1822-8. PMID: 29804294
182. Menees S, **Chey WD**. The gut microbiome and irritable bowel syndrome. F1000 Research 2018; <https://f1000research.com/articles/7-1029/v1> .
 183. Shah ED, Farida JD, Menees S, **Chey WD**. Examining balloon expulsion testing as an office-based, screening test for dyssynergic defecation: A systematic review and meta-analysis. Am J Gastroenterol 2018; 113:1613-20. PMID: 30171220
 184. Almario C, **Chey WD**, Spiegel BMR. Burden of Gastrointestinal Symptoms in the United States: Results of a Nationally Representative Survey of Over 71,000 Americans. Am J Gastroenterol 2018; 113:1701-10. PMID: 30323268
 185. Fodor A, Pimentel M, **Chey WD**, Lembo A, Golden PL, Israel RJ, Carroll IM. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes 2019;1022-33. PMID: 29708822
 186. Eswaran S, Dolan R, Ball S, Jackson K, **Chey WD**. The impact of a 4 week low FODMAP diet on nutrient intake in a sample of US adults with IBS-D. J Acad Nutrition Dietetics. 2019;120:641-9.
 187. **Chey WD**, Lacy BE, Cash BD, Epstein M, Corsino PE, Shah SM. A novel duodenal-release formulation of a combination of caraway oil and L-menthol for the treatment of functional dyspepsia: an RCT. Clin Translational Gastroenterol 2019;10: UNSP e-00021.
 188. Olden KW, **Chey WD**, Shringarpure R, Nicandro JP, Chuang E, Earnest DL. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. Current Medical Research and Opinion 2019; 35(3):461-472. PMID: 30293448
 189. Ahmed S, Almario CV, **Chey WD**, Robbins LA, Chang B, Ahn J, Ko J, Gu P, Siu A, Spiegel BMR. Electronic patient agenda form: comparing agreement between the reason for specialty consultation reported by referring providers and patients. Inform Health Soc Care 2019; 44:105-13. PMID: 29509054
 190. Carrasco-Labra A, Lytvyn L, Falck-Ytter Y, Surawicz CM, **Chey WD**. American Gastroenterology Association Institute Technical Review on the Evaluation of functional diarrhea and Diarrhea Predominant Irritable Bowel Disease in adults (IBS-D). Gastroenterol 2019;157:859-80.
 191. Riehl M, Kinnucan J, **Chey WD**, Stidham R. Nuances of the psychogastroenterology patient: A predictive model for gastrointestinal quality of life improvement. Neurogastroenterol Motil 2019;31:e13663.
 192. Taylor DCA, Abel JL, Doshi JA, Hunter AG, Esoi B, Korrer S, Reasner DS, Carson RT, **Chey WD**. The impact of stool consistency on bowel movement satisfaction in patients with IBS-C or CIC treated with linaclotide or other medications: Real world evidence from the CONTOR study. J Clin Gastroenterol 2019;53:737-43.
 193. Liu J, **Chey WD**, Haller E, Eswaran S. Low FODMAP Diet for Irritable Bowel Syndrome: What we know and what we have yet to learn. Ann Rev Med 2020;71:303-14.
 194. Menees S, Chandrasekhar D, Liew EA, **Chey WD**. A Low FODMAP Diet May Reduce Symptoms in Patients with Fecal Incontinence. Clin Translation Gastroenterol 2019;10:e-00060.
 195. Spechler SJ, Hunter JG, Jones KM...**Chey WD**, et al. Randomized trial of medical and

- surgical treatments for patients with heartburn that is refractory to PPIs: A VA Cooperative Study. *N Engl J Med* 2019;381:1513-23.
196. Carrington EV, Heinrich H, Knowles CH, Fox M, Rao S, Altomare DF, Bharucha AE, Burgell R, **Chey WD**, Chiarioni G, Dinning P, Emmanuel A, Farouk R, Felt-Bersma RJF, Jung KW, Lembo A, Malcolm A, Mittal R, Mion F, Myung SJ, O'Connell PR, Pehl C, Remes Troche JM, Reveille RM, Vaizey CJ, Vitton V, Whitehead WE, Wong RK, Scott SM. The international anorectal physiology working group recommendations: Standardized testing protocol and the London Classification for disorders of anorectal function. *Neurogastroenterol Motil* 2019, e13679.
 197. Nojkov B, Baker JRB, Menees S, Saad R, **Chey WD**. Is dyssynergic defecation an unrecognized cause of chronic constipation in patients using opioids? *Am J Gastroenterol* 2019;114:1772-77..
 198. Shah ED, Saini SD, **Chey WD**. Value-based pricing for rifaximin increases access of patients with IBS-D to therapy. *Clin Gastroenterol Hepatol* 2019;17:2687-95.
 199. Carrasco-Labra A, Lytvyn L, Falck-Ytter Y, Surawicz CM, **Chey WD**. American Gastroenterology Association Institute Technical Review on the Evaluation of functional diarrhea and Diarrhea Predominant Irritable Bowel Disease in adults (IBS-D). *Gastroenterol* 2019;157:859-80.
 200. **Chey WD**, Shah E, Dupont H. Mechanism of action of rifaximin and therapeutic effects in IBS. *Ther Adv Gastroenterol*. 2020;131756284819897531, Published: JAN 2020.
 201. McRorie JW, Fahey EC, Gibb RD, **Chey WD**. Laxative effects of wheat bran and psyllium: resolving enduring misconceptions about fiber in treatment guidelines for chronic idiopathic constipation. *J Am Assoc Nurse Practitioners*. 2020;32:15-23.
 202. Attari A, **Chey WD**, Baker JRB, Ashton-Miller JAA. Comparison of anorectal function measured using wearable digital manometry and a high resolution manometry system. *PLOS*. 2020;15: Issue: 9 , Article Number: e0228761 Published: SEP 29 2020.
 203. **Chey WD**, Lembo AL, Rosenbaum D. Efficacy of Tenapanor in Treating Patients with Irritable Bowel Syndrome with Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial. *Am J Gastroenterol* 2020;115:281-93.
 204. Shah ED, Suresh S, Jou J, **Chey WD**, Stidham RW. Evaluating when and why patients discontinue chronic therapy for irritable bowel syndrome with constipation and chronic idiopathic constipation. *Am J Gastroenterol* 2020;115:596-602.
 205. Shah ED, Almario CV, Spiegel BM, **Chey WD**. Presentation and characteristics of abdominal pain vary by IBS subtype: results of a nationwide population-based study. *Am J Gastroenterol* 2020;115:294–301.
 206. Almario CV, **Chey WD**, Spiegel BR. Prevalence and predictors of GERD and PPI-refractory GERD symptoms in the US: Results from a population-based survey. *Gastroenterol*, 2020;158:1250-61.
 207. Rao SSC, Lembo A, **Chey WD**, Friedenberg K, Quigley EMM. The vibrating capsule augments colonic circadian rhythm during treatment of chronic idiopathic constipation. *Neurogastroenterol Motil*, Nov 2020; 32:e13890.
 208. Menees S, Rosenberg J, Patel R, **Chey WD**. Evaluation of Plecanatide for the Treatment of CIC and IBS-C in Patients Aged 65 Years or Older. *Clinical Therapeutics*. 2020;42:1406+.
 209. Lacy BE, Pimentel M, Brenner D, **Chey WD**, Keefer L, Moshiree B. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. *Am J Gastroenterol*, 2020;116:17-

- 44.
210. Baker JR, Moshiree B, Rao S, Neshatian L, Nguyen L, **Chey WD**, Saad R, Garza J, Waseem S, Khan AR, Pandolfino JE, Gyawali CP. American Neurogastroenterology and Motility Society (ANMS) Task Force Recommendations for Resumption of Motility Laboratory Operations During the COVID-19 Pandemic. *Am J Gastroenterol* 2020;115:1575-83.
 211. Almario C, **Chey WD**, Spiegel BR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. *Am J Gastroenterol*, 2020;115:1707-15.
 212. Menees SB, Baker JR, Jackson K, **Chey WD**. The Prevalence and Impact of Dyssynergic Defecation in Patients Who Solely Report Fecal Incontinence. *World J Gastroenterol Hepatol Endo* 2020;3: DOI: <http://dx.doi.org/10.47690/WJGHE.2020.3304>.
 213. Nojkov B, Zhou SY, Dolan R, Davis EM, Appelman HD, Guo X, Jackson K, Sturm M, Wang TD, Owyang C, Liu JJ, **Chey WD**. Evidence of Duodenal Epithelial Barrier Impairment and Increased Pyroptosis in Patients with Functional Dyspepsia on Confocal Laser Endomicroscopy and “Ex-vivo” Mucosa Analysis. *Am J Gastroenterol*, 2020;115:1891-1901.
 214. Shah ED, Chang L, Salween-Deremer JK, Gibson PR, Keefer L, Muir J, Eswaran S, **Chey WD**. Contrasting Clinician and Insurer Perspectives to Managing Irritable Bowel Syndrome: Multilevel Modeling Analysis. *Am J Gastroenterol* 2021;116:748-57.
 215. **Chey WD**, Keefer L, Whelan K, Gibson P. Behavioral and diet therapies in integrated care for patients with Irritable Bowel Syndrome. *Gastroenterol* 2021;160:47-62.
 216. Feingold J, Drossman DA, **Chey WD**, Kurlander J, Morris CB, Bangdiwala S, Keefer L. Preliminary development and validation of the Patient-Physician Relationship Scale for Physicians (PPRS-Physician) for Disorders of Gut-Brain Interaction. *Neurogastroenterol Motil*, 2021;33:e13976.
 217. Shah ED, Chang L, Lembo A, Staller K, Curley MA, **Chey WD**. Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis. *Dig Dis Sci Jan* 2021;10.1007/s10620-020-06806-1.
 218. **Chey WD**, Sayuk GS, Bartolini W, Reasner DS, Fox SM, Bochenek W, Boinpally R, Shea E, Tripp K, Borgstein N. Randomized trial of 2 delayed release formulations of Linaclotide in patients with IBS-C. *Am J Gastroenterol*, 2021; 116:354-61.
 219. Shah E, Salween-Deremer JK, Gibson PR, Muir JG, Eswaran S, **Chey WD**. Comparing costs and outcomes of treatments for irritable bowel syndrome with diarrhea: cost-benefit analysis. *Clin Gastroenterol Hepatol*, 2021; in press.
 220. **Chey WD**, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of tenapanor in treating patients with IBS-C: A 26 week, placebo-controlled phase 3 trial. *Am J Gastroenterol*, 2021;116:1294-1303.
 221. **Chey SW**, **Chey WD**, Jackson K, Eswaran S. US comparative effectiveness trial of kiwifruit, prunes, or psyllium in patients with chronic constipation. *Am J Gastroenterol*, 2021;116:1304-12.
 222. Baker JR, **Chey WD**, Watts L, Armstrong M, Collins K, Lee AA, Dupati A, Menees S, Saad RJ, Harer K, Hasler WL. How the North American Consensus protocol affects the performance of glucose breath testing for bacterial overgrowth vs. a traditional method. *Am J Gastroenterol* 2021;116:780-7.
 223. Jagielski CH, **Chey WD**, Riehl ME. Influence of trauma on clinical outcomes, quality of life and healthcare resource utilization following psychogastroenterology intervention. *J*

- Psychosomatic Res, 2021;146:10.1016/j.jpsychores.2021.110481.
224. Ortengren A, Ramkissoon R, **Chey WD**, Baker JR, Shah ED. Anorectal manometry to diagnose dyssynergic defecation: A systematic review and meta-analysis of diagnostic test performance. *Neurogastroenterol Motil.* March 2021; 10.1111/nmo.14137.
 225. Lacy BE, Brenner D, **Chey WD**. Reevaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data. *Clin Gastroenterol Hepatol.* 2021, in press.
 226. Shah ED, Lacy BE, **Chey WD**, Chang L, Brenner DM. Tegaserod for Irritable Bowel Syndrome with Constipation in Women Less Than 65 Years of Age Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials. *Am J Gastroenterol* 2021; in press.
 227. Rej A, Shaw CC, Buckle RL, Trott N, Agrawal A, Mosey K, Sanders K, Allen R, Martin S, Newton A, Robinson K, Elphick D, **Chey WD**, Aziz I, Sanders DS. The low FODMAP diet for IBS: A multicenter UK study assessing long-term follow-up. *Dig Liv Dis* 2021; in press.
 228. Azcarate-Peril MA, Roach J, **Chey WD**, Sandborn WJ, Ritter AJ, Savaiano DA, Klaenhammer TA. A Double-Blind, 377-Subject Randomized Study Identifies Ruminococcus, Coprococcus, Christensenella, and Collinsella as Long-Term Potential Key Players in the Modulation of the Gut Microbiome of Lactose Intolerant Individuals by Galacto-Oligosaccharides. *Gut Microbes* 2021;13:.10.1080/19490976.2021.1957536.
 229. Shah ED, Staller K, Nee J, Ahuja NK, Chan WW, Lembo A, **Chey WD**. Evaluating the impact of cost on the treatment algorithm for chronic idiopathic constipation: cost-effectiveness analysis. *Am J Gastroenterol* 2021, in press.
 230. Chey SW, **Chey WD**. Lymphocytic colitis following the SARS-CoV2 mRNA vaccine. *Am J Gastroenterol* 2021, in press.
 231. Scarlata K, Eswaran SE, **Chey WD**, Baker JR. Utilization of dietitians in the management of irritable bowel syndrome (IBS) by members of the American College of Gastroenterology. *Am J Gastroenterol* 2021, in press.
 232. Howden CW, Sheldon KI, Almenoff JS, **Chey WD**. Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data. *Dig Dis Sci* 2021, in press.
 233. Koo E, Watts L, **Chey WD**, Nojkov B. Can a Defecation Posture Modifying Device Correct an Abnormal Balloon Expulsion Test in Chronically Constipated Patients? *Clin Gastroenterol Hepatol* 2021, in press.
 234. **Chey WD**, Baker JR, Watts L, Harris A, Shah ED. Development of a Simple, Point-of-Care Device to Test Anorectal Function in Patients with Constipation: Randomized Clinical Trial. *Clin Gastroenterol Hepatol* 2021, in press.
 235. **Chey WD**, Habash JG, Manning L, Chang L. AGA Clinical Practice Update on Role of Diet in Irritable Bowel Syndrome: Expert Review. *Gastroenterol*, in press.
 236. Menees S, Lembo AJ, **Chey WD**. Polyethylene Glycol 3350 in the Treatment of Chronic Idiopathic Constipation: Post-hoc Analysis using FDA Endpoints. *Clin Translational Gastroenterol*, in press.

Non-Peer-Reviewed Publications

1. **Chey WD** and Elta GH. Selected Summary: Natural history of gastric varices. *Gastroenterol* 1995; 105:599-602.

2. Mayer E, **Chey WD**. The role of visceral hyperalgesia in the irritable bowel syndrome. *The Regulatory Peptide Letter* 1996; 7:22-6.
3. **Chey WD**. The diagnosis of *Helicobacter pylori*. *Hospital Physician* 1997; 33:11-22.
4. **Chey WD**. Treating *Helicobacter pylori*: candidate and regimen selection. *Contemporary Internal Medicine* 1997; 9:52-61.
5. Peura DA, **Chey WD**. *Helicobacter pylori* and peptic ulcer disease. *The Regulatory Peptide Letter*, in press.
6. Fendrick AM, **Chey WD**. Approach to the patient with *Helicobacter pylori*-associated epigastric pain. *Hospital Physician* 1998; 34:36-44.
7. **Chey WD**. Therapy for nonulcer dyspepsia: a new application for an old drug? *Adv Gastroenterology, Hepatology & Clin Nutrition* 1998; 3:157-59.
8. **Chey WD**. *H. pylori* and nonulcer dyspepsia: an unaccommodating relationship? *Adv Gastroenterology, Hepatology & Clin Nutrition* 1998; 3:265-7.
9. **Chey WD**. Case Report: anti-TNF antibody case study and discussion. *The Regulatory Peptide Letter* 1999; 8:1-2.
10. **Chey WD**. Accurate diagnosis of *H. pylori*: breath tests. *Gastroenterology Clinics of North America* 2000; 29:895-901.
11. **Chey WD**. Treatment of *H. pylori*. *Current Treatment Options in Gastroenterology* 1999; 2:171-81.
12. Rhee J, **Chey WD**. Antibody testing for *H. pylori*. *LabMedica International* 2000; 17:16-17.
13. **Chey WD**, Murthy U, Shaw S, Zawadski A, Linscheer W, Laine L. A comparison of 3 fingerstick, whole blood antibody tests for *H. pylori* infection: a US multi-center trial. *ACP Journal Club* 2000; 132:34.
14. **Chey WD**, Murthy U, Toskes P, Carpenter S, Laine L. The ¹³C-urea blood test accurately detects active *H. pylori* infection: a US, multicenter trial. *ACP Journal Club* 2000; 132:35.
15. **Chey WD**. Comment on meta-analysis of smooth muscle relaxants in the treatment of Irritable Bowel Syndrome. *ACP Journal Club* 2001; 135:53.
16. **Chey WD**. Review: Smooth muscle relaxants improve symptoms and reduce pain in irritable bowel syndrome. *Evidence-Based Medicine* 2001; 6:153.
17. Cutler A, **Chey WD**. Update on the treatment of *H. pylori*. *Gastroenterology and Endoscopy News*, November, 2001, pages 25-6.
18. Ladabaum U, **Chey WD**. Management of uninvestigated dyspepsia. *Current Treatment Options in Gastroenterology* 2002; 5:125-31.
19. Cutler A, **Chey WD**. Update on the treatment of *Helicobacter pylori*: Initial options and salvage therapy. *Gastroenterology and Endoscopy News*, pages 21-3, November 2002.
20. Rubenstein J, **Chey WD**. Review: Tegaserod or alosetron are effective for the irritable bowel syndrome. *ACP Journal Club* 2003; 138:50.
21. Howden CW, **Chey WD**. Clinical Update: Gastroesophageal reflux disease. *J Family Practice* 2003; 52:1-8.
22. **Chey WD**. Tegaserod and other serotonergic agents: What is the evidence? *Reviews in Gastroenterological Disorders* 2003; 3: S35-40.
23. Cash BD, **Chey WD**. Diagnostic testing in IBS patients. *Digestive Health Matters* 2003; 12:4-7.

24. Cash BD, **Chey WD**. Advances in IBS management. *Current Gastroenterology Reports* 2003; 5:468-75.
25. **Chey WD**, Saad R. *Helicobacter pylori* eradication had no effect on heartburn or gastroesophageal reflux in patients with *H. pylori* infection. *ACP Journal Club* 2004; 141:75.
26. **Chey WD**, Moayyedi P. Uninvestigated dyspepsia and non-ulcer dyspepsia – the use of endoscopy and the roles of *H. pylori* eradication and antisecretory therapy. *Aliment Pharmacol Ther* 2004; 19(suppl 1):1-8.
27. **Chey WD**. Endoscopy negative reflux disease: Concepts and clinical practice. *Am J Med* 2004; 117:5A-36S-43S.
28. Bhuket T, **Chey WD**. Hypnotherapy for irritable bowel syndrome: effectively expanding the arsenal? *Evidence-Based Gastroenterology* 2004; 5(2):54-55.
29. **Chey WD**. Tegaserod: The global experience. *Aliment Pharmacol Ther* 2004; 20 (suppl 7):15-19.
30. Cash BD, **Chey WD**. Update on the management of chronic constipation: What differentiates chronic constipation from IBS with constipation? *Medscape Gastroenterology*, posted 8/26/04, http://www.medscape.com/viewprogram/3375_pnt .
31. Cash BD, **Chey WD**. Diagnosis of the Irritable Bowel Syndrome. *Gastroenterol Clin N Am* 2005; 34:205-20.
32. **Chey WD**. Update on the pathophysiology and treatment of the irritable bowel syndrome. *Korean J Neurogastroenterol Motil* 2005; 11:29-43.
33. **Chey WD**. Implications for treatment: pH, *Helicobacter pylori*, or alternative approaches? *Aliment Pharmacol Ther* 2005; 21(Suppl 1):17-18.
34. Cash BD, **Chey WD**. Irritable bowel syndrome: update on colonic neuromuscular dysfunction and treatment. *Curr Gastroenterol Reports* 2006; 8:273-81.
35. **Chey WD**, Richter JE, Kane SV, Siegel JH, Zein N. Meeting Coverage: Highlights from Digestive Diseases Week and the 107th Annual Meeting of the American Gastroenterological Association Institute. *Gastroenterol Hepatol* 2006; 2:515-7.
36. Saad R, **Chey WD**. Irritable bowel syndrome with constipation in the elderly. *Geriatrics & Aging* 2007; 10:84-90.
37. Cash BD, **Chey WD**. Update on the irritable bowel syndrome. *US Gastroenterol*, in press.
38. **Chey WD**. Presentations in IBS from DDW 2007. *Gastroenterol Hepatol* 2007; 3:629-33.
39. Rangnekar A, **Chey WD**. Commentary: tTG is almost as accurate as EMA antibody test for diagnosis of celiac disease. *Evidence-Based Medicine* 2007; 12:24.
40. Saad R, **Chey WD**. Review: Prokinetics, histamine 2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia. *Evidence-Based Medicine* 2007; 12:79.
41. Rangnekar, AS, **Chey WD**. Review: tissue transglutaminase test is almost as accurate as endomysial antibody test for diagnosis of coeliac disease. *Archives of Disease in Childhood Education & Practice* 2007; 92(1): e32.
42. Spiegel B, Chang L, **Chey WD**. Irritable bowel syndrome and bacterial overgrowth: Unifying hypothesis or a spurious consequence of proton pump inhibitors? *Am J Gastroenterol* 2008; 103:2972-6.
43. **Chey WD**. Presentations in IBS from DDW 2008. *Gastroenterol Hepatol* 2008 134:(4 suppl 1).

44. Rangnekar A, **Chey WD**. Selected Summary: Methylnaltrexone: A new treatment for an old problem. *Gastroenterol* 2008; 135:1792-4.
45. **Chey WD**. Antibiotics for IBS: Paradigm shift or the Emperor's new clothes? *AGA Perspectives* 2009; 4:5-8.
46. Luther J, **Chey WD**. Selected Summary: Sequential Therapy for *H. pylori*: A two for one deal that's worth the extra effort? *Gastroenterol* 2009; 136:720-721.
47. **Chey WD**. A patient with constipation-predominant IBS. *Gastroenterol Hepatol* 2009; 5 (suppl 1):6-8.
48. Brenner D, **Chey WD**. *Bifidobacterium infantis* 35624: A Novel Probiotic for the Treatment of Irritable Bowel Syndrome. *Rev Gastroenterol Disorders* 2009; 9:7-15.
49. Rangnekar A, **Chey WD**. Selected Summary: The FODMAP diet for IBS: Food fad or roadmap to a new treatment paradigm? *Gastroenterol* 2009; 137:383-6.
50. Rude MK, **Chey WD**. Selected Summary: Proton Pump Inhibitors, Clopidogrel, and Cardiovascular Adverse Events: Fact, Fiction, or Something In Between? *Gastroenterol* 2009; 137:1168-71.
51. **Chey WD**. IBS diagnosis and confirmation. *Gastroenterol Hepatol* 2009; 5 (supplement 20):6-9.
52. **Chey WD**, Moayyedi P. Passing the torch: The American Journal of Gastroenterology 2010 Introduction. *Am J Gastroenterol* 2010; 105:4-7.
53. Luther J, **Chey WD**. Psyllium increased symptom relief in patients with the irritable bowel syndrome more than bran or placebo. *ACP Journal Club* 2010; 152: J1.
54. Moayyedi P, Ford AC, Quigley EMM, Foxx-Orenstein AE, **Chey WD**, Talley NJ, Brandt L. The American College of Gastroenterology IBS Monograph: Translating systematic review data to clinical practice. *Gastroenterol* 2010; 138:789-90.
55. Maneerattanaporn M, **Chey WD**. Book review: Understanding the Irritable Gut. *Gastroenterol* 2010; 138:786.
56. Maneeratannaporn M, **Chey WD**. Selected Summary: Acupuncture for IBS: Sham or the Real Deal? *Gastroenterol* 2010; 139:348-51.
57. **Chey WD**, Spiegel BS. PPIs, IBS, and Small Intestinal Bacterial Overgrowth: Coincidence or Newton's Third Law Revisited? *Clin Gastroenterol Hepatol* 2010; 8:480-482.
58. Moayyedi P, **Chey WD**. Is Lumping Peer-Reviewed Case Reports Together With Non-Peer-Reviewed Comments for Publication as Letters to the Editor Appropriate? Response *Am J Gastroenterol* 2010; 105:1901-1902.
59. Vakil N, Malferheiner P, **Chey WD**. Bismuth and *H. pylori*. *New Engl J Med* 2010; 363:595.
60. **Chey WD**. Efficacy and safety of probiotics in the treatment of Irritable Bowel Syndrome. *US Gastroenterology & Hepatology Review* 2010; 6:48-53.
(<http://www.touchbriefings.com/ebooks/A1q1ey/usgastro6/>).
61. Brenner D, **Chey WD**. Selected Summary: St. John's Wort and Irritable Bowel Syndrome: Reminders of the Hippocratic Oath. *Gastroenterol* 2010; 139:1788-90.
62. Adams M, **Chey WD**. Selected Summary: Biofeedback training for dyssynergic defecation: an approach whose time has come. *Gastroenterol* 2011; 140:1682-5.
63. Luther J, **Chey WD**, Saad RJ. A clinician's guide to salvage therapy for persistent *Helicobacter pylori* infection. *Hosp Pract* 2011; 39:133-40.

64. **Chey WD.** Preface: Irritable Bowel Syndrome. *Gastroenterol Clin North Am* 2011; 40: XII-XIV.
65. Eswaran S, Tack J, **Chey WD.** Food: The forgotten factor in IBS. *Gastroenterol Clin North Am* 2011; 40:141-62.
66. Maneeratannaporn M, Chang L, **Chey WD.** Emerging therapies for IBS. *Gastroenterol Clin North Am* 2011; 40:223-43.
67. **Chey WD,** Rai J. Exercise and IBS: no pain, no gain. *Gastroenterology* 2011; 141:1941-3.
68. Greenberg ER, Anderson GL, Morgan DR, Torres J, **Chey WD.** Treatment of *Helicobacter pylori* in Latin America – Author’s reply. *Lancet* 2012; 379:4-10.
69. Schmulson M, **Chey WD.** Editorial: Abnormal immune regulation and low-grade inflammation in IBS: Does one size fit all? *Am J Gastroenterol* 2012; 107:273-5.
70. Ferch C, **Chey WD.** IBS and gluten sensitivity without celiac disease: Separating the wheat from the chafe. *Gastroenterol* 2012; 142:664-6.
71. Foxx-Orenstein A, **Chey WD.** Manipulation of the gut microbiota as a novel treatment strategy for gastrointestinal disorders. *Am J Gastroenterol Suppl* 2012; 1:34-40.
72. **Chey WD.** Current Consensus and Remaining Questions Regarding the Diagnosis and Treatment of *Helicobacter pylori* Infection. *Gastroenterol Hepatol* 2012; 8:621-5.
73. Moayyedi P, **Chey WD.** Stoking the Flame: *American Journal of Gastroenterology* 2013. *Am J Gastroenterol* 2013; 108:162-5. PMID: 23381063
74. Chey WY, Chang V, Lubukin M, Lee KY, Hoellrich CM, **Chey WD.** Mega-cecum: A novel clinical entity which explains overlapping gastrointestinal and urogynecologic symptoms in women with chronic constipation. *Am J Gastroenterol* 2013 Oct 1 [Epub ahead of print]. PMID 24091519
75. Eswaran S, Guenther A, **Chey WD.** Emerging therapies for chronic constipation and IBS-C. *J Neurogastroenterol Motil* 2014; 20:141-51.
76. Lacy BE, **Chey WD,** Chang L. An evidence-based look at misconceptions in the treatment of patients with IBS-D. *Gastroenterology & Hepatology* 2013; 9 (supplement 5): 3-19.
77. Saad R, **Chey WD.** First-line treatment of *H. pylori* infection in 2014. *Gastroenterology & Endoscopy News* 2014; 65(2):1-8.
78. **Chey WD,** Howden C, Vakil N. Clinical rationale for confirmation testing after *H. pylori* treatment: Implications of rising antibiotic resistance. *Gastroenterol & Hepatol* 2014; 10 (7, supplement 3):3-18.
79. Brenner DB, **Chey WD.** An evidence based review of novel and emerging therapies for opiate induced constipation. *Am J Gastroenterol Suppl* 2014; 2 (issue1):38-46.
80. **Chey WD.** The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized, controlled trials. PracticeUpdate website. Available at: <http://www.practiceupdate.com>. Accessed August 2014.
81. Spencer M, **Chey WD,** Eswaran S. Dietary renaissance in IBS: Has food replaced medications as a primary treatment strategy? *Curr Treatment Op Gastroenterol* 2014; 12:424-40.
82. **Chey WD,** Eswaran S, Kurlander J. Irritable Bowel Syndrome Patient Page. *JAMA* 2015; 313:982.
83. **Chey WD.** Current insights into the pathophysiology of IBS. *Gastroenterol Hepatol* 2015; 11:2-5, supplement 2.

84. **Chey WD**, Lacy BE, Lembo AL. New and emerging treatment options for IBS: Q&A. Gastroenterol Hepatol 2015; 11:16-8, supplement 2.
85. VanDam L, **Chey WD**. The low-FODMAP diet and IBS. Whole Foods Magazine 2015; <http://www.wholefoodsmagazine.com/blog/low-fodmap-diet-and-ibs>
86. **Chey WD**. Dietary Interventions in Patients with Irritable Bowel Syndrome. PracticeUpdate website. Available at: <http://www.practiceupdate.com/c/23013/48/9>. Accessed April 21, 2015.
87. Menees S, Powell C, **Chey WD**. Response to Dai et al. Am J Gastroenterol 2015; 110:1243-4.
88. Moayyedi P, **Chey WD**. The light shines on: American Journal of Gastroenterology 2015. Am J Gastroenterol 2015; 110:1638-9.
89. **Chey WD**, Owyang C. Timothy T. Nostrant, MD, MACG, October 20, 1947-October 2, 2015. Gastroenterol 2016; 150:289-90.
90. **Chey WD**. David Sun Lecture: Food - The main course to wellness and illness in patients with IBS. Am J Gastroenterol 2016; 111:366-71.
91. Gupta A, **Chey WD**. Breath Testing for Small Intestinal Bacterial Overgrowth: A means to enrich rifaximin responders in IBS patients? Am J Gastroenterol 2016; 111:305-6.
92. Spencer M, Gupta A, Van Dam L, Shannon C, Menees S, **Chey WD**. Artificial sweeteners: A systematic review and primer for gastroenterologists. J Neurogastroenterol Motil 2016; 22:168-80.
93. **Chey WD**, Whelan K. Dietary guidelines for irritable bowel syndrome are important for gastroenterologists, dietitians and people with irritable bowel syndrome. J Human Nutrition Dietetics 2016; 29:547-8.
94. Kerdsirichairat T, Choi EYK, **Chey WD**. An atypical coincidence of colon ischemia and bilateral distal ureteral strictures. Gastroenterol 2017; 153: E13-E16.
95. **Chey WD**. An evidence-based approach to IBS and CIC: Applying new advances to daily practice. Gastroenterol Hepatol 2017; 13 (supplement 1):3-14.
96. **Chey WD**, Leontiadis GI, Howden CW, Moss SF, Which Regimens Should Be Used and Which Rejected for the Treatment of Helicobacter pylori? Response. Am J Gastroenterol 2017; 112:1169-70.
97. **Chey WD**. Introduction. J Gastroenterol Hepatol 2017;32 (suppl 1):3-4.
98. **Chey WD**. Treatment of *H. pylori* infection: What the clinician needs to know. ACG Magazine. 2017; 1:20-21.
99. Eswaran S, Farida J, Green J, Miller JD, **Chey WD**. Nutrition in the management of GI diseases and disorders: the evidence for the low FODMAP diet. Curr Opin Pharmacol 2017; 37:151-7.
100. **Chey WD**, Leontiadis G, Moss S, Howden C. Response to Hsu et al. Am J Gastroenterol 2018; 113:143.
101. Shah E, **Chey WD**. Editorial: recurrence of *Helicobacter pylori* infection - still the same after all these years... Aliment Pharmacol Ther 2018;47:131-132.
102. **Chey WD**. Sucrase isomaltase deficiency: hiding in plain sight? J Gastroenterol Hepatol, 2018, in press.
103. Staudacher H, **Chey WD**. Design of clinical trials assessing the efficacy of diet interventions for GI diseases. J Gastroenterol Hepatol 2018, in press.

104. Dolan R, **Chey WD**, Eswaran S. The role of diet in the management of IBS: a focus on FODMAPs. *Exp Rev Gastroenterol Hepatol* 2018; 12:607-15.
105. **Chey WD**, Howden CW, Leontiadis G. Houston *H. pylori* Clarifying the Houston Consensus on *Helicobacter pylori* (Letter to the Editor). *Clin Gastroenterol Hepatol* 2018;16:2003-4.
106. **Chey WD**. Editorial: Elimination diets for IBS: Approaching the end of the beginning. *Am J Gastroenterol* 2019;114:201-3.
107. Zheng T, Eswaran S, **Chey WD**, Merchant J, D'Amato M. Reduced efficacy of low FODMAP diet in patients with IBS-D carrying sucrase-isomaltase hypomorphic variants. *Gut* 2020;69:397+
108. **Chey WD**. Treatment of *Helicobacter pylori*: When we should... *Am J Gastroenterol* 2019;114:1829-32.
109. **Chey WD**. Microbiome-based treatment strategies for IBS. *Gastroenterol Hepatol* 2019; 15:164-6.
110. **Chey WD**. Highlights from the AGA Technical Review on value of diagnostic tests in functional diarrhea and IBS-D. *Gastroenterol Hepatol* 2019;15:488-92.
111. **Chey WD**. Highlights in Neurogastroenterology & Motility from DDW 2019. *Gastroenterol Endo News* 2019, in press.
112. **Chey WD**. Oral FMT with antibiotics does not improve symptoms of IBS-D: Perspective. *Healio Gastroenterol Liv Dis* 2019;5:28.
113. **Chey WD**. Comment on "Family history of gastric cancer and *Helicobacter pylori* treatment" 2020, www.PracticeUpdate.com
114. Desai T, **Chey WD**. Epidemiology and the impact of therapies on the outcome of COVID-10 in patients with inflammatory bowel disease response. *Am J Gastroenterol* 2020;115:1726.
115. Shapiro JM, Deutsch JK, **Chey WD**. An evidence-based review of oral supplements for the treatment of patients with IBS. *Neurogastroenterol LATAM Rev.* 2020;4:in press.
116. **Chey WD**. Integrated care for disorders of gut-brain interaction. *Lancet Gastroenterol Hepatol* 2020;5:876-7.
117. Mullin G, **Chey WD**, Crowe S. Meeting Summary: 2019 James W. Freston Conference: Food at the intersection of gut health and disease. *Gastroenterol* 2020;159:20-25.
118. Ginnebaugh B, **Chey WD**, Saad R. Small intestinal bacterial overgrowth. *Gastroenterol CI North Am.* 2020;49:571-87.
119. **Chey WD**, Cash B, Lembo A, Patel D, Scarlata K. Congenital sucrose-isomaltase deficiency: What, When, and How? *Gastroenterol Hepatol* 2020;16 (10), Suppl 5;3-11.
120. **Chey WD**, Cash BD, Lembo A, Patel DB, Scarlata K. Congenital sucrose-isomaltase deficiency: What, when, and how? *Gastroenterol Hepatol* 2020;16:Suppl 5.
121. Almario CV, **Chey WD**, Spiegel BMR. Response to Hajifathalian and Katz regarding risk of COVID-19 among users of PPIs. *Am J Gastroenterol* 2020;115:1922-3.
122. Gyawali CP, Baker JR, Moshiree B...**Chey WD**... An alternative recommendation by experienced esophagologists: Response to Richter and Vaezi. *Am J Gastroenterol* 2021;116:214-5.
123. Brandler J, **Chey WD**. Fishing for IBS: Which alarm features weave the best net? *Clin Gastroenterol Hepatol*, 2021; online early 2/9/21.
124. Lenhart A, **Chey WD**, Eswaran S. Sucrase-isomaltase deficiency: Hiding in plain sight? *Curr Treatment Opt Gastroenterol*; 2021, in press.

125. **Chey WD.** Preface to GI Clinics of North America issue on Irritable Bowel Syndrome. *GI Clinics North Am.* 2021;50:xv-xvi.
126. Berry S, **Chey WD.** Integrated care for IBS: the road to personalized care. *GI Clinics North Am.* 2021;50:713-20.
127. Nojkov B, **Chey WD.** Response to Dr. Keszthelyi. *Am J Gastroenterol* 2021;116:1557.
128. **Chey WD.** Renewed interest in the management of *H. pylori* infection. *Am J Managed Care* July 14, 2021. <https://www.ajmc.com/view/renewed-interest-in-the-management-of-helicobacter-pylori-infection>

Articles Submitted for Publication

1. Joint ACG/AGA Clinical Practice Guideline: Medical Management of Chronic Constipation. *Am J Gastroenterol/Gastroenterol*, in preparation.
2. **Chey WD**, Tack J. Rome Foundation Working Group: Role of food in the pathogenesis and management of Disorders of Gut-Brain Interaction. *Am J Gastroenterol*, in preparation.
3. Singh P, Gibson PR, Tuck C, **Chey WD.** Role of food in the pathogenesis and management of Bowel Disorders. *Am J Gastroenterol*, in preparation.
4. Staudacher H, Yao CK, **Chey WD**, Whelan K. Proper design of clinical trials of nutrition interventions in patients with disorders of gut-brain interaction. *Am J Gastroenterol*, in preparation
5. **Chey WD**, Megraud F, Laine L, Lopez LJ, Hunt BJ, Howden CW. Effect of vonoprazan triple or dual therapy vs lansoprazole triple therapy on *Helicobacter pylori* eradication in US and European patients: a randomized clinical trial. *JAMA.* 2021, in revision.
6. Talley N, Kamboj AP, **Chey WD** et al. Eosinophilic gastritis and eosinophilic duodenitis: An under-recognized disease in patients with unexplained moderate-severe gastrointestinal symptoms. *Am J Gastroenterol*, submitted 11/21.
7. Lacy BE, King J, Shortino D, Schaumburg C, Haad-Molkenteller C, **Chey WD.** Efficacy and Safety of Vibegron for the Treatment of Irritable Bowel Syndrome in Women: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. In prep.
8. Shah ED, Pelletier EA, Greeley C, Sieglinger EE, Sanchez JD, Northam KA, Perrone JA, Navas CM, Ostler TL, Burnett AR, Martinez-Cambor P, Baker JR, Harris A, **Chey WD.** An investigational office-based, point-of-care test predicts real-world treatment outcomes with pelvic floor physical therapy among chronic constipated patients: Clinical trial. *Gastroenterol*, in preparation.
9. Oh J, **Chey WD**, Spiegel B. Abdominal bloating in the US: Results of a national survey of 88,969 Americans examining prevalence, burden of illness, and healthcare seeking. In preparation.

Chapters in Books

1. **Contributor of questions** to Textbook of Gastroenterology: Self -Assessment Review, First Edition. Ed: T Yamada. JB Lippincott Co. Philadelphia, PA, 1993.
2. **Chey WD.** "Chapter 1: The esophagus" and "Chapter 5: The pancreas" for Textbook of Gastroenterology: Self -Assessment Review. 2nd Edition. Ed: T Yamada. JB Lippincott Co. Philadelphia, PA, 1995.

3. **Chey WD.** “Chapter 4: The Pathophysiology of Nausea and Vomiting” in Gastrointestinal Pathophysiology, First Edition. Ed: J Henderson. JB Lippincott Co. Philadelphia, PA, 1996.
4. **Chey WD**, Hasler WL. “Chapter 26: Gastroduodenal Motility Disorders and Gastroparesis” in Clinical Practice of Gastroenterology, First Edition. Ed: L Brandt. Current Medicine. Philadelphia, PA, 1999.
5. **Chey WD**, Chey WY. “Chapter 132: Tests of Gastric and Exocrine Pancreatic Function and Absorption” in Textbook of Gastroenterology, Third Edition. Ed: T Yamada. JB Lippincott Co. Philadelphia, PA, 1999.
6. **Chey WD**, Chey WY. “Chapter 8.7: Colonic diseases in elderly people” in Oxford Textbook of Geriatric Medicine, Second Edition. Ed: JG Evans. Oxford University Press. Oxford, UK, 2000.
7. **Chey WD**, Fendrick MA. “Non-invasive *Helicobacter pylori* diagnostic tests: recent innovations” in Harrison’s Textbook of Internal Medicine Online, 1999.
8. **Chey WD**, Kim HR. “Chapter 2: Stomach” in Textbook of Gastroenterology: Self - Assessment Review. 3rd Edition. Ed: T Yamada. JB Lippincott Co. Philadelphia, PA, 2000.
9. **Section Editor**, Stomach and Duodenum, Current Treatment Options in Gastroenterology, 5:125-160, 2002.
10. **Editor** for “Chapter 121: Peptic acid disorders” and “Chapter 123: Hiatus hernia, bezoars, and foreign bodies” in Merck Manual of Medical Information – Home Edition, 2nd Edition. Ed: MH Beers. Merck Research Laboratories, Whitehouse Station, NJ, 2003.
11. **Chey WD**, Chey WY. “Chapter 151: Evaluation of secretion and absorption functions of the GI tract” in Textbook of Gastroenterology, Fourth Edition. Ed: T Yamada. JB Lippincott Co. Philadelphia, PA, 2003.
12. Delvalle J, **Chey WD**, Scheiman JM, “Chapter 66: Acid-peptic disorders” in Textbook of Gastroenterology, Fourth Edition. Ed: T Yamada. JB Lippincott Co. Philadelphia, PA, 2003.
13. **Chey WD**, Scheiman JM. “Chapter 20: Peptic ulcer disease” in Current diagnosis and treatment in Gastroenterology: Second Edition, Ed: McQuaid KR. McGraw-Hill. New York, NY, 2003.
14. Cash BD, **Chey WD**. “Chapter 22: Dyspepsia – Current treatments” in Hot Topics in GERD and Dyspepsia, Ed: Fass R. Hanley & Belfus, Inc. Philadelphia, PA, 2003.
15. Rubenstein JH, **Chey WD**. “Chapter 2: A case of refractory heartburn” in Acid-related Disorders, Ed: Howden CW. McMahon Publishing Group, New York, NY, 2003.
16. **Chey WD**, Saad R. “Chapter 4c - Female patient with severe, persistent GI symptoms.” In Functional Gastrointestinal Disorders, Ed: Carol Burke, McMahon Publishing Group, New York, NY, 2005.
17. **Editor** for “Bezoars and Foreign Bodies” in Merck Manual of Medical Information, 18nd Edition. Ed: MH Beers. Merck Research Laboratories, Whitehouse Station, NJ, 2006.
18. Longstreth G, Thompson WG, **Chey WD**, Houghton L, Mearin F, Spiller R, Wang WA. “Chapter 9: Functional Bowel Disorders” in Rome III: The functional gastrointestinal disorders, Third Edition, Ed: Drossman D, et al. Degnon Associates, 2007.
19. Irvine EJ, Whitehead W, **Chey WD**, Matsueda K, Shaw M, Talley NJ, van Zanten S. “Chapter 15: Design of treatment trials for Functional Gastrointestinal Disorders” in

- Rome III: The functional gastrointestinal disorders, Ed: Drossman D, et al. Degnon Associates, 2007.
20. **Chey WD**, DiMagno MJ, Chey WY. “Tests of gastric and exocrine pancreatic function and absorption” in Textbook of Gastroenterology, Fifth Edition. Ed: T Yamada. Blackwell Publishing Co. Malden, MA, 2008.
 21. Bhuket T, **Chey WD**. “Evaluation and management of the Irritable Bowel Syndrome” in Functional GI Disorders, Ed: MP Jones, McMahon Group, in press.
 22. Saad R, **Chey WD**. Chapter 32: Functional Dyspepsia. GI Motility Testing: A Laboratory and Office Handbook, First Edition, SLACK Inc., Thorofare, NJ, Ed: HP Parkman, S Rao, R McCallum, 2010.
 23. Maneerattanaporn M, **Chey WD**. Chapter 35: Small Intestinal Bacterial Overgrowth. Practical Gastroenterology and Hepatology: Small and Large Intestine and Pancreas, First Edition, Ed: NJ Talley. Wiley-Blackwell, West Sussex, UK, 2010.
 24. Saad R, **Chey WD**. Functional Dyspepsia. Gut instincts – A Clinician’s Handbook of Digestive and Liver Diseases, Ed: E Estralian. SLACK Incorporated, 2012.
 25. **Chey WD**. Foreword: The Complete low-FODMAP Diet. Shepherd & Gibson. The Experiment, New York, New York, 2013.
 26. Mearin F, Lacy B, Chang L, **Chey WD**, Lembo A, Simren M, Spiller R. Rome IV: Functional Gastrointestinal Disorders. Disorders of Gut-Brain Interaction. 4th Edition, 2016.
 27. **Chey WD**. Foreword: A Teen’s Guide to Gut Health. Meltzer Warren R. The Experiment, New York, NY, 2017.
 28. **Chey WD**. Foreword: The IBS elimination diet and cookbook. Catsos P. Harmony Books, New York, 2017.
 29. **Chey WD**. Endorsement: The Low FODMAP Diet: Step by step. Kate Scarlata, Dede Wilson. 2018.
 30. **Chey WD**. Endorsement: The Low-FODMAP IBS Solution and Cookbook. Rachel Pauls. 2020.
 31. Brandler J, Koo E, **Chey WD**. Chapter 9: Irritable Bowel Syndrome. Health Professional’s Guide to Gastrointestinal Nutrition, Second Edition. 2021

Books

1. **Special Editor and contributor**, Textbook of Gastroenterology: Self -Assessment Review. 3rd Edition. Ed: T Yamada. JB Lippincott Co. Philadelphia, PA, 2000.
2. **Guest Editor and contributor**, Irritable Bowel Syndrome. Gastroenterology Clinics of North America, WB Saunders, Philadelphia, PA, 2011;40:1.
3. **Contributing Editor**, Multi-Dimensional Clinical Profile for the Functional Gastrointestinal Disorders. 1st Edition. Ed: Rome Foundation, Raleigh, NC, 2014.
4. **Contributing Editor**, Rome IV: Functional Gastrointestinal Disorders. Disorders of Gut-Brain Interaction. 4th Edition, 2016
5. **Contributing Editor**, Rome IV: Functional Gastrointestinal Disorders. Disorders of Gut-Brain Interaction. 4th Vol 2, Edition, 2016
6. **Contributing Editor**, Multi-Dimensional Clinical Profile for the Functional Gastrointestinal Disorders. 2nd Edition. Ed: Rome Foundation, Raleigh, NC, 2016.

7. **Contributing Editor**, Functional Gastrointestinal Disorders: Disorders of Gut-Brain Interaction. Special Issue Gastroenterology; Vol 150, Number 6, May 2016
8. **Contributing Editor**, Rome IV: Diagnostic Algorithms for Common GI Symptoms. 2nd Edition, 2016
9. **Contributing Editor**, Rome IV: Pediatric Functional Gastrointestinal Disorders: Disorders for Gut-Brain Interaction, 1st Edition, 2016
10. **Contributing Editor**, Rome IV: Functional Gastrointestinal Disorders for Primary Care and Non-GI Clinicians. 1st Edition, 2016
11. **Contributing Editor**, Rome IV: Diagnostic Questionnaires and Tables for Investigators and Clinicians, 1st Edition, 2016.
12. **Guest Editor and contributor**, Irritable Bowel Syndrome. Gastroenterology Clinics of North America, WB Saunders, Philadelphia, PA, 2021;in press.

Other Media

1. **Chey WD**. Proton pump inhibitors and the urea breath test: how long is long enough? *Am J Gastroenterol*. 92:720-1, 1997 (letter).
2. **Chey WD**. Response to Dr. Stermer, et al. *Am J Gastroenterol*. 92:1575, 1997.
3. **Chey WD**. The channel occlusion technique: a novel method of retrieving polyps following snare resection. *Am J Gastroenterol* 95:1608-9,2000 (letter).
4. Drossman DA, Clouse RE, **Chey WD**, Koch KL, Lembo T, Locke R, Longstreth GF, Mertz H, Norton N, Toner B, Whitehead WE, Wilson JAP. Irritable Bowel Syndrome: New Visions (part 1) Nosology, Epidemiology, and Pathophysiology. Monograph of the Digestive Health Initiative, 1999.
5. Drossman DA, Clouse RE, Camilleri M, **Chey WD**, Lebovitz PJ, Lembo T, Longstreth GF, Mertz H, Naliboff BD, Thompson G, Toner B, Whitehead WE. Irritable Bowel Syndrome: New Visions (part 2): Diagnosis and Treatment. Monograph of the Digestive Health Initiative, 2000. (*Award of excellence in education from the American Society of Association Executives in the outstanding print-based education program category*)
6. **Chey WD**. Medical Simulations in the Diagnosis and Management of Acid-Related Disorders. CME Monograph accredited by Albert Einstein College of Medicine, 10/2000.
7. **Chey WD**. Testing for *H. pylori* infection: which test should you use? SCOPE Issue 1, May 2002, pages 17-20.
8. **Chey WD**. Non-erosive esophageal disorders. SCOPE Issue 2, July 2002, pages 14-17.
9. Cash BD, **Chey WD**. Irritable bowel syndrome. Northwestern University, Feinberg School of Medicine Reports on Digestive Disorders. 1:4, 2002.
10. **Chey WD**. Critical analysis of current therapy of IBS and anticipating future improvements. CME supplement to *Gastroenterology and Endoscopy News* pg 5-7, February 2003.
11. **Chey WD**. Long-term management of GERD: PPI vs. newer endoscopic interventions vs. surgery. *Advanced Studies in Medicine*. 3:S123-7, 2003.
12. Cash BD, **Chey WD**. The role of endoscopy in irritable bowel syndrome. *ASGE Clinical Update*. 11:1-4, January 2004.

13. Chang L, **Chey WD**, Prather C. Coping with the complexities of IBS: Practical aspects of patient management. CME supplement to Gastroenterology and Endoscopy News, February 2004.
14. Chang L, **Chey WD**. Translating Science into Clinical Outcomes: New Advances in the Management of Irritable Bowel Syndrome, CME Monograph, Rush University Medical Center, April 2004.
15. Cash BD, **Chey WD**. A clinical and safety update on serotonergic agents for irritable bowel syndrome and chronic constipation. Family Practice Recertification Supplement, September 2004.
16. Cash BD, **Chey WD**. Book Review: Neuro-Gastroenterology. Gastroenterology. 27:1858-9, 2004.
17. **Chey WD**, Saad R. Case 4c: Female with severe, persistent GI symptoms. Gastroenterology and Endoscopy News, October 2004.
18. Saad R, **Chey WD**. Book Review: Digestion, diet, and disease. Gastroenterology, 128:2175, 2005.
19. Cash BD, **Chey WD**. Irritable bowel syndrome and chronic constipation: The latest serotonergic agents. Family Practice Recertification Supplement, January 2005.
20. Saad R, **Chey WD**. Peptic ulcer disease in patients with chronic liver disease: Looking beyond bugs and drugs. Gastrointest Endosc 62:357-9, 2005.
21. **Chey WD**. Clinical perspectives in chronic constipation. Medscape Gastroenterology, posted 5/27/05, <http://www.medscape.com/viewarticle/505146> .
22. **Chey WD**. New insights in IBS-C and chronic constipation. Medscape Gastroenterology, posted 5/31/06, <http://www.medscape.com/viewarticle/532440> .
23. Saad R, **Chey WD**. What is the optimal therapy for patients with *Helicobacter pylori*-negative dyspepsia? Gastroenterology Today. X:135-6, 2006.
24. **Chey WD**, Rao S. Update on chronic constipation. Clinical Symposia, 2006.
25. **Chey WD**. Examining the issues in Functional Bowel Disorders. Medscape Gastroenterology, posted 10/23/07, <http://www.medscape.com/viewarticle/563731>.
26. **Chey WD**. Update on gastroparesis. Reach MD. <http://www.reachmd.com/xmsegment.aspx?sid=1870>
27. **Chey WD**. Newer thoughts on irritable bowel syndrome. Reach MD. <http://www.reachmd.com/xmsegment.aspx?sid=1871>
28. University of Michigan Health System Press Release: Phase III lubiprostone trials for IBS, 5/19/08: <http://www2.med.umich.edu/prmc/media/newsroom/details.cfm?ID=307>
29. University of Michigan Health System Press Release: IBS guideline, 12/18/08: <http://www2.med.umich.edu/prmc/media/newsroom/details.cfm?ID=945>
30. University of Michigan Health System Press Release: Celiac disease, 2/2/09: <http://www2.med.umich.edu/prmc/media/newsroom/details.cfm?ID=1030>
31. **Chey WD**, Chang L. Providing patient centered care for individuals with IBS. Reach MD. February 2009. <http://www.reachmd.com/cmedetails.aspx?sid=4112>
32. **Chey WD**, Chang L. Nonpharmacologic vs. pharmacologic treatments options for chronic constipation and IBS-C. Reach MD. February 2009. <http://www.reachmd.com/cmedetails.aspx?sid=4113>
33. **Chey WD**, Chang L. IBS and abuse in women. Reach MD. February 2009. <http://www.reachmd.com/cmedetails.aspx?sid=4114>
34. **Chey WD**, Pimentel M. The role of antibiotic therapy in IBS. Reach MD. August 2009.

35. **Chey WD**, Rubenstein J. The Evolving Landscape in GERD and Acid-Related Disorders: What Are the Issues/Unmet Needs and Solutions? Medscape CME Gastroenterology, September 2009, <http://cme.medscape.com/viewarticle/707669>
36. Johnson DA, **Chey WD**, Rangarajan M. Managing Challenging Patient Populations With GERD: Common Clinical Challenges and Evidence-Based Solutions. Medscape CME Gastroenterology November 2009, <http://cme.medscape.com/viewarticle/712073>
37. University of Michigan Health System Press Release: Shift workers at more risk for IBS, a UM study says, 3/18/10: <http://www2.med.umich.edu/prmc/media/newsroom/details.cfm?ID=1525>
38. University of Michigan Health System Press Release: IBS patients not at more risk of colon cancer, 3/9/10: <http://www2.med.umich.edu/prmc/media/newsroom/details.cfm?ID=1515>
39. **Chey WD**, Heidelbaugh J, Vaezi M. Contemporary Issues in GERD: The Economic and Clinical Burden of Disease. Medscape CME Gastroenterology, May 2010, <http://cme.medscape.com/viewarticle/722389>
40. University of Michigan Health System Press Release: Rifaximin for IBS, 1/5/11: <http://www2.med.umich.edu/prmc/media/newsroom/details.cfm?ID=1883>
41. **Chey WD**, Johnson D. Expert to expert interview on IBS. Medscape Gastroenterology, May 2011.
42. **Chey WD**, Saad R. The Management of Constipation – Related Functional GI Disorders: An Update on Recent Advances. Medscape Gastroenterology, 2012. <http://www.medscape.org/viewarticle/765791>
43. **Chey WD**, Rex D. Update from San Diego 2012: Therapies on the horizon for constipation. Medscape Gastroenterology, 2012. <http://www.medscape.org/viewprogram/32497>
44. **Chey WD**. Treatments for Chronic Constipation. Medscape Gastroenterology, 2012.
45. University of Michigan Health System Press Release: Drug may relieve IBS symptoms, UM study finds, 9/18/12: <http://umhsheadlines.org/19/drug-may-relieve-irritable-bowel-syndrome-symptoms-u-m-study-finds/>
46. AJG Podcasts: Monthly discussions between the Editors and lead authors of interesting articles from the American Journal of Gastroenterology, <http://www.nature.com/ajg/index.html>
47. Expert Perspectives from ACG: Reporting on IBS. GI Health Foundation. November 2012, http://www.ibscme.tv/programming_guide/topics/xpert_acg2012/index.cfm?cme_proj_id=40
48. **Chey WD**, Curtiss C; Kamdar MM; Peppin JF. Medscape CME Roundtable - Making A Difference in Opioid-Induced Constipation: Adding Targeted Therapies to the Treatment Regimen. January 4, 2013. <http://www.medscape.org/viewarticle/779122>
49. **Chey WD**, Dorn S. Medscape Education: Curbside Consult on IBS-C. May 20, 2013.
50. GERD and Obesity: What's the Connection? Healthy Body, Healthy Mind – Episode 1401, Public Broadcasting System. http://www.itvisus.com/programs/hbhm/episode_1401_Gerd.asp
51. Talking About Your GI Health: Improving the Dialogue with Your Doctor. Healty Body, Healthy Mind - Episode 1501, Public Broadcasting System. http://www.itvisus.com/programs/hbhm/episode_1501_GI_health.asp

52. Controlling Irritable Bowel Syndrome. Healthy Body, Healthy Mind – Episode 2504, Public Broadcasting System. http://www.itvisus.com/programs/hbhm/episode_2504.asp
53. New and emerging therapies for FGIDs. Audio-Digest Gastroenterology, Volume 27, Issue 20, October 21, 2013, ISSN 0892-9386 <http://www.audio-digest.org/pages/htmls/15251.3.1051358327615669202>
54. Topics in Otolaryngology: GERD. Audio-Digest Family Practice, Volume 61, Issue 41, November 7, 2013, ISSN 0271-1362.
55. Treatment of *H. pylori* infection. Audio-Digest Family Practice, Volume 61, Issue 45, December 7, 2013, ISSN 0271-1362.
56. Chronic Constipation – Episode 2901, Public Broadcasting System. <http://www.itvisus.com/programs/hbhm/episode>
57. Gastroenterology Update: Managing IBS. Audio-Digest Internal Medicine, Volume 61, Issue 2, January 14, 2014, ISSN 0271-1303.
58. **Chey WD**, Eswaran S, Cash BD. Advances in probiotic therapy for diarrhea-associated illnesses. CME Monograph, Gastroenterology & Endoscopy News, 2014.
59. IBS: Current Medical Management Options. Audio Digest Family Practice, Volume 62, Issue 13, April 7, 2014, ISSN 0271-1362.
60. Lacy BE, **Chey WD**. Medscape CME discussions on IBS and Chronic Constipation from DDW 2014. May 4, 2014.
61. University of Michigan Health System Press Release: Doctors miss the chance to recommend equally effective generics, May 3, 2014, <http://www.uofmhealth.org/news/archive/201405/doctors-miss-chance-recommend-equally-effective-generics>
62. University of Michigan Health System Press release on NEJM article on naloxegol for opiate induced constipation, June 4, 2014: <http://www.uofmhealth.org/news/archive/201406/drug-trial-shows-promise-treating-constipation-caused-pain>
63. University of Michigan Health System Press release: U-M home to nation’s most trusted sources for GI research, September 3, 2014. <https://www.umhsheadlines.org/2014/09/u-m-home-to-nations-most-trusted-sources-for-gi-research/>
64. What is gluten? TED-ed video, January 2015. <http://ed.ted.com/lessons/what-s-the-big-deal-with-gluten-william-d-chey>
65. **Chey W**. FODMAPs Alter Symptoms and the Metabolome of Patients With IBS: A Randomised Controlled Trial. PracticeUpdate website. Available at: <http://www.practiceupdate.com/content/fodmaps-and-symptoms-in-patients-with-irritable-bowel-syndrome/36735/65/9/1>. Accessed April 15, 2016.
66. **Chey WD**, Lacy B, Cash B. IBS-D: From Diagnosis to Management. Medscape. February 24, 2017: <http://www.medscape.org/viewarticle/872892>.
67. **Chey WD**. FDgard demonstrated rapid relief of symptoms in functional dyspepsia. Medicalresearch.com, June 5, 2017, <https://medicalresearch.com/author-interviews/fdgard-demonstrated-rapid-relief-of-symptoms-in-functional-dyspepsia/35035/#more-35035>.
68. **Chey WD**, Lembo AL. Optimizing management of patients with IBS-D, AGA & Med-IQ, May 12, 2017 <https://www.med-iq.com/family-medicine/gastroenterology/internal-medicine/free-cme-course/optimizing-the-management-of-patients-with-ibs-today.html>

69. **Chey WD.** Individualized IBS diets reduce symptoms better than placebo: Perspective. Helio Gastroenterol, September 21, 2017
https://www.healio.com/gastroenterology/irritable-bowel-syndrome/news/online/%7Ba6f4365c-92a2-4926-abee-38550bc2bcf4%7D/individualized-ibs-diets-reduce-symptoms-better-than-placebo?utm_source=selligent&utm_medium=email&utm_campaign=gastroenterology%20news&m_bt=129297058195
70. **Chey WD.** Expert Picks from 2017 WCOG/ACG: Part 2. Gastroenterology & Endoscopy News, January 22, 2018.
71. UM Health Blog: Irritable Bowel Syndrome: Symptoms, Treatments, Effects.
<https://healthblog.uofmhealth.org/digestive-health/physical-and-financial-toll-of-irritable-bowel-syndrome>
72. **Chey WD.** Most GIs believe IBS diets ‘as good or better’ than medical therapy. Healio GI, June 21, 2018. <https://www.healio.com/gastroenterology/irritable-bowel-syndrome/news/online/%7Bc3f69219-fb1f-4bc9-8901-5df500e015a4%7D/most-gis-believe-ibs-diets-as-good-or-better-than-medical-therapy>
73. **Chey WD.** Data highlights diet, nutrition impact on GI disorders. Healio GI, October 11, 2018. <https://www.healio.com/gastroenterology/nutrition/news/online/%7B9ca5f287-806c-4e28-8df9-19f48dc06c7d%7D/video-data-highlights-diet-nutrition-impact-on-gi-disorders>
74. **Chey WD.** How to bridge the patient education gap in chronic constipation. Healio GI, November 27, 2018.
<https://www.healio.com/gastroenterology/motility/news/online/%7Bfaedf629-8f37-4052-9371-57ec8fc0215f%7D/video-how-to-bridge-the-patient-education-gap-in-chronic-constipation>
75. **Chey WD.** Podcast: Managing Constipation, April 5, 2019.
<https://www.breastcancer.org/community/podcasts/constipation-20190412>
76. **Chey WD.** Physicians’ words guide patients from hopeless to hopeful. Healio GI, May 23, 2019. <https://www.healio.com/gastroenterology/practice-management/news/online/%7Bc1e38310-a030-4a81-a36c-73dad8aa055a%7D/video-physicians-words-guide-patients-from-hopeless-to-hopeful>
77. **Chey WD.** Opioids lead to dyssynergic defecation. Healio GI, June 14, 2019.
<https://www.healio.com/gastroenterology/motility/news/online/%7Bf1d6979c-e837-4c09-af15-5760a84c4514%7D/video-opioids-lead-to-dyssynergic-defecation>
78. Multiple appearances on the Ira Breit Show, Sirius XM Radio,
<https://doctorira.blogspot.com/2017/09/monday-september-18th-on-doctor-ira.html>
79. Dr. Nandi Show, <https://askdrmandi.com/ask-dr-nandi-show/>. June 5, 2019 – show to be aired later in 2019.
80. **Chey WD.** Episode 3 Podcast on IBS, May 2019. <https://www.ibspatient.org/podcasts/>
81. **Gut Feeling.** WHYY PBS, September 13, 2019. <https://whyy.org/episodes/gut-feeling/>
82. **Fodmap 101:** The beginner’s guiden to a low fodmap diet. Weight Watchers.
<https://weightwatchers.com>
83. Radio Interview about chronic constipation. [Health Professional Radio, January 30, 2020.](#)
84. Expert guest, Ira Breit Show, Sirius XM-[Doctor Radio, February 10, 2020.](#)
85. Michigan Health Lab, January 2020- <https://labblog.uofmhealth.org/lab-report/are-digestive-issues-a-symptom-of-covid-19>

86. Unusual symptoms of COVID-19 you need to know about. AARP.
<http://www.aarp.org/health/conditions-treatments/info=2020/unusual-coronavirus-symptoms.html>
87. Expert guest, Doctor Radio with Mark Pochapin, Sirius XM- [Doctor Radio, April 9, 2020.](#)
88. Expert guest, Ira Breit Show, Sirius XM-Doctor Radio, May 18, 2020.
89. Expert guest, Ira Breit Show, Sirius XM-Doctor Radio, August 10, 2020
90. Holistic care of IBS – Facebook Live, Twitter Chat, Rome Foundation, August 12, 2020.
91. Epicurators – 3 tips for patients with FGIDs August 10, 2020: https://preview.hs-sites.com/_hcms/preview/content/33387418205?portalId=5196012&preview=true&cacheBust=0&preview_key=1Wnmigdd&from_buffer=false
92. Healthy Now: What is IBS? Parade.com, February 5, 2021:
<https://parade.com/1159037/ashleylauretta/what-is-ibs/>
93. Healthy Now: Got heartburn again? Might be time to check your diet. Parade.com. February 3, 2021: <https://parade.com/1158601/jenniferlarsen/foods-that-cause-heartburn/>
94. “Myths and misconceptions about IBS”, a webinar for patients, April 19, 2021.
https://commdx.com/ibs-myths-and-misconceptions-webinar-series-resources/?utm_medium=email&utm_source=sharpspring&sslid=Mze1MjG3MDQ0tTAxAgA&sseid=MzIyNLc0MzE1MQMA&jobid=968ed5ef-ab50-47af-8d60-9d74ade09a94
95. “Chief Rounds with Mark Pochapin” Sirius XM-Doctor Radio, April 22, 2021.
96. “Myths and misconceptions about IBS”, a webinar for providers, April 26, 2021.
97. “Gut health and exercise” Time Health, May 2021.

Podcasts:

1. Founding Co-host AJG Author Podcasts 2012-2015
2. AJG Author Podcast: Food: The Main Course to Wellness and Illness in Patients with IBS. February 2016.
3. AJG Author Podcast: Low FODMAP Diet vs. NICE Guidelines in US Adults with IBS-D. December 2016.
4. ACG Clinical Guideline Podcast: Treatment of Helicobacter pylori infection. February 2017
5. Gut Talk: COVID 19 Updates. Mark Pochapin & David Greenwald. March 2020
6. Gut Talk: Non-traditional careers in Medicine. Tachi Yamada. April 2020
7. Gut Talk: Health Policy: Debbie Dingell. May 2020
8. Gut Talk: Nutrition, Innovation, and Entrepreneurship. Peter Gibson. September 2020.
9. Gut Talk: Curiosity and Persistence: The discovery of *H. pylori*: Barry Marshall. October 2020.
10. Gut Talk: Telemedicine: A silver lining of the pandemic? Jordan Karlitz, Jacqueline Gaulin, August 2020.
11. Gut Talk: COVID 19 and IBD: What gastroenterologists need to know. Gil Melmed, September 2020.
12. Gut Talk: The Rome IV Criteria and What’s Next for Rome V. Doug Drossman, December, 2020.
13. Gut Talk: Probiotics: Should we or shouldn’t we? Eammon Quigley, March 2021.
14. AJG Author Podcast: Evidence of duodenal epithelial barrier impairment in patients with functional dyspepsia. February 2021.

15. Gut Talk: ACG IBS Clinical Practice Guideline. Brian Lacy, March 2021.
16. Gut Talk: Virtual reality in GI. Brennan Spiegel, June 2021.
17. Gut Talk: Diversity, Equity, and Inclusion, Sophie Balzora, July 2021.

Abstracts, Preliminary Communications, Panel Discussions

1. **Chey WD** and Owyang C. VIP has a selective relaxant effect on colonic myocytes contracted by agonists that utilize an IP₃ dependent pathway. Submitted to the 9th International Symposium on GI Hormones, Leuven, Belgium. September, 1992 (Poster presentation).
2. **Chey WD**, Patel A, and Owyang C. Galanin receptors in longitudinal and circular colonic myocytes of guinea pig are coupled to different intracellular mediators: Differential involvement of extracellular calcium and cyclic AMP pathways to mediate contraction and relaxation. *Gastroenterol* 104: A489, 1993 (Oral presentation).
3. Gutanalog reduces perception of rectal distention by specific inhibition of spinal afferent pathways. *Gastroenterol* 1993; 104: A571 (Oral presentation).
4. **Chey WD**, Hasler W, Soudah H, and Owyang C. Intraduodenal lipid induces isobaric gastric fundus relaxation, antral motor inhibition, and pyloric contraction: Role of endogenous CCK. *Gastroenterol* 1993; 104: A817.
5. **Chey WD**, Beydoun A, Hasler W, Kim M, and Owyang C. Octreotide reduces spinal afferent transmission in diarrhea-predominant Irritable Bowel Patients. *Gastroenterol* 1994; 106: A478 (Oral presentation).
6. Hasler W, **Chey WD**, Kim M, and Owyang C. Distinct mechanisms mediate tachygastria evoked by acute hyperglycemia and experimental motion sickness: Roles of endogenous prostaglandins and cholinergic pathways. *Gastroenterol* 1994; 106: A508 (Oral presentation).
7. Sims M, Hasler W, **Chey WD**, Kim M, and Owyang C. Acute hyperglycemia inhibits gastrocolonic and colonic peristaltic reflexes measured by an electronic barostat in healthy humans. *Gastroenterol* 1994; 106: A566 (Oral presentation).
8. Kohagen K, Hasler W, Kim M, McDonnell M, **Chey WD**, and Owyang C. Transdermal nicotine evokes gastric dysrhythmias via a prostaglandin-dependent pathway with associated antral hypomotility: a model for decreased gastric motility with smoking. *Gastroenterol* 1994; 106: A525 (Oral presentation).
9. **Chey WD**, Beydoun A, Hasler W, Kim M, and Owyang C. Octreotide reduces spinal afferent transmission in diarrhea-predominant Irritable Bowel Patients. *Dig Dis Sci* 39: 1792, 1994 (10th International Symposium on Gastrointestinal Hormones, Santa Barbara, CA. August 29, 1994, Oral Presentation).
10. **Chey WD**, Kim ML, Hasler WL, Owyang C. Acute hyperglycemia alters perception of rectal balloon distention and blunts the rectoanal inhibitory reflex in healthy volunteers: implications for diabetic constipation. *Gastroenterol* 107: 1240, 1994 (American Motility Society Biennial Symposium, Wintergreen, VA. October 1994, Oral Presentation).
11. Hasler WL, Kohagen K, Kim M, McDonnell M, **Chey WD**, Owyang C. Nicotine effects of prostaglandin-dependent gastric slow wave rhythmicity and antral motility in non-smokers and smokers. *Gastroenterol* 107: 1245, 1994 (American Motility Society Biennial Symposium, Wintergreen, VA. October 1994, Poster presentation).

12. **Chey WD**, Beydoun A, Kim M, Hasler W, Spybrook M, Owyang C. Hyperglycemia blunts perception of electrical rectal stimulation by effects on central processing of afferent input. *Gastroenterol* 1995; 108: A582 (Oral Presentation).
13. **Chey WD**, Hasler W, Kim M, Owyang C. Suppression of gastric acid secretion corrects the prolongation of migrating motor complex duration in patients with gastroesophageal reflux. *Gastroenterol* 1995; 108: A582 (Poster Presentation).
14. Kim M, **Chey WD**, Owyang C, Hasler W. Role of plasma vasopressin as a possible mediator of nausea and gastric slow wave dysrhythmias in experimental motion sickness. *Gastroenterol* 1995; 108: A628 (Poster Presentation).
15. Carpenter S, **Chey WD**, Hasler W, Fey D, Kim M, Spybrook M, Owyang C. Modulation of CCK and non-CCK dependent pancreatic enzyme secretion by inhibitory 5-HT3 pathways. *Gastroenterol* 1995; 108: A346 (Oral Presentation).
16. **Chey WD**, Kim ML, Hasler WL, Owyang C. Acute hyperglycemia alters perception of rectal balloon distention and blunts the rectoanal inhibitory reflex in healthy volunteers: implications for diabetic constipation. Glaxo Institute for Digestive Health Research Awards Alumni Symposium. Research Triangle Park, NC. January 28, 1995.
17. Kim M, Lu Y, **Chey WD**, Owyang C, Hasler W. Desensitization of the prostaglandin-dependent slow wave dysrhythmic response to acute hyperglycemia in healthy chronic smokers. Submitted to the Third International Workshop on EGG, May, 1995 (Trainee Travel Award Winner).
18. Hasler W, Kim M, **Chey WD**, Owyang C. Correlation of tachygastria and EGG signal power with plasma vasopressin levels and symptoms in response to distinct dysrhythmic stimuli. Submitted to the Third International Workshop on EGG, May, 1995 (Walter Alvarez Award for Excellence in Electrogastrography Research).
19. **Chey WD**, Beydoun A, Kim M, Hasler W, Spybrook M, Owyang C. Hyperglycemia blunts perception of electrical rectal stimulation by effects on central processing of afferent input. Third International Symposium on Brain-Gut Interactions, Cambridge, UK, July 20-22, 1995 (Travel Scholarship Winner).
20. Kim M, Lu Y, **Chey WD**, Owyang C, Hasler W. Hyperglycemia induces gastric dysrhythmias: mediation by prostaglandin-dependent pathways. Submitted to XV International Symposium on Gastrointestinal Motility, Rome, Italy, November, 1995.
21. Hasler W, Kim M, **Chey WD**, Owyang C. Cholinergic blockade in the CNS prevents gastric dysrhythmias and nausea during experimental motion sickness: mediation by inhibition of release and action of vasopressin. Submitted to XV International Symposium on Gastrointestinal Motility, Rome, Italy, November, 1995.
22. **Chey WD**, Stevens M, Hasler WL, Hooper F, Greene D, Owyang C. Hyperglycemia blunts rectal afferent transmission and increases rectal compliance in diabetic patients: A possible model of diabetic constipation. *Gastroenterol* 1996; 110: A647 (Presidential plenary poster presentation at DDW '96).
23. **Chey WD**, Fey D, Scheiman J, Nostrant T, Del Valle. The role of acid suppression in the effects of lansoprazole and ranitidine on the ¹⁴C-urea breath test. *Gastroenterol* 1996; 110: A80, (Poster presentation).
24. **Chey WD**, Murthy UK, Linscheer WG, Weisenfeld B, Bennett T, Barnett J, Elta G, Hasler W, Nostrant T, Scheiman JM. A comparison between 4 different commercially available serology tests for *Helicobacter pylori*. *Gastroenterol* 1996; 110: A80 (Poster presentation).

25. Hasler W, Fey D, Woods M, Hooper F, **Chey WD**, Owyang C. Relative roles of gastric mechanoreceptors and intestinal nutrient chemoreceptors in postprandial electrogastrographic signal increases. *Gastroenterol* 1996; 110: A676.
26. Jednak M, Shadigian E, Hooper F, Woods M, **Chey WD**, Owyang C. Effects of nutrient composition on symptoms and slow wave dysrhythmias in nausea of pregnancy. *Gastroenterol* 1996; 110: A686.
27. Hasler W, Lu Y, Li Y, Fey D, **Chey WD**, Owyang C. Hyperglycemia induces gastric dysrhythmias via endogenous prostaglandin production: mediation by cholinergic pathways in the central nervous system. *Gastroenterol* 1996; 110: A1078.
28. **Chey WD**, Fey D, Scheiman J, Nostrant T, Del Valle. The role of acid suppression in the effects of lansoprazole and ranitidine on the ¹⁴C-urea breath test. *Developments in Helicobacter Research: From the Basic Laboratory to the Patient*, St. Petersburg, FL, February 1996.
29. **Chey WD**, Fisher L, Elta GH, Barnett J, Nostrant T, Del Valle J, Scheiman J. One week, BID therapy for *H. pylori*: A randomized comparison of 2 strategies. *Gastroenterol* 1997; 112: A87 (Poster presentation).
30. **Chey WD**, Murthy U, Barish C, Rapier R, Riff R, Rubin H, Safdi M, Schwartz H, Shah H, Wruble L, Genta R. The ChemTrak AccuMeter whole blood serology test for the detection of *H. pylori* infection. *Gastroenterol* 1997; 112: A87 (Poster presentation).
31. Fendrick WD, Fennerty MB, **Chey WD**. Estimating the demand for *H. pylori* confirmatory testing after eradication treatment. *Gastroenterol* 1997; 112: A14 (Poster presentation).
32. Bjornsson E, **Chey WD**, Ladabaum U, Hooper F, Woods M, Owyang C, Hasler W. Mediation of both the mechano and chemoreceptor components of the gastrocolonic response but not the colonic peristaltic reflex by serotonergic 5-HT₃ pathways in healthy humans. *Gastroenterol* 1997; 112: A700 (Oral presentation).
33. Wille RT, Barnett JL, **Chey WD**, Scheiman JM, Elta GH. Randomized controlled trial of droperidol as routine premedication for ERCP. *Gastrointest Endosc* 1997; 45: AB152 (ASGE Plenary Session).
34. Ladabaum U, **Chey WD**. Eosinophilic gastroenteritis mimicking complicated peptic ulcer disease. Submitted to the ACG National Fellows Forum, Colorado Springs, CO, August, 1997 (Oral presentation).
35. **Chey WD**, Fisher L, Barnett J, Del Valle J, Elta GH, Nostrant T, Palaniappan J, Scheiman J. The effectiveness of therapies with low and high dose azithromycin to treat *H. pylori* infection. The Fourth International Conference on the Macrolides, Azilides, Streptogramins & Ketolides, Barcelona, Spain, January 1998.
36. Rich M, Scheiman JM, **Chey WD**. Comparison of ¹⁴C-urea breath test utilization between gastroenterologists and primary care physicians. *Am J Gastroenterol* 1997; 92:1663.
37. **Chey WD**, Murthy U, Toskes P, Carpenter S, Laine L. Validation of the ¹³C-urea blood test for *H. pylori* infection: a US, multicenter trial. *Gastroenterol* 1998; 114: A371 (oral presentation).
38. **Chey WD**, Fisher L, Barnett J, Delvalle J, Elta GH, Nostrant T, Palaniappan J, Scheiman J. Triple therapy with low versus high dose azithromycin to treat *H. pylori* infection. *Gastroenterol* 1998; 114: A370 (poster presentation).
39. **Chey WD**, Murthy U, Linscheer W, Barnett J, Delvalle J, Elta GH, Fisher L, Nostrant T, Scheiman J, Zawadski A, Fayyad A. A comparison of 2 commercially available fingerstick,

- whole blood antibody tests for *H. pylori* infection. *Gastroenterol* 1998; 114: A369 (poster presentation).
40. Bjornsson E, **Chey WD**, Hooper F, Woods M, Owyang C, Hasler W. Selectively enhanced phasic but not tonic gastro-colonic contractions in diarrhea-predominant irritable bowel syndrome: role of serotonin 5-HT₃ neural pathways. *Gastroenterol* 1998; 114: A2986 (oral presentation).
 41. Stern MA, Gunaratnum N, **Chey WD**. Colonic intussusception from pneumatosis cytoidea intestinalis. Best case report winner - Michigan Society of Gastrointestinal Endoscopy Fellows competition, May 6, 1998.
 42. **Chey WD**, Murthy U, Toskes P, Carpenter S, Laine L. Validation of the ¹³C-urea blood test for *H. pylori* infection: a US, multicenter trial. World Congress of Gastroenterology, Vienna, Austria, September 1998 (President's Plenary Poster selection).
 43. Stern MA, McDonnell WM, Gunaratnum N, Moseley R, **Chey WD**. Interim analysis of a randomized, controlled trial to assess technical and clinical outcomes of a novel colorectal cancer screening strategy. *Am J Gastroenterol* 1998; 93: 1701 (Oral presentation, Astra Merck Fellow Research Award).
 44. Mao HV, Lak BV, Long T, Chung NQ, Thang DM, Hop TV, Chien NN, Hoan PQ, Henley KS, Connor BA, Stone CD, **Chey WD**. Omeprazole or ranitidine bismuth citrate with clarithromycin and amoxicillin for 10 days to treat *H. pylori* infection: A randomized, controlled trial in Vietnamese patients with duodenal ulcer. *Gastroenterol* 1999; 116; A136 (Poster of Distinction - DDW '99).
 45. **Chey WD**, Shaw S, Montague J, Jones M, Murthy U. Appropriate timing of the ¹⁴C-urea breath test to establish eradication of *H. pylori* infection: An interim analysis. *Gastroenterol* 1999; 116; A136 (poster presentation).
 46. **Chey WD**, Shapiro B, Zawadski A, Goodman K. Gastric emptying characteristics of a novel muffin meal: Comparison of ¹³C-octanoate breath testing and scintigraphy. *Gastroenterol* 1999; 116; A971 (poster presentation).
 47. Stern MA, Fendrick AM, Gunaratnam N, McDonnell WM, Moseley RH, **Chey WD**. Analysis of a randomized, controlled trial to assess clinical and economic outcomes of a novel colorectal cancer screening strategy. *Gastroenterol* 1999; 116; A510 (oral presentation).
 48. Stern MA, Rhee JY, **Chey WD**. Pilot study of a novel use of oral fleets phosphasoda for screening sigmoidoscopy preparation. *Gastrointest Endosc* 1999; 49: AB69 (poster presentation).
 49. Stern MA, Minoshima S, Montague J, Cross DJ, Ladabaum U, Hasler WL, **Chey WD**. Differential cerebral activation in response to painful somatic thermal or visceral esophageal stimulation in healthy volunteers. *Gastroenterol* 1999; 116; A1087 (poster presentation).
 50. Ladabaum U, Minoshima S, Hasler W, Cross D, **Chey WD**, Owyang C. Cerebral representation of a distal gastric mechano-receptor activation. *Gastroenterol* 1999; 116; A4444 (oral presentation).
 51. Gorelick AB, Cannon ME, Barnett JL, **Chey WD**, Scheiman JM, Elta GH. Sphincterotomy outcome with two different electrocautery currents. *Gastrointest Endosc* 1999; 49: AB179 (poster presentation).

52. Jednak MA, Barnett JL, Scheiman JM, **Chey WD**, Elta GH. A randomized trial of needle knife fistulotomy versus needle knife precut sphincterotomy for biliary access. *Gastrointest Endosc* 1999; 49: AB216 (poster presentation).
53. Nandi PS, Barnett JL, Nostrant TT, **Chey WD**, Francis IR, Prince MR, Carlos C, Scheiman JM. A prospective, blinded comparison of EUS and MRCP with ERCP in patients with suspected extrahepatic biliary disease. *Gastrointest Endosc* 1999; 49: AB95 (ASGE plenary session).
54. Cross DJ, Minoshima S, Ladabaum U, Hasler W, **Chey W**, Paulson PE, Morrow TJ, Owyang C, Casey KL. Cerebral representation of somatic versus visceral pain as revealed by PET. Submitted to Society for Neuroscience, Miami Beach, FLA, October 1999.
55. **Chey WD**, Stern MA, Montague J, Cross DJ, Ladabaum U, Hasler WL, Minoshima S. Cerebral activation in response to painful visceral esophageal or somatic thermal stimulation. *Neurogastroenterol Motil* 1999; 11:253.
56. Gonlachanvit S, **Chey WD**, Parkman HP, Goodman KJ. Effect of meal size and test duration on gastric emptying as determined by breath test in normal subjects using a muffin meal labeled with ¹³C-sodium octanoate. *Gastroenterol*. 118: A143, 2000 (Alvarez Award for Best Scientific Paper at the International EGG Meeting).
57. Chathadi K, Murthy U, Montague J, Jones M, **Chey WD**. A modified ¹⁴C-urea breath test eliminates false negative results in patients taking a proton pump inhibitor. *Gastroenterol* 2000; 118: A504 (Runner-up, Student Abstract Prize from the AGA).
58. **Chey WD**, Abrahmse P, Fendrick M. Active or antibody testing to diagnose *H. pylori* infection? Examining the clinical and economical tradeoffs using decision analysis. *Gastroenterol* 2000; 118: A504.
59. Brown WH, **Chey WD**, Elta, GH. The number of responses on a review of systems questionnaire predicts the diagnosis of functional GI disorders. *Gastroenterol* 2001; 120; A1205 (poster presentation).
60. Chang L, Olden KW, Carter EG, Boyle J, **Chey WD**. Bowel habit predominance has a significant impact on symptoms and daily activities in women with IBS. *Gastroenterol* 2001; 120; A3214 (poster presentation).
61. Olden K, **Chey WD**, Boyle J, Chang L. Health Related Quality of Life in Irritable Bowel Syndrome: A Community Based Study. *Gastroenterol* 2001; 120; A3216 (poster presentation).
62. **Chey WD**, Chang L, Carter E, Boyle J, Olden K. Do the Rome I and Rome II criteria identify the same IBS pts? *Gastroenterol* 2001; 120; A3221 (poster presentation).
63. Gonlachanvit S, Chen YH, Sun WM, **Chey WD**. Effects of selective 5HT3 antagonist on anorectal function in normal female subjects. *Gastroenterol* 2001; 120; A3258 (poster presentation).
64. **Chey WD**, Ladabaum U, Fendrick AM, Scheiman JM. Cost-effectiveness of empiric PPI therapy vs. test and treat in uninvestigated dyspepsia: impact of decreasing *H. pylori* prevalence and increasing non-*H. pylori* ulcers. *Am J Gastroenterol* 2001; 96; A836.
65. Gorelick AB, Barnett JL, **Chey WD**, Anderson MA, Elta GH. A study of Botulinum toxin injection into the residual pancreatic sphincter after biliary sphincterotomy in patients with sphincter of oddi dysfunction. *Gastrointest Endos* 2001; 53; A3354 (poster presentation).
66. Quallich LG, Stern MA, Rich M, **Chey WD**, Barnett JL, Elta GH. Bile duct crystals do not contribute to post-cholecystectomy syndrome. *Gastrointest Endosc* 2001; 53; A3405 (poster presentation).

67. Gonlachanvit S, Kim H, Rhee J, Sun WM, **Chey WD**. Acute acoustic stress alters rectal compliance in healthy humans. *Gastroenterol* 2002; 122; T1282 (poster presentation).
68. Schoenfeld PS, **Chey WD**, Drossman D, Kim HM, Thompson WG. Effectiveness and safety of tegaserod in the treatment of Irritable Bowel Syndrome: a meta-analysis of randomized controlled trials. *Gastroenterol* 2002; 122; T1486 (poster presentation).
69. Ahmed F, Murthy UK, **Chey WD**, Toskes P, Wagner DA. Evaluation of the Ez-HBT *Helicobacter* blood test to establish *Helicobacter pylori* eradication. *Gastroenterol* 2002; 122; A386 (oral presentation).
70. **Chey WD**, Carr-Locke DL. Proton pump inhibitors do not affect the sensitivity of Urea breath testing when using a citrate meal. *Gastroenterol* 2002; 122; S1322 (poster presentation).
71. **Chey WD**, Inadomi J, Fendrick AM, Sharma VK, Howden C. Primary care physicians' perceptions of Barrett's esophagus, the relationship between GERD & *H. pylori*, and treatment of nocturnal heartburn: results of a national survey. *Am J Gastroenterol* 2002; 97: S231-2 (oral presentation).
72. Cash BD, Schoenfeld PS, **Chey WD**. Value of diagnostic testing in Irritable Bowel Syndrome: A systematic review. *Am J Gastroenterol* 2002; 97: S227 (poster presentation).
73. **Chey WD**, Inadomi JM, Booher AK, Fendrick AM, Sharma VK, Howden CW. Primary care physicians perceptions and practices on the management of GERD: results of a national survey. *Gastroenterol* 2003; 124: A505 (poster presentation).
74. **Chey WD**, Inadomi JM, Booher AK, Fendrick AM, Sharma VK, Howden CW. What do primary care physicians think about Barrett's esophagus, the relationship between GERD & *H. pylori*, and treatment of nocturnal heartburn? *Gastroenterol* 2003; 124: A108 (oral presentation).
75. **Chey WD**, Shaw MJ, Inadomi JM, Popovski S, Adlis S, Nojkov B, Cleary MJ. Erosive esophagitis, nonerosive esophageal disorders, and dyspepsia: population characteristics and effectiveness of rabeprazole therapy. *Gastroenterol* 2003; 124: A227 (poster presentation).
76. Green C, **Chey WD**, Jones MP, Eisen GM, Briseno M, Garewal HS, Fass R. Clinical predictive factors for long-segment Barrett's esophagus. *Gastroenterol* 2003; 124: A642 (poster presentation).
77. Wald A, Johanson JF, Tougas G, **Chey WD**, Novick J, Lembo A, Fordham F, Guella M, Nault B. Safety and tolerability of Tegaserod in patients treated for chronic constipation (CC): a 12 week, double blind, placebo controlled multicenter study performed in the Americas. *Gastroenterol* 2003; 124: A573 (poster presentation).
78. Johanson JF, Tougas G, **Chey WD**, Novick J, Lembo A, Fordham F, Guella M, Nault B. Tegaserod provides rapid and sustained relief of chronic constipation and associated abnormal symptoms: An American double blind, placebo controlled multicenter study. *Gastroenterol* 2003; 124: A47 (oral presentation).
79. Wagner DA, Bolt DB, **Chey WD**. Novel breath test detects fructose malabsorption in IBS patients. *Gastroenterol* 2003; 124: A394 (poster presentation).
80. Kim B, Rhee J, Elta GH, Inadomi J, Chotisprashidhi P, Wamsteker E, Scheiman JM, **Chey WD**, Anderson MA. Droperidol is superior to phenergen for sedation in patients undergoing ERCP: Results of a randomized, double-blind trial. *Gastrointest Endosc* 2003; 57: AB79 (oral presentation).

81. **Chey WD**, Lukasik N, Huang B, Joseph-Ridge N. Lansoprazole provides symptom relief in ulcer free patients who are taking chronic NSAIDs. *Am J Gastroenterol* 2003; 98: S296 (oral presentation).
82. Fisher R, Thistle J, Lembo A, Novick J, O’Kane P, **Chey W**, Ruegg P, Shi V, Dogra A, Luo D, Ernest D. What is the impact of tegaserod on gallbladder emptying? *Am J Gastroenterol* 2003; 98: S270 (poster presentation).
83. Sherif A, Coleski R, Sun WM, **Chey WD**, Hasler WL. 5-HT4 receptor stimulation of colonic peristaltic reflex and basal tonic colon activity by tegaserod in healthy humans: possible mechanisms of its action in constipation. *Gastroenterol* 2004; 126: Ab109 (oral presentation).
84. Fass R, Green, **Chey WD**, Jones MP, Eisen GM, Briseno M, Garewal HS, Ramirez FC. Patients who presently do not smoke have longer lengths of Barrett's esophagus (BE) as compared to those who actively smoke—a multi-center survey. *Gastroenterol* 2004; 126: AbS1702 (poster presentation).
85. Nojkov B, Shaw MJ, Adlis S, **Chey WD**. Symptom severity, quality of life (QoL), and psychological distress in patients with erosive esophagitis (EE) vs. nonerosive esophageal disorders (NEED): are they really similar? *Gastroenterol* 2004; 126: AbW1263 (poster presentation).
86. Mulhall B, Cash BD, Schoenfeld P, **Chey WD**. How do US gastroenterologists diagnose irritable bowel syndrome? *Gastroenterol* 2004; 126: AbW1287 (poster presentation).
87. **Chey WD**, Nojkov B, Adlis S, Inadomi J, Shaw MJ. Does co-morbid irritable bowel syndrome influence the effectiveness of PPI therapy for gastroesophageal reflux disease? *Gastroenterol* 2004; 126: AbW1464 (poster presentation).
88. **Chey WD**, Eswaran S, Scheiman JM, Fendrick M, Inadomi JM, Howden C. Facts and fantasies concerning aspirin: results of a US national survey of 1000 primary care physicians. *Am J Gastroenterol* 2004; 99: Ab99 (oral presentation).
89. Howden CW, Metz DC, **Chey WD**, Triadafilopoulos G, Peura DA. Degree of conformity between US gastroenterologists and experts concerning Barrett's esophagus (BE). *Gastroenterol* 2005; 128: Ab912 (oral presentation).
90. Nojkov B, **Chey WD**, Adlis S, Shaw M. Predictors of response to PPI therapy in patients with GERD: the influence of co-morbid IBS and psychological disease. *Gastroenterol* 2005; 128: Ab416 (oral presentation).
91. Saad R, Schoenfeld P, Kim HM, **Chey WD**. Levofloxacin triple or PPI quadruple salvage therapy for persistent *Helicobacter pylori* infection: results of a systematic review. *Gastroenterol* 2005; 128: Ab431 (oral presentation).
92. **Chey WD**, Chan L, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis in clinical trials and post-marketing surveillance amongst patients using alosetron after blinded adjudication. *Gastroenterol* 2005; 128: AbT1139 (poster presentation).
93. Eswaran SL, **Chey WD**, Askari F, Lok AS, Fontana RJ, Marrero JA. Prevalence of abnormal liver function chemistries in an American cohort of patients with celiac disease. *Am J Gastroenterol* 2005; 100: Ab211 (poster presentation).
94. **Chey WD**, Novick J, Sherman J, Jones J, Cohard-Radice M. Patients improve on tegaserod regardless of primary constipation complaint. *Am J Gastroenterol* 2005; 100: Ab914, (poster presentation).

95. Lee DH, Andrews AH, Dobhan R, Kim CH, Cash BD, **Chey WD**. A prospective, multicenter US trial to determine the yield of routine diagnostic testing in suspected diarrhea-predominant and alternating IBS patients. *Am J Gastroenterol* 2005; 100: Ab918 (poster presentation).
96. **Chey WD**, Bottoli I, Walter V, Shetzline M, Cohard-Radice M. Tegaserod is superior to placebo in normalizing stool consistency and in increasing frequency of complete spontaneous bowel movements (CSBMs) in chronic constipation (CC) patients who present with hard stools. *Am J Gastroenterol* 2005; 100: Ab929 (poster presentation).
97. **Chey WD**, Pare P, Viegas A, Ligozio G, Shetzline MA. Tegaserod improves symptoms in women with mixed/alternating bowel habits as well as those with IBS-C. *Gastroenterol* 2006; 130: Ab135 (oral presentation).
98. Cash BD, Andrews AH, Lee DH, Smith JH, Kim CH, Saad R, Rai JK, **Chey WD**. Yield of diagnostic testing in patients with suspected irritable bowel syndrome (IBS): a prospective, US multi-center trial. *Gastroenterol* 2006; 130: Ab771 (oral presentation).
99. Bottoli I, **Chey WD**, Ddunger-Baldauf C, Kralstein J. Complete spontaneous bowel movement (CSBM) correlates better than spontaneous bowel movement (SBM) to global endpoints in chronic constipation (CC) trials. *Gastroenterol* 2006; 130: AbM1192 (poster presentation).
100. Hasler WL, Parkman HP, Hutson A, **Chey WD**, Koch KL, McCallum RW, Wo JM, Kuo B, Sitrin M, Stevens K, Landrigan B, Semler JR, Coleski R. Postprandial gastric acid neutralization-reacidification measured with an ingested pH telemetry capsule: correlation with emptying of digestible and indigestible solids. *Gastroenterol* 2006; 130: AbM2076 (poster presentation).
101. Hasler WL, Coleski R, **Chey WD**, Koch KL, McCallum RW, Wo JM, Kuo B, Sitrin M, Stevens K, Landrigan B, Semler JR, Parkman HP. Postprandial gastric acid neutralization and reacidification in diabetic vs. idiopathic gastroparesis: relation to degree of gastric stasis. *Gastroenterol* 2006; 130: AbM2201 (poster presentation).
102. Kuo B, McCallum R, Koch K, **Chey WD**, Wo JM, Sitrin M, Hasler W, Lackner J, Katz L, Landrigan B, Selover K, Hutson A, Barthel D, Semler J, Parkman HP. Smartpill, a novel ambulatory diagnostic test for measuring gastric emptying in health and disease. *Gastroenterol* 2006; 130: AbM2205 (poster presentation).
103. Hatfield CD, **Chey WD**, Barthel D, Semler J, Harrel S, Wo J. Making a diagnosis of gastroparesis reduces diagnostic cost and unnecessary surgeries in patients with recurrent nausea and vomiting. *Gastroenterol* 2006; 130: AbS1136 (poster presentation).
104. **Chey WD**, Nojkov B, Saad R, Rai J, Adlis SA, Shaw MJ. Does the absence of erosive esophagitis really predict a worse response to Proton Pump Inhibitor (PPI) therapy in patients with Gastroesophageal Reflux Disease? *Gastroenterol* 2006; 130: AbS1219 (poster presentation).
105. Parkman HP, Hutson A, Maurer AH, Knight LC, Kuo B, Hasler WL, **Chey WD**, McCallum RW, Wo JM, Koch KL, Sitrin M, Lackner JM, Semler J. Optimizing gastric emptying scintigraphy for the detection of gastroparesis. *Gastroenterol* 2006; 130: AbT1249 (poster presentation).
106. Sabbagh LC, **Chey WD**, Barton G, Viegas A, Ligozio G, Shetzline MA. Tegaserod is proven safe in IBS-C patients and those with mixed/alternating bowel habits. *Gastroenterol* 2006; 130: AbT2047 (poster presentation).

107. Rubenstein J, Nojkov B, Korsnes S, Weinman B, Inadomi JM, **Chey WD**. Patients with successfully treated GERD are persistently hypersensitive to esophageal balloon distension. *Gastroenterol* 2006; 130: AbW1794 (poster presentation).
108. Sarosiek I, Koch K, Selover K, Kuo B, Parkman H, Hasler W, Wo JM, Sitrin M, **Chey WD**, Lackner J, D'Andrea D, McCallum RW. A new non-scintigraphic method for measuring gastrointestinal transit in gastroparetic patients. *Gastroenterol* 2006; 130: AbW1833 (poster presentation).
109. Sarosiek I, McCallum RW, Sitrin M, Wo J, Parkman H, Kuo B, Hasler W, **Chey WD**, Hooker J, Landrigan B, Koch K. Smartpill as a novel-non scintigraphic, ambulatory method for assessing GI transit: results in normal subjects. *Gastroenterol* 2006; 130: AbW1844 (poster presentation).
110. Parkman HP, Hutson A, Sarosiek I, Kuo B, **Chey WD**, Katz L, Semler J, McCallum RW. SmartPill capsule for assessment of gastric emptying—comparison with simultaneous gastric emptying scintigraphy. *Am J Gastroenterol* 2006; 102: S99 (Ab#168).
111. Elnachef N, McMorris M, **Chey WD**. Treatment of diarrhea in Common Variable Immunodeficiency: a novel use for budesonide. *Am J Gastroenterol* 2006; 102: S230 (Ab#549).
112. Andrews A, Cash BD, Lee DH, Saad R, Rai J, Maydonovitch C, Kim CH, **Chey WD**. The high false positive rate of inflammatory bowel disease serological markers in patients with irritable bowel syndrome. *Am J Gastroenterol* 2006; 102: S475 (Ab#1226).
113. **Chey WD**, Andrews AH, Lee DH, Smith JH, Kim CH, Saad RJ, Rai JK, Cash BD. Are anti-endomysial or anti-tissue transglutaminase antibodies alone sufficient to screen for celiac sprue in patients with the Irritable Bowel Syndrome? *Am J Gastroenterol* 2006; 102: S477 (Ab#1232).
114. **Chey WD**, Whorwell PJ, Viegas A, Venezia M, Ligozio G, Shetzline MA. Differences in clinical parameters between IBS with constipation and IBS with mixed bowel habits. *Am J Gastroenterol* 2006; 102: S484 (Ab#1250).
115. Rao SS, McCallum R, Parkman HP, Kock K, Saad RJ, **Chey WD**, DiBaise JK, Hutson A, Semler J, Sitrin MD, Lackner JM, Katz L, Kuo B. A comparative study of Smartpill® and radiopaque markers for the assessment of colonic transit time in humans. *Gastroenterol* 2007; 132: A458 (Ab#M2136).
116. Hasler WL, Coleski R, Sarosiek I, McCallum R, Kuo B, Parkman HP, Sitrin MD, Lackner JM, Katz L, Koch K, Wo JM, **Chey WD**, Hutson A, Semler J. Colon transit and regional colon motor activity in diabetics with gastroparesis compared to healthy volunteers and diabetics with near normal gastric emptying. *Gastroenterology* 2007; 132: A459 (Ab#M2143).
117. Talley NJ, **Chey WD**, Vakil N, Omar M, Ligozio G, Kralstein J. Baseline health-related quality of life is correlated with baseline symptom severity and is improved by tegaserod in patients with moderate to severe functional dyspepsia dysmotility symptoms. *Gastroenterol* 2007; 132: A268 (Ab#S1870).
118. **Chey WD**, Tack J, Howden CW, Zakko SF, Rueegg PC, Demissie S, Earnest DL, Kralstein J. Safety and tolerability of long-term therapy with tegaserod in patients with functional dyspepsia and dysmotility symptoms: results of multicenter extension studies. *Gastroenterol* 2007; 132: A266 (Ab#S1859).

119. Rubenstein JH, Nojkov B, Korsnes S, Adlis S, Shaw MJ, Weinman B, Inadomi JM, **Chey WD**. Esophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. *Gastroenterol* 2007; 132: A595 (Ab#T1976).
120. Cash BD, Kim C, Lee D, Andrews AH, Smith JH, Saad RJ, Rai J, Nojkov B, **Chey WD**. Yield of diagnostic testing in patients with suspected irritable bowel syndrome (IBS): a prospective, US multi-center trial. *Gastroenterol* 2007; 132: A678 (Ab#W1182).
121. **Chey WD**, Whorwell PJ, Viegas Andrea, Dolker M, Shetzline MA. Satisfactory relief of overall IBS symptoms correlates strongly with improvements in patients individual symptoms. *Gastroenterol* 2007;132: A679 (Ab#W1189).
122. Reddymasu S, Sarosiek I, Koch K, Hasler WL, Lackner J, Katz L, Sitrin MD, Parkman HP, Wo JM, **Chey WD**, Semler J, Hwang J, Kuo B, McCallum R. Non-digestible capsule technology to measure frequency of gastric contractions- comparison between healthy and gastroparetic subjects. *Gastroenterol* 2007;132: A677 (Ab#W1179).
123. **Chey WD**, Nojkov B, Saad RJ, Rai J, Kim CH, Lee DH, Andrews AH, Cash BD. Screening for celiac sprue in patients with suspected irritable bowel syndrome: results from a prospective US multi-center trial. *Gastroenterol* 2007; 132: A147 (Ab#986).
124. Sarosiek I, Reddymasu S, Koch K, Hasler W, Lackner J, Katz L, Sitrin M, Parkman H, Wo J, Sarosiek J, **Chey W**, Semler J, Kuo B, McCallum R. Relationship between the frequency of gastric contractions and gastric emptying of a non-digestible solid in controls and gastroparetics using Smartpill pressure recording capsule: its future clinical potential. *Gastroenterol* 2007; 132: A379 (Ab#M1175).
125. Elnachef N, Scheiman J, Fendrick AM, Howden CW, **Chey WD**. Changing perceptions and practices regarding aspirin, NSAIDs, and coxibs amongst US primary care providers (Peps): a tale of 2 surveys. *Gastroenterol* 2007; 132: A136 (Ab#921).
126. Vakil N, **Chey WD**, Howden CW, Earnest DL, Ligozio G, Kralstein J, Rueegg PC. Tegaserod significantly improves moderate-sever dysmotility symptoms in patients with functional dyspepsia. *Gastroenterol* 2007; 132: A93 (Ab#643).
127. Lembo AJ, Rosenbaum DP, **Chey WD**, Drossman DA. Safety and efficacy of crofelemer in patients with diarrhea predominant Irritable Bowel Syndrome (D-IBS). *Gastroenterol* 2007; 132: A141 (Ab#944).
128. Menees SB, **Chey WD**, McLeod A, Marcum R, Fenner D. Patient-centered goals in constipation. *Gastroenterol* 2007; 132: A350 (Ab#M1045).
129. Menees SB, **Chey WD**, McLeod A, Marcum R, Fenner D. Patient-centered goals in fecal incontinence. *Gastroenterol* 2007; 132: A473 (Ab#T1131).
130. Zakko S, Vakil N, **Chey WD**, Earnest DL, Ligozio G, Kralstein J, Rueegg PC. Symptom distribution and characteristics of patients with functional dyspepsia: data from two large multicenter trials. *Gastroenterol* 2007; 132: A478 (Ab#T1152).
131. Gaman A, Hutson A, Hwang J, Stevens K, Koch K, Parkman H, McCallum R, **Chey WD**, Katz L, Sitrin MD, Lackner JM, Hasler W, Wo JM, Semler J, Kuo B. A non-digestible device discriminates motility patterns with a luminal acidic pH change within the distal small bowel and proximal colon. *Gastroenterol* 2007; 132: A460 (Ab#M2148).
132. Kloetzer L, Gaman A, Nojkov B, **Chey WD**, Hwang J, Stevens K, Koch K, Parkman H, McCallum R, Katz L, Sitrin MD, Lackner JM, Hasler W, Wo JM, Semler J, Kuo B. Complete pH profiling of the gastrointestinal tract in health volunteers with an ambulatory pH capsule. *Gastroenterol* 2007; 132: A461 (Ab#M2149).

133. Drossman DA, **Chey WD**, Panas R, Wahle A, Scott C, Ueno R. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two, twelve-week, randomized, placebo-controlled, double-blind trials. *Gastroenterol* 2007; 132: P90 (Ab#639f).
134. **Chey WD**, Nojkov B, Rubenstein JR, Adlis S, Shaw MJ. Prevalence and impact of comorbid psychological distress on response to PPI therapy in patients with GERD. *Gastroenterol* 2007; 102: S126-7 (Ab#23).
135. Kaur N, Coffing BN, Greenson J, **Chey WD**. Iron pill gastropathy: a case report and review of the literature. *Gastroenterol* 2007; 102: S168 (Ab#138).
136. Sarosiek I, Sarosiek J, Rao S, **et al**. Comparisons of alimentary tract transit times among normal subjects from two multicenter trials using SmartPill wireless pH/pressure recording capsule: its clinical implication. *Gastroenterol* 2007; 102: S170 (Ab#145).
137. Rao S, Kuo B, **Chey W**, et al. Simultaneous assessment of colonic transit using wireless capsule (SmartPill®) and radiopaque markers in healthy subjects and effects of gender. *Gastroenterol* Fehmi SA, Saini S, Chey W. Uncommon presentation of PTLD in the esophagus. *Gastroenterol* 2007; 102: S372 (Ab#693). 2007; 102: S270 (Ab#423).
138. Brenner DM, Moeller M, **Chey WD**, Schoenfeld P. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. *Gastroenterol* 2007; 102: S500 (Ab#1040).
139. **Chey WD**, Nojkov B, Rubenstein JR, Adlis SA, Shaw MJ. Prevalence and impact of comorbid psychological distress on response to PPI therapy in patients with GERD. *Am J Gastroenterol* 2007; 102: S126 (Ab#23).
140. Kaur N, Coffing BN, Greenson J, **Chey WD**. Iron pill gastropathy: a case report and review of the literature. *Am J Gastroenterol* 2007; 102: S168 (Ab#138).
141. Sarosiek I, Sarosiek J, Rao S, Parkman H, Kuo B, Lackner J, Katz L, Sitrin M, **Chey WD**, Hasler W, DiBaise J, Wo J, Koch K, Semler J, McCallum R. Comparisons of alimentary tract transit times among normal subjects from two multicenter trials using SmartPillWireless pH/Pressure recording capsule: Its clinical implication. *Am J Gastroenterol* 2007; 102: S170 (Ab#145).
142. Rao S, Kuo B, **Chey WD**, Dibaise J, Katz L, Koch K, Lackner J, McCallum R, Saad R, Selover K, Semler J, Sitrin M, Wilding G, Parkman H. Simultaneous assessment of colonic transit using wireless capsule (SmartPill) and radiopaque markers in healthy subjects and effects of gender. *Am J Gastroenterol* 2007; 102: S270 (Ab#423).
143. Fehmi SA, Saini S, **Chey WD**. Uncommon presentation of PTLD in the esophagus. *Am J Gastroenterol* 2007; 102: S372 (Ab#693).
144. Brenner DM, Moeller M, **Chey WD**, Schoenfeld P. The utility of probiotics in the treatment of Irritable Bowel Syndrome: A systematic review. *Am J Gastroenterol* 2007; 102: S500 (Ab#1040).
145. Rao S, Kuo B, **Chey WD**, Dibaise J, Katz L, Koch K, Lackner J, McCallum R, Saad R, Selover K, Semler J, Sitrin M, Wilding G, Parkman H. Investigation of wireless capsule (SmartPill) for colonic transit: A comparative study with radiopaque markers in health and constipation. *Am J Gastroenterol* 2007; 102: S512 (Ab#1075).
146. Spiegel BM, Harris LA, Lucak SL, Mayer EA, Naliboff BD, Bolus RE, Esrailian E, **Chey WD**, et al. Measuring IBS patient reported outcomes with a single item numeric rating scale: results from the PROOF cohort. *Gastroenterol* 2008; 134: A467 (Ab#T1026).

147. Rangnekar AS, Morgan D, Knechtges P, Saad RJ, Fenner D, Morris AM, **Chey WD**. Complaints suggestive of Irritable Bowel Syndrome are common in patients with Puborectalis Dyssynergia: An under-recognized overlap syndrome. *Gastroenterol* 2008; 134: A423 (Ab#M1806).
148. Drossman DA, **Chey WD**, Scott C, Panas RM, Ueno R. Health-related quality of life in adults with Irritable Bowel Syndrome with Constipation: Results of a combined analysis of two phase 3 studies with lubiprostone. *Gastroenterol* 2008; 134: A469 (Ab#T1036).
149. **Chey WD**, Drossman DA, Scott C, Panas RM, Ueno R. Lubiprostone is effective and well tolerated through 48 weeks of treatment in adults with irritable bowel syndrome and constipation. *Gastroenterol* 2008; 134: A215 (Ab#S1272).
150. **Chey WD**, Saad RJ, Panas RM, Wahle A, Ueno R. Discontinuation of lubiprostone treatment for irritable bowel syndrome with constipation is not associated with symptom increase or recurrence: Results from a randomized withdrawal study. *Gastroenterol* 2008; 134: A401 (Ab#M1706).
151. Kloetzer L, Gaman A, Napadow V, McCallum R, Koch KL, Sitrin MD, **Chey WD**, et al. Spectral analysis of contractile frequency in the ileum and proximal colon: characterization of motility patterns using an ambulatory capsule, SmartPill. *Gastroenterol* 2008; 134: A676 (Ab#W1303).
152. Kloetzer L, Gaman A, McCallum R, Koch KL, Sitrin MD, **Chey WD**, et al. Characterization of Pressure Patterns in Distal Colonic and Rectal Motility Activity between Healthy Volunteers and Patients with Dyssynergic Defecation Using An Ambulatory Capsule, SmartPill. *Gastroenterol* 2008; 134: A281 (Ab#S1838).
153. **Chey WD**, Mody R, Kothari S. et al. Are Proton Pump Inhibitors (PPIs) sufficient in controlling symptoms of gastro-esophageal reflux disease (GERD)? A community-based US survey study. *Gastroenterol* 2008; 134: A325 (Ab#M1041).
154. **Chey WD**, Mody R, Chen L, et al. Nighttime symptoms and sleep impairment among patients with gastro-esophageal reflux disease (GERD) receiving prescription (Rx) proton pump inhibitors (PPIs). *Gastroenterol* 2008; 134: A323-4 (Ab#M1033).
155. Saad RJ, **Chey WD**, Rao SS, et al. How well does stool form and stool frequency correlate with colonic and whole gut transit in healthy controls and constipated patients? *Gastroenterol* 2008; 134: A420 (Ab#M1794).
156. Hasler WL, Saad RJ, Rao SS, Katz LA, Parkman HP, Koch KL, McCallum R, Kuo B, Sarosiek I, Sitrin MD, Lackner JM, Wilding GE, Miller C, Semler J, **Chey WD**. Heightened motor activity measured by a wireless capsule in unprepared colons of patients with complaints of constipation: relation to colon transit and IBS. *Gastroenterol* 2008; 134: A678 (Ab#W1312).
157. Hasler WL, Rao SS, Koch KL, Sarosiek I, McCallum R, Lackner JM, Parkman HP, **Chey WD**, et al. Wireless capsule quantification of region-specific gastrocolonic response and sleep inhibition of colon motor activity in unprepared colons of humans with normal colon transit. *Gastroenterol* 2008; 134: A678 (Ab#W1313).
158. Reddymasu S, Sarosiek I, Parkman HP, Koch KL, Sitrin MD, Wo JM, Hasler WL, Katz LA, **Chey WD**, et al. Non-digestible capsule technology to measure gastric motility-comparison between healthy controls and gastroparetic patients with a normal gastric emptying study. *Gastroenterol* 2008; 134: A629 (Ab#W1081).

159. **Chey WD**, Nojkov B, Saad R, Adlis S, Shaw M. Differences in GERD patients evaluated by primary care physicians and gastroenterologists. *Am J Gastroenterol* 2008; 103: S26 (Ab#65).
160. Rao S, Paulson J, Kuo B, **et al**. Assessment of inter-observer agreement of colonic transit time (Ctt) with radiopaque markers. *Am J Gastroenterol* 2008; 103: S194 (Ab#502).
161. Sarosiek I, Rao S, Parkman H, **et al**. Comparison of GI transit parameters in functional/idiopathic versus constipation predominant irritable bowel syndrome (IBS) patients assessed by wireless pH/pressure recording capsule. *Am J Gastroenterol* 2008; 103: S202 (Ab#522).
162. Luther J, Faje A, Saad R, **Chey WD**. Anaplastic intra-abdominal lymphoma as a cause of sclerosing mesenteritis: a case report. *Am J Gastroenterol* 2008;103: S305 (Ab#773).
163. **Chey WD**, Drossman D, Baum C, Ueno R. Influence of responder definition on placebo response: insights gained from phase III clinical trials with lubiprostone for IBS-C. *Am J Gastroenterol* 2008; 103: S395 (Ab#1010).
164. **Chey WD**, Mody R, Izat E. Patient and physician satisfaction with proton pump inhibitors (PPI) for GERD symptoms – are there opportunities for improvement? *Am J Gastroenterol* 2008; 103: S396 (Ab#1011).
165. Luther J, Schoenfeld P, Moayyedi P, Vakil N, George S, **Chey WD**. Triple versus quadruple therapy as primary treatment for *Helicobacter pylori* infection: a meta-analysis of efficacy and tolerability. *Am J Gastroenterol* 2008; 103: S397 (Ab#1015).
166. **Chey W**, Talley N, Lembo A, Yu J, Bortey E. Rifaximin significantly improves quality of life versus placebo in patients with diarrhea-predominant irritable bowel syndrome. *Am J Gastroenterol* 2008; 103: S461 (Ab#1182).
167. Cash B, Lee D, Riddle M, **et al**. Yield of diagnostic testing in patients with suspected irritable bowel syndrome (IBS): a prospective, U.S. multi-center trial. *Am J Gastroenterol* 2008; 103: S462 (Ab#1184).
168. Ford A, **Chey W**, Talley N, et al. Utility of diagnostic tests for celiac disease in irritable bowel syndrome: systematic review and meta-analysis. *Am J Gastroenterol* 2008; 103: S463 (Ab#1185).
169. Baker J, Saad R, Rubenstein J, **Chey WD**. Effects of age and gender on anorectal function in chronic constipation. *Am J Gastroenterol* 2008; 103: S466 (Ab#1193).
170. Nojkov B, Rubenstein J, Hoogerwerf S, **Chey WD**. The effect of shift work on the prevalence and clinical impact of functional bowel disorders in nurses. *Am J Gastroenterol* 2008; 103: S469 (Ab#1200).
171. Rao S, Paulson J, Kuo B, **et al**. Relationship between the colonic transit of wireless capsule (Smartpill®) and radio opaque markers in constipation. *Am J Gastroenterol* 2008; 103: S475 (Ab#1215).
172. Ford A, Brandt L, Foxx-Orenstein A, **Chey W**, Schoenfeld P, Moayyedi P. Efficacy of 5HT3-antagonists in non-constipation predominant irritable bowel syndrome: systematic review and meta-analysis. *Am J Gastroenterol* 2008; 103: S477 (Ab#1220).
173. Ford A, Brandt L, Foxx-Orenstein A, **Chey W**, Schoenfeld P, Moayyedi P. Efficacy of 5HT4-agonists in non-diarrhea predominant irritable bowel syndrome: systematic review and meta-analysis. *Am J Gastroenterol* 2008; 103: S478 (Ab#1222).
174. Saad RJ, **Chey WD** (2/15), Rao SS... Wilding GE. Reduced stool frequency does not predict colonic and whole gut transit in constipated patients. *Gastroenterol* 2009; 136: A373 (Ab# M1209).

175. Rangnekar AS, Saad RJ, Morgan DM, Fenner D, **Chey WD**. Do abnormalities on testing for dyssynergic defecation correlate with abdominal pain and bloating in constipated patients? *Gastroenterol* 2009; 136: A217 (Ab# S1227).
176. Bucur MC, Michalek W, McCallum R... **Chey WD** (6/12)...Kuo B. The impact of using different standardized meals in the assessment of motility of upper gastrointestinal tract. *Gastroenterol* 2009; 136: A781 (Ab#W2053).
177. Michalek W, Bucur MC, McCallum R...**Chey WD** (6/11)...Kuo B. A comparison of small bowel pH profiles in healthy subjects and patients with gastroparesis as measured by a non-invasive wireless capsule. *Gastroenterol* 2009; 136: A683-A684 (Ab#W1234).
178. Michalek W, Bucur MC, McCallum R...**Chey WD** (6/11)...Kuo B. Impact of age on upper gastrointestinal function in healthy and gastroparetic populations, as measured by a non-invasive wireless capsule. *Gastroenterol* 2009; 136: A144 (Ab#949).
179. Rao SS, Paulson JA, Saad RJ...**Chey WD** (8/8). 950 Assessment of colonic, whole gut and regional transit in elderly constipated and healthy subjects with a novel wireless pH/pressure capsule (SmartPill®). *Gastroenterol* 2009; 136: A144 (Ab#950).
180. Hasler WL, McCallum R, Rao SS...**Chey WD** (8/12)...Semler JR. Region-specific motor patterns and pH profiles in unprepared human colon quantified by simultaneous radiography and wireless capsule measurements. *Gastroenterol* 2009; 136: A225-A226 (Ab# S1268).
181. Hong S, Mann N, **Chey WD**, Chang L, Spiegel B. Do proton pump inhibitors (PPIs) predispose to the development of SIBO in IBS versus non-IBS patients? *Am J Gastroenterol* 2009; 104: S103 (Ab#269).
182. Hong S, Mann N, **Chey WD**, Chang L, Spiegel B. Is IBS a predictor of SIBO as identified by hydrogen/methane breath testing? *Am J Gastroenterol* 2009; 104: S110 (Ab#289).
183. **Chey WD** (1/8), Xu Y, Baum C...Dabbous O. Gender differences in primary care management of chronic constipation: a study from the examination of chronic constipation treatment and outcomes in everyday medical practice (EXCCEED) registry. *Am J Gastroenterol* 2009; 104: S402 (Ab#1095).
184. Saad R, Baker J, Rubenstein J, **Chey WD**. Dyssynergic defecation is a common finding in men with chronic constipation. *Am J Gastroenterol* 2009; 104: S490 (Ab#1313).
185. Pimentel M, Lembo A, **Chey WD**, Ringel Y, Zakko S, Mareya SM, Shaw AL, Yu J, Bortey E, Forbes WP. Rifaximin treatment for 2 weeks provides acute and sustained relief over 12 weeks of IBS symptoms in non-constipated irritable bowel syndrome: results from 2 North American Phase 3 trials (Target 1 and Target 2). *Gastroenterol* 2010; 138: S64-65 (Ab#475i).
186. Spiegel BM, Bolus RE, Harris LA, Lucak SL, Esrailian E, **Chey WD**, Sayuk GS, Lembo A, Karsan HA, Tillisch K, Talley J, Naliboff BD, Mayer EA, Chang L. Characterizing abdominal pain attributes in IBS: guidance for study inclusion criteria and outcome measurement. *Gastroenterol* 2010; 138: S99-S100 (Ab#733).
187. Spiegel BM, Bolus RE, Harris LA, Lucak SL, Esrailian E, **Chey WD**, Lembo A, Karsan HA, Tillisch K, Talley J, Chang L. Patient-reported symptom relief from current therapy is a robust marker of illness severity in IBS. *Gastroenterology* 2010;138: S119 (Ab#865).
188. Saad RJ, Semler JR, Wilding GE, **Chey WD**. The effect of age on regional and whole gut transit times in healthy adults. *Gastroenterol* 2010; 138: S127 (Ab#896).

189. Jankowski M, **Chey WD**, Maneerattanaporn M, Hasler WL, Wilding GE, Semler JR, Saad RJ. A comparison of two radio-opaque marker methodologies in the assessment of colonic transit of adults with constipation. *Gastroenterol* 2010; 138: S231 (Ab#S1333).
190. Spiegel BM, Bolus RE, Harris LA, Lucak SL, Esrailian E, **Chey WD**, Lembo A, Karsan HA, Tillisch K, Talley J, Chang L. Do IBS patients understand the difference between abdominal pain vs. discomfort? Implications for clinical practice and clinical trial design. *Gastroenterol* 2010; 138: S379 (Ab#M1319).
191. Spiegel BM, Bolus RE, Harris LA, Lucak SL, Esrailian E, **Chey WD**, Lembo A, Karsan HA, Tillisch K, Talley J, Chang L. Characterizing “Bowel Urgency”: Guidance for outcome assessment in patients with diarrhea predominant IBS. *Gastroenterol* 2010; 138: S379 (Ab#M1320).
192. Mody R, Beaulieu N, Wu EQ, Dabbous F, McHale J, **Chey WD**. Impact of nighttime symptoms (NTS) on treatment patterns and healthcare costs among gastroesophageal reflux disease (GERD) patients. *Gastroenterol* 2010; 138: S480 (Ab#T1065).
193. Hasler WL, Rao SS, Parkman HP, Saad RJ, **Chey WD**, McCallum R, Kuo B, Koch KL, Sitrin MD, DiBaise JK, Rohde B, Semler JR. Bristol stool form in slow transit constipation correlates inversely with regional colon contractile activity measured by a wireless motility capsule. *Gastroenterol* 2010; 138: S628 (Ab#T2081).
194. **Chey WD**, Nojkov B, Rubenstein JH, Greenson JK, Cash BD. The yield of colonoscopy in patients with non-constipation irritable bowel syndrome (IBS): results from a prospective, controlled United States Trial. *Gastroenterol* 2010; 639: S379 (Ab#W1044).
195. Sun S, Spiegel B, Mody R, Dabbous F, Dabbous O, **Chey W**. Economic and humanistic burden of chronic constipation. *Am J Gastroenterol* 2010; 105: S391 (Ab#1081).
196. **Chey W**, Schoenfeld P, Sun S, Dabbous F, Baum C, Mody R. Management of chronic constipation: results from the EXCCEED Registry. *Am J Gastroenterol* 2010; 105: S482 (Ab#1310).
197. Sun S, Lembo A, Mody R, Dabbous F, Baum C, **Chey W**. Characteristics of US Patients with Chronic Constipation Encountered in Primary Care: Data from the Examination of Chronic Constipation Treatment and Outcomes in Everyday Medical Practice (EXCCEED) Registry. *Am J Gastroenterol* 2010; 105: S483 (Ab#1311).
198. Lembo A, Pimentel M, **Chey W**, Lacy B, Schoenfeld P, Yu J, Mareya S, Shaw A, Bortey E, Forbes W. Rifaximin treatment consistently demonstrated relief across daily symptoms in patients with non-constipation Irritable Bowel Syndrome: results from 2 phase 3 trials (TARGET 1 and TARGET 2). *Am J Gastroenterol* 2010; 105: S483 (Ab#1312).
199. Maneerattanaporn M, Baker J, Saad R, **Chey W**. What are the key questions which aid in the diagnosis of dyssynergic defecation? *Am J Gastroenterol* 2010; 105: S493 (Ab#1335).
200. **Chey W**, Pimentel M, Lembo A, Brown K, Yu J, Mareya S, Shaw A, Bortey E, Forbes W. The responsiveness and validity of a binary weekly recall question and the proposed FDA composite endpoint as measures of daily symptom severity in non-constipation Irritable Bowel Syndrome: results of TARGET 1 and TARGET 2. *Am J Gastroenterol* 2010; 105: S494 (Ab#1337).
201. Kuo B, Maneerattanaporn M, Lee A, Baker J, Wiener S, **Chey W**, Wilding G, Hasler W. Generalized transit delay on wireless motility capsule in patients with clinical suspicion of gastroparesis, intestinal dysmotility, or slow transit constipation. *Am J Gastroenterol* 2010; 105: S501 (Ab#1356).

202. **Chey WD**, Lembo A, MacDougall JE, Lavins BJ, Schneier H, Johnston JM. Efficacy and safety of once-daily linaclotide administered orally for 26 weeks in patients with IBS-C: results from a randomized, double-blind, placebo-controlled phase 3 trial. *Gastroenterol* 2011; 140: S135 (Ab#837).
203. Maneerattanaporn M, Baker J, **Chey WD**. The number of retained rectosigmoid markers during colonic transit testing does not reliably predict the presence of dyssynergic defecation. *Gastroenterol* 2011; 140: S609 (Ab#Mo1313).
204. Smith TM, Menees SB, Xu X, Saad RJ, **Chey WD**, Fenner D. Factors associated with quality of life among women with fecal incontinence. *Gastroenterol* 2011; 140: S201 (Ab#Sa1002).
205. Ferreccio C, Anderson GL, Morgan DR, Torres J, Bravo LE, Dominguez R, Herrero R, Meza-Montenegro M, Peña R, Salazar-Martinez E, **Chey WD**, Valdivieso M, Crowley J, Goodman GE, Greenberg ER, Baker LH. A randomized trial comparing 14-day triple, 10-day sequential, and 5-day concomitant therapy to eradicate *Helicobacter pylori* in seven Latin American populations. *Gastroenterol* 2011; 140: S137 (Ab#842).
206. **Chey WD**, Pimentel M, Riff DS, Weinstock LB, Yu J, Mareya SM, Bortey E, Forbes WP. Time to onset and durability of relief in non-constipation IBS patients over 12 weeks following a 2-week course of rifaximin. *Gastroenterol* 2011; 140: S605 (Ab#Mo1299).
207. **Chey WD**, Camilleri M, Chang L, Rikner L, Graffner H. A3309, an ileal bile acid transport (IBAT /ASBT) inhibitor, significantly improved stool frequency and other constipation-related complaints in adults with chronic constipation: data from an 8-week, randomized, double-blind, placebo-controlled study. *Gastroenterol* 2011; 140: S3 (Ab#10).
208. Menees SB, Maneerattanaporn M, **Chey WD**. Efficacy of rifaximin in patients with irritable bowel syndrome: a meta-analysis. *Gastroenterol* 2011; 140: S49-50 (Ab#215).
209. Menees SB, Smith TM, Xu X, **Chey WD**, Saad RJ, Fenner D. Factors associated with severity of fecal incontinence: a study of patient characteristics and fecal incontinence severity index (FISI). *Gastroenterol* 2011; 140: S801-802 (Ab#Tu1343).
210. Maneerattanaporn M, Luther J, Waljee AK, Saini SD, **Chey WD**. Biofeedback therapy compared to standard treatment for patients with dyssynergic defecation: results from a meta-analysis. *Gastroenterol* 2011; 140: S797 (Ab#Tu1323).
211. Spiegel BM, Bolus RE, Agarwal N, Sayuk GS, Harris LA, Lucak SL, Esrailian E, **Chey WD**, Lembo A, Karsan HA, Tillisch K, Talley J, Chang L. Factors analysis of bowel symptoms in IBS: guidance for patient reported outcome (PRO) development. *Gastroenterol* 2011; 140: S605-606 (Ab#Mo1299).
212. Spiegel BM, Bolus RE, Agarwal N, Sayuk GS, Harris LA, Lucak SL, Esrailian E, **Chey WD**, Lembo A, Karsan HA, Tillisch K, Talley J, Chang L. Do patients understand the Bristol Stool Scale? Results of cognitive de-briefing of IBS patients. *Gastroenterol* 2011; 140: S615 (Ab#Mo1337).
213. **Chey W**, Rao S, Lembo A, Shao J, Shi K, Lavins B, Shiff S, Schneier H, Johnston J. Efficacy and safety of once-daily linaclotide administered orally for 12 weeks to patients with IBS-C: pooled results from two randomized, double-blind, placebo-controlled phase 3 trials. *Am J Gastroenterol* 2011; 106: S504-5 (Ab#1322).
214. Pimentel M, Lembo A, **Chey W**, Yu J, Merchant K, Bortey E, Forbes W. Evaluation of rifaximin efficacy in non C-IBS patients by baseline disease severity: subanalysis of the TARGET 1 and TARGET 2 studies. *Am J Gastroenterol* 2011; 106: S505 (Ab#1323).

215. **Chey WD**, Spiegel BM, Lavins BJ, Hao X, Currie MG, Schneier H, Johnston JM. The Effect of Comorbid Psychological Distress on Baseline Irritable Bowel Syndrome with Constipation Symptoms and Response to Linaclotide Treatment. *Gastroenterol* 2012; 142: S301 (Ab#Sa1421).
216. **Chey WD**, Shringarpure R, Nicandro JPA, Chuang E, Olden K. Alosetron Treatment Reduced Health Care Utilization and Improved Symptoms More Effectively Than Traditional Therapy in Women with Severe IBS-D. *Gastroenterol* 2012; 142: S818 (Ab#Tu1386).
217. **Chey WD**, Quigley EM, Lavins BJ, Baird MJ, Fitch DA, Hao X, Shi K, Currie MG, Schneier H, Johnston JM. Effects of 26 Weeks of Linaclotide Treatment on Adequate Relief and IBS Severity in Patients with Irritable Bowel Syndrome with Constipation. *Gastroenterol* 2012; 142: S817 (Ab#Tu1381).
218. Chang L, **Chey WD**, Drossman DA, Lembo A, Pimentel M, Schoenfeld PS, Yu J, Merchant K, Paterson C, Bortey E, Forbes WP. Safety and Tolerability Profile of Rifaximin for Treatment of IBS Without Constipation: Results of a Pooled Analysis of Double-Blind, Placebo-Controlled Randomized Controlled Trials. *Gastroenterol* 2012; 142: S823 (Ab#Tu1403).
219. Baker J, **Chey WD**, Fenner D, Menees SB. Anorectal Manometry Parameters in a Fecal Incontinence Cohort Related to Body Mass Index. *Gastroenterol* 2012; 142: S904 (Ab#Tu2025).
220. Ferch C, **Chey WD**, Saad RJ. The Prevalence and Impact of Lower Gastrointestinal Symptoms in an Ambulatory Elderly Outpatient Population. *Gastroenterol* 2012; 142: S710-S711 (Ab#Mo1969).
221. Rai J, **Chey WD**, Maneerattanaporn M, Baker J, Saad RJ. Do Constipation Symptoms Identify Patients with Dyssynergic Defecation? *Gastroenterol* 2012; 142: S901 (Ab#Tu2013).
222. Locke GR, **Chey WD**, Kurtz CB, Carson R, Baird MJ, MacDougall JE, Jia XD, Currie MG, Schneier H, Johnston JM. Effects of Linaclotide Treatment on Patient-Reported Ratings of Change for Symptoms of Irritable Bowel Syndrome with Constipation (IBS-C): Pooled 12-Week Findings from Two Phase 3 Trials. *Gastroenterol* 2012; 142: S737 (Ab#Tu1086).
223. Schoenfeld PS, **Chey WD**, Lavins BJ, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, Schneier H, Currie MG, Johnston JM. Linaclotide Significantly Improved Abdominal Pain Compared with Placebo in Patients with Irritable Bowel Syndrome Regardless of Baseline Pain Severity in Two Phase 3 Trials. *Gastroenterol* 2012; 142: S701 (Ab#Mo1856).
224. Jones MP, **Chey WD**, Gong H, Shringarpure R, Chuang E, Singh S, Talley NJ. Psychological Variables Add Incremental Value to Biological Markers in Differentiating IBS from Healthy Volunteers. *Gastroenterol* 2012; 142: S820 (Ab#Tu1392).
225. Lembo A, Chang L, **Chey WD**, Drossman DA, Pimentel M, Schoenfeld PS, Yu J, Merchant K, Paterson C, Bortey E, Forbes WP. Impact of Concurrent use of PPIs or Anti-Depressants on Efficacy of Rifaximin for IBS Without Constipation. *Gastroenterol* 2012; 142: S824 (Ab#Tu1406).
226. Pimentel M, Chang L, **Chey WD**, Drossman DA, Lembo A, Schoenfeld PS, Yu J, Merchant K, Paterson C, Bortey E, Forbes WP. Efficacy of Rifaximin for IBS Without Constipation in Men and Women. *Gastroenterol* 2012; 142: S182-S183 (Ab#1041).

227. Baker J, Wilding GE, **Chey WD**, Hasler WL. Gastrocolonic Response Activity After Meal Ingestion in Health vs. Constipation: Rigorous Quantification in Relation to Colon Transit and Associated IBS in a Large Cohort. *Gastroenterol* 2012; 142: S308 (Ab#Sa1448).
228. Rubenstein JH, Morgenstern H, **Chey WD**, Murray J, Scheiman JM, Schoenfeld PS, Appelman HD, McMahon LF, Metko V, Near E, Inadomi JM. Acid Reflux, Erosive Esophagitis, and Barrett's Esophagus Are Associated with Different Measures of Abdominal Obesity in Men. *Gastroenterol* 2012; 142: S754 (Ab#Tu1131).
229. Hasler WL, Wilding GE, **Chey WD**, Baker J. Comparison of Sleep Inhibition of Colon Motor Activity in Healthy Humans vs. Patients with Constipation: Relation to Colon Transit, IBS, and Sleep Parameters. *Gastroenterol* 2012; 142: S833-S834 (Ab#Tu1441).
230. Menees SB, Smith TM, Xu X, **Chey WD**, Saad RJ, Fenner D. Depressive Symptoms in Patients with Fecal Incontinence: Is There a Gender Difference? *Gastroenterol* 2012; 142: S904 (Ab#Tu2024).
231. Saad RJ, Semler JR, Wilding GE, **Chey WD**. Advancing Age is Associated With Progressive Delays in Colon Transit in Patients With Chronic Constipation. *Gastroenterol* 2012; 142: S710 (Ab#Mo1968).
232. Morgan DR, Torres J, Greenberg ER, Sexton R, Salazar-Martinez E, Dominguez R, Ferreccio C, Bravo LE, Pena EM, Herrero R, Meza-Montenegro M, Martinez ME, Correa P, **Chey WD**, Valdivieso M, Anderson GL, Baker LH. *H. pylori* Recurrence One Year After Eradication Treatment in a Population Randomized Trial (SWOG S0701) in Seven Latin American Sites. *Gastroenterol* 2012; 142: S478-S479 (Ab#Su1673).
233. Herrero R, Salazar-Martinez E, Sexton R, Morgan DR, Dominguez R, Torres, Ferreccio C, Bravo LE, Martinez ME, Pena EM, Correa P, Valdivieso M, Meza-Montenegro M, Anderson GL, **Chey WD**, Greenberg ER, Crowley J, Baker LH. Predictors of Success of *Helicobacter pylori* Eradication Treatment in a Multicentric Randomized Clinical Trial (SWOG S0701) in Latin America. *Gastroenterol* 2012; 142: S183-S184 (Ab#1046).
234. Torres J, Morgan DR, Greenberg ER, Salazar-Martinez E, Dominguez R, Ferreccio C, Bravo LE, Pena R, Herrero R, Meza-Montenegro M, Martinez ME, Correa P, Valdivieso M, Anderson GL, **Chey WD**, Crowley J, Baker LH. One-Year Effectiveness and Costs of Six Alternative *H. Pylori* Test/Treat and Retest/Retreat Strategies Using Triple, Concomitant or Sequential Drug Regimens in Seven Latin American Sites (SWOG Trial S0701). *Gastroenterol* 2012; 142: S115-S116 (Ab#590).
235. Dominguez R, Morgan DR, Sexton R, Pena EM, Greenberg ER, Rollan A, **Chey WD**. ROME III Criteria-Based Prevalence of Dyspepsia Symptoms in General Populations in Six Countries in Latin America (SWOG Trial S0701). *Gastroenterol* 2012; 142: S465 (Ab#Su1618).
236. **Chey WD**, Baker JRB, Shiffert J. Assessment of abdominal symptoms before and after biofeedback therapy in patients with dyssynergic defecation. *Am J Gastroenterol* 2012; 107 (suppl 1): S718 (Ab#1764).
237. Kurlander JE, Zhao B, Rupley D, Drossman DA, **Chey WD**. Factors associated with positive and negative patient-physician interactions: Results from focus groups with IBS patients (1598831). *Gastroenterol* 2013; 144: S572 (Ab#Mo1083).
238. **Chey WD**, Webster L, Sostek M, Lappalainen JN, Barker PN, Tack JF. Efficacy and Safety of Naloxegol in Patients with Opioid-Induced Constipation: Results From 2 Prospective, Randomized, Controlled Trials (1594557). *Gastroenterol* 2013; 144: S159-S160 (Ab#900).

239. Baker J, Eswaran SL, Rai J, **Chey WD**. Comparison Between Spontaneously Reported Stool Form using the Bristol Stool Form Scale and Stool Form Calculated from a Seven-Day Diary in Patients with Chronic Constipation (1606280). *Gastroenterol* 2013; 144: S921 (Ab#Tu2075).
240. **Chey WD**, Lavins BJ, Shiff SJ, MacDougall JE, Kurts CB, Shi K, Currie MG, Johnston JM. Determining the Minimum Duration for Initial Treatment with Linaclotide in IBS-C Patients: Results from Pooled Phase 3 Trials. *Gastroenterol* 2013; 144: S537-S538 (Ab#Su2033).
241. Saad R, Nahlawi L, **Chey W**. Effect of the chloride channel activator, lubiprostone, on gastrointestinal and colonic transit, motility and pH in patients with the irritable bowel syndrome and constipation (IBS-C). *Am J Gastroenterol* 2013; 108: S565 (Ab#1872).
242. Baker J, **Chey W**. Does rectal hyposensitivity play a role in outlet obstruction constipation? *Am J Gastroenterol* 2013; 108: S568 (Ab#1879).
243. Webster L, **Chey W**, Tack J, Lappalainen J, Barker P, Sostek M. Long-term safety and tolerability of naloxegol in patients with opioid-induced constipation. *Am J Gastroenterol* 2013; 108: S568-S569 (Ab#1880).
244. **Chey W**, Tack J, Webster L, Lappalainen J, Barker P, Sostek M. Naloxegol symptom responder rates in patients with opioid-induced constipation: results from two prospective, randomized controlled trials. *Am J Gastroenterol* 2013; 108: S570 (Ab#1883).
245. **Chey W**, Tack J, Webster L, Barker P, Lappalainen J, Sostek M. Efficacy of naloxegol in a subpopulation of patients with opioid-induced constipation and an inadequate baseline response to laxatives: results from two prospective, randomized controlled trials. *Am J Gastroenterol* 2013; 108: S570 (Ab#1884).
246. **Chey W**, Shiff S, Schneier H, Xinming H, Lavins B, Chickering J, Kurtz, C, Currie M, Johnston J. Two years on linaclotide: tolerability and treatment satisfaction in IBS-C patients with and without diarrhea. *Am J Gastroenterol* 2014; 109: S530 (Ab#1791).
247. **Chey W**, Baker J, Menees S, Maneerattanaporn M, Saad R. Predictive value and interexaminer variability of digital rectal examination for dyssynergic defecation in constipated patients undergoing anorectal manometry. *Am J Gastroenterol* 2014; 109: S537 (Ab#1814).
248. Haefner J, Baker J, **Chey W**, Fairchild P, Berger M. Assessment of sexual function and attitudes in female patients with functional bowel disorders. *Am J Gastroenterol* 2014; 109: S646 (Ab#2224).
249. Nojkov B, Eswaran S, **Chey WD**. Dietary restrictions predict worse disease-specific quality of life in patients with irritable bowel syndrome. *Gastroenterol* 2014; 146: S199 (Ab#Sa1099).
250. Baker J, **Chey WD**, Kao J, Saad R. The impact of helicobacter pylori status following a course of eradication therapy on common gastrointestinal symptoms. *Gastroenterol* 2014; 146: S564 (Ab#Mo1129).
251. Guentner A, Menees S, Saad R, **Chey WD**. How do US gastroenterologist use over-the-counter and prescription laxatives in patients with chronic constipation? *Gastroenterol* 2014; 146: S194 (Ab#Sa1082).
252. **Chey WD**, Baker J, Attari A, Spiegel B, Ashton-Miller J. A glove-based, disposable, point-of service device which allows detailed physiological assessment of the anorectum: A proof of concept study in healthy volunteers. *Gastroenterol* 2014; 146: S720 (Ab#Mo2022).

253. Guentner A, Menees S, Saad R, **Chey WD**. US gastroenterologists' use of over-the-counter medications for gastroesophageal reflux disease (GERD): translating perception to reality. *Gastroenterol* 2014; 146: S756-S756 (Ab#Tu1111).
254. Menees S, Kurlander J, Goel A, Powell C, **Chey WD**. A meta-analysis of the utility of common serum and fecal biomarkers in adults with IBS. *Gastroenterol* 2014; 146: S194 (Ab#Sa1079).
255. Baker J, **Chey WD**, Saad R, Menees S. Effects of vaginal delivery on anorectal parameters and rectal sensation measurements in a fecal incontinence cohort. *Gastroenterol* 2014; 146: S721 (Ab#Mo2027).
256. Guivatchian T, Koeppe E, Foor-Pessin C, **Chey WD**, Eswaran S, Kolars J, Menees S, Rajala M, Rice M, Rizk R, Rubenstein J, Sharma P, Todisco A, Stoffel E. Implementation of a brief familial cancer assessment tool improves surveillance recommendations and identification of patients at increased risk for colorectal cancer. *Gastroenterol* 2014; 146: S408-S409 (Ab#Su1231).
257. Almario C, **Chey WD**, Kaung A, Whitman C, Fuller G, Reid M, Bolus R, Dennis R, Encarnacion R, Martinez B, Talley J, Modi R, Agarwal N, Lee A, Bolus S, Chang L, Spiegel B. Computer Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Outperforms Physician-Documented History of Presenting Illness (HPI): Results of a Blinded Comparison. *Gastroenterol* 2014; 146: S189 (Ab#Sa1064).
258. Nojkov B, **Chey WD**. Effects of age and gender on disease-specific quality of life (QOL) in patients with irritable bowel syndrome (IBS). *Gastroenterol* 2015; 148: S656 (Ab#Mo1272).
259. **Chey WD**, Lembo A, Phillips J, Rosenbaum D. Efficacy and safety of tenapanor in patients with constipation predominant irritable bowel syndrome: a 12-week, double-blind, placebo-controlled, randomized phase 2b trial. *Gastroenterol* 2015; 148: S191-S192 (Ab#1020).
260. **Chey WD**, Baker J, Attari A, Ashton-Miller J. A glove-based, disposable, point-of service device which allows physiological assessment of the anorectum: concordance with anorectal manometry in chronic constipation patients. *Gastroenterol* 2015; 148: S178 (Ab#931).
261. Baker J, Haefner J, Fairchild P, **Chey WD**, Saad R, Menees S, Berger M. Assessment of sexual function in relation to a male cohort experiencing functional bowel disorders. *Gastroenterol* 2015; 148: S307 (Ab#Sa1374).
262. Chang L, **Chey WD**, Drossman D, Losch-Beridon T, Wang M, Lichtlen P, Mareya S. Effects of baseline abdominal pain on response to lubiprostone in patients with constipation-predominant irritable bowel syndrome. *Gastroenterol* 2015; 148: S653 (Ab#Mo1262).
263. Spencer M, **Chey WD**, Evans S, Han-Markey T, Ball S, Eswaran S. Differences in nutrient intake between irritable bowel syndrome (IBS) patients and healthy volunteers. *Gastroenterol* 2015; 148: S489-S490 (Ab#Su1374).
264. **Chey WD**, Dove S, Andrae D, Davenport J, Michael, Turner L, Lopez R, Covington P. Eluxadolone demonstrates sustained efficacy for the treatment of diarrhea-predominant irritable bowel syndrome in phase 3 clinical trials. *Gastroenterol* 2015; 148: S70 (Ab#316).
265. **Chey WD**, Chang L, Lembo A, Aggarwal K, Bortey E, Paterson C, Forbes W. Effects of rifaximin on urgency, bloating, and abdominal pain in patients with IBS-D: a randomized, controlled, repeat treatment study. *Gastroenterol* 2015; 148: S69 (Ab#313).

266. Almario C, **Chey WD**, Iriana S, Whitman C, Fuller G, Reid M, Bolus R, Dennis R, Encarnacion R, Martinez B, Talley J, Modi R, Agarwal N, Lee A, Kubomoto S, Bolus S, Chang L, Spiegel B. Automated evaluation of gastrointestinal symptoms (AEGIS) versus physician identification of gastrointestinal alarm features. *Gastroenterol* 2015; 148: S205-S206 (Ab#Sa1044).
267. Lacy B, **Chey W**, Lembo A, Dove L, Covington P. Eluxadoline demonstrates efficacy for the treatment of irritable bowel syndrome (IBS) with diarrhea (IBS-D) among multiple clinically relevant patient subgroups. *Am J Gastroenterol* 2015; 110: S747 (Ab#1760).
268. **Chey WD**, Lembo A, Wolf R. Infection-related safety profile of rifaximin repeat treatment for diarrhea-predominant irritable bowel syndrome (IBS-D). *Am J Gastroenterol* 2015; 110: S750 (Ab#1766).
269. **Chey WD**, Lembo A, Rosenbaum D. Tenapanor's sustained response in patients with constipation predominant irritable bowel syndrome: post-hoc analysis from a 12-week, double-blind, placebo-controlled, randomized phase 2b trial. *Am J Gastroenterol* 2015; 110: S756 (Ab#1779).
270. Fass R, **Chey WD**, Want M, Mareya S, Losch-Beridon T. Durability and predictability of treatment response to lubiprostone in patients with constipation-predominant irritable bowel syndrome. *Am J Gastroenterol* 2015; 110: S761 (Ab#1792).
271. Spiegel B, Doshi J, Buono J, Taylor D, Goolsby Hunter A, Carson R, Martin C, Buzinec P, Essor B, **Chey WD**. Characteristics Associated with Probiotic Use Among Patients Experiencing Constipation-Related Symptoms: Results from the Contor Study. *Am J Gastroenterol* 2015; 110: S932 (Ab#2245).
272. Taylor C, **Chey WD**, Doshi J, Buono J, Martin C, Buzinec P, Goolsby Hunter A, Carson R, Essor B, Spiegel B. Treatment satisfaction among patients with constipation-related bowel and abdominal symptoms: results from the Contor study. *Am J Gastroenterol* 2015; 110: S933 (Ab#2246).
273. Almario C, **Chey WD**, Khanna D, Whitman C, Fuller G, Reid M, Bolus R, Dinnis B, Encarnacion R, Martinez B, Soares J, Modi R, Agarwal N, Lee A, Kubomato S, Sharma G, Bolus S, Spiegel B. Impact of NIH patient-related outcome measurement information system (PROMIS): gastrointestinal measures on patient outcomes. *Am J Gastroenterol* 2015; 110: S944 (Ab#2277).
274. Almario C, **Chey WD**, Khanna D, Whitman CB, Fuller G, Reid M, Bolus R, Dennis B, Encarnacion R, Martinez B, et al. Impact of NIH Patient-Reported Outcome Measurement Information System (PROMIS®): Gastrointestinal Measures on Patient Outcomes. *Am J Gastroenterol* Oct 2015: S944-S945 (Ab#2277).
275. Almario CV, **Chey WD**, Spiegel B. Prevalence and Predictors of Irritable Bowel Syndrome in the United States. *Gastroenterol* Apr 2016; 150: S172 (Ab#822).
276. Chey SW, Menees SB, Saini SD, Weissman A, Harris LJ, **Chey WD**. US Primary Care Providers Use of Over-the-Counter Medications for Gastroesophageal Reflux Disease and Chronic Constipation. *Gastroenterol* Apr 2016; 150: S236-S237 (Ab#Sa1089).
277. **Chey WD**, Almario CV, Spiegel B. Differences in Lower and Upper Gastrointestinal Symptoms in Individuals with Constipation Taking and Not Taking Opioids: Results from a Survey of Over 70,000 Persons Residing in the United States. *Gastroenterol* Apr 2016; 150: S193 (Ab#965).
278. Eswaran SL, **Chey WD**, Jackson K, Ball S, Han-Markey T. A Low FODMAP Diet Reduces Abdominal Symptoms to a Greater Degree than Bowel Symptoms in Patients with

- Irritable Bowel Syndrome and Diarrhea: Results of Daily Data from a US Randomized Controlled Trial. *Gastroenterol* Apr 2016; 150: S229-S230 (Ab#1132).
279. Eswaran SL, **Chey WD**, Han-Markey T, Jackson K, Ball S. A United States, Randomized, Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in Adults with IBS-D: Primary and Key Secondary Endpoints. *Gastroenterol* Apr 2016; 150: S160 (Ab#774).
 280. Eswaran SL, **Chey WD**, Jackson K, Pillai SG, Chey SW, Han-Markey T. A Low FODMAP Diet Improves Quality of Life, Reduces Activity Impairment, and Improves Sleep Quality in Patients with Irritable Bowel Syndrome and Diarrhea: Results from a US Randomized, Controlled Trial. *Gastroenterol* Apr 2016; 150: S172 (Ab#821).
 281. Shah ED, **Chey WD**, Almario CV, Spiegel B. Similarities and Differences in Clinical Phenotype Between Individuals with Irritable Bowel Syndrome with Constipation and Chronic Functional. *Gastroenterol* Apr 2016; 150: S231 (Ab#1136).
 282. Zhou SY, Eswaran SL, Wu XY, **Chey WD**, Chung OY. Low FODMAP Diet Modulates Visceral Nociception by Changing Gut Microbiota and Intestinal Permeability in IBS. *Gastroenterol* Apr 2016; 150: S63-S64 (Ab#261).
 283. Almario CV, **Chey WD**, Spiegel B. Burden of Gastrointestinal Symptoms in the United States: Results from a Survey of over 71,000 Americans. *Gastroenterol* Apr 2016; 150: S831-S832 (Ab#Tu1066).
 284. **Chey WD**, Andrae D, Dove LS, Covington PS. A 1-month Trial with Eluxadoline for IBS-D Predicts a Durable Response: Continuation Analysis of Response in Two Phase 3 Studies. *Gastroenterol* Apr 2016; 150: S494-S495 (Ab#Su1204).
 285. Cohen ER, Almario CV, **Chey WD**, Spiegel B. Comparing Irritable Bowel Syndrome Symptoms and Severity Between Men and Women. *Gastroenterol* Apr 2016; 150: S900 (Ab#Tu1421).
 286. Freeman AE, Roberts SC, **Chey WD**, Kao JY, Rao K. New Onset Functional GI Disorders Following Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection-Prevalence and Risk Factors. *Gastroenterol* Apr 2016; 150: S495 (Ab#Su1206).
 287. Hosmer A, Baker J, **Chey WD**, Fisher LR, Sheth N, Rice MD. Does Sedation Affect Upper Gastrointestinal Transit and Study Completion Rates Measured by Small Bowel Video Capsule Endoscopy? *Gastroenterol* Apr 2016; 150: S1016 (Ab#Tu2075).
 288. Kurlander JE, **Chey WD**, Morris C, Hu YM, Bangdiwala S, Norton NJ, Norton W, Drossman DA. Development and Validation of the Patient-Provider Relationship Scale among Patients with Irritable Bowel Syndrome. *Gastroenterol* Apr 2016; 150: S900-S901 (Ab#Tu1423).
 289. Merchant JL, Photenhauer A, Eswaran SL, Jackson K, **Chey WD**. A US, Randomized, Controlled Trial Comparing the Low FODMAP Diet vs NICE Guidelines in Adults IBS-D Adults: Predictive Value of a Tryptophan Hydroxylase 1 (TPH1) Promoter Variant. *Gastroenterol* Apr 2016; 150: S953 (Ab#Tu1807).
 290. Nojkov B, Baker J, Saad RJ, **Chey WD**. Dyssynergic Defecation is More Common in Younger Patients with Chronic Constipation in Both Females and Males. *Gastroenterol* Apr 2016; 150: S539 (Ab#Su1598).
 291. Pan DN, Almario CV, **Chey WD**, Spiegel B. Prevalence and Severity of Concomitant Gastrointestinal Symptoms in Crohn's Disease. *Gastroenterol* Apr 2016; 150: S790 (Ab#Mo1839).

292. Riehl ME, **Chey WD**, Stidham RW. Comparison of Quality of Life and Treatment Response in IBS and IBD Patients Undergoing GI-Focused Behavioral Health Interventions. *Gastroenterol* Apr 2016; 150: S443 (Ab#Su1011).
293. Zhang A, Almario CV, **Chey WD**, Spiegel B. Prevalence and Severity of Gastrointestinal Symptoms in Cirrhosis. *Gastroenterol* Apr 2016; 150: S1051-S1052 (Ab#817).
294. Irvine AJ, Ford AC, **Chey WD**. Screening for Coeliac Disease in Irritable Bowel Syndrome is Still Worthwhile: An Updated Systematic Review and Meta-Analysis. *Gut* Jun 2016; 65: A113 (Ab#PTU-117).
295. Ahmed S, Almario CV, **Chey WD**, Ahn J, Ko JZ, Robbins L, Spiegel B. Marked Disagreement Between Referring Physicians and Patients' Reason for GI Consultation. *Gastroenterol* Apr 2016; 150: S234-S235 (Ab#Sa1083).
296. Zhou SY, Eswaran SL, Wu X, **Chey WD**, Owyang C. LPS mediated intestinal barrier dysfunction and visceral hypersensitivity in the IBS is prevented by low FODMAP diet. *Neurogastroenterol and Motility* Aug 2016; 28:9 (Ab#13).
297. Baker JR, **Chey WD**, Saad R, Nojkov B. Anorectal Manometry characteristics of constipated fibromyalgia patients in relationship to self-reported abdominal symptom severity. *Neurogastroenterol and Motility* Aug 2016; 28:34 (Ab#97).
298. Abel JL, Taylor DCA, Doshi JA, Martin C, Hunter AG, Essoi B, Buzinec P, Carson RD, Reasner DS, Spiegel B, **Chey WD**, et al. Chronic Constipation and IBS-C Treatment and Outcomes Real World Research Platform (CONTOR): A Large, Longitudinal Observational Study. *Am J Gastroenterol* Oct 2016; 111: S257 (Ab#563).
299. **Chey WD**, Lembo AJ, Rosenbaum D. The Effect of Tenapanor on Global Endpoints in Patients with Constipation Predominant Irritable Bowel Syndrome: Results from a 12-Week, Double-Blind, Placebo-Controlled, Randomized Phase 2b Trial. *Am J Gastroenterol* Oct 2016; 111: S236 (Ab#520).
300. Lacy BE, **Chey WD**, Cash BD, Lembo AJ, Dove LS, Covington PS. Efficacy and Safety of Eluxadoline in IBS-D Patients Who Report Prior Inadequate Symptom Control with Loperamide. *Am J Gastroenterol* Oct 2016; 111: S249-S250 (Ab#547).
301. Menees SB, Almario CV, **Chey WD**, Spiegel B. Prevalence and Predictors of Bowel Incontinence: Results from a US Population-Based Study 2016 ACG Category Award (Functional Bowel Disease). *Am J Gastroenterol* Oct 2016; 111: S247-S248 (Ab#543).
302. Taylor DCA, Abel JL, Spiegel B, Doshi JA, Martin C, Buzinec P, Hunter AG, Essoi B, Reasner DS, Carson RD, **Chey WD**, et al. Impact of Linaclotide and Stool Form on Bowel Movement Satisfaction in Patients with Irritable Bowel Syndrome with Constipation or Chronic Idiopathic Constipation: Results from the Contor Study. *Am J Gastroenterol* Oct 2016; 111: S238-S239 (Ab#526).
303. Abel J, Taylor DC, Doshi JA, Martin C, Hunter AG, Essoi B, Buzinec P, Carson RT, Reasner DS, **Chey WD**. Differences in Demographic and Symptom-Related Characteristics Among Patients with Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC): Results from the CONTOR Study. *Gastroenterol* Apr 2017; 152: S745 (Ab#Mo1666).
304. Almario CV, **Chey WD**, Spiegel B. Prevalence and Predictors of "IBS-Like" Symptoms in the United States: Results from a Survey of over 71,000 Americans. *Gastroenterol* Apr 2017; 152: S67-S68 (Ab#258).

305. Baker J, Saad RJ, Menees SB, Eswaran SL, Lee A, **Chey WD**, Nojkov B. Symptom and Anorectal Manometry Characteristics of Constipated Patients with Fibromyalgia. *Gastroenterol* Apr 2017; 152: S508 (Ab#Su1521).
306. **Chey WD**, Chamberlin P, Bochenek W, Tripp K, Higgins CS, Omniewski N, Fox SM, Hall M, Hashash A, Miller M, et al. Targeted Delivery of Linaclotide to Specific Areas of the Intestine Affects Clinical Efficacy in Patients with Irritable Bowel Syndrome with Constipation (IBS-C). *Gastroenterol* Apr 2017; 152: S1314-S1315 (Ab#Tu2013).
307. **Chey WD**, Lacy BE, Cash BD, Epstein M, Shah SM. yy Randomized Controlled Trial to Assess the Efficacy & Safety of Caraway Oil/L-Menthol Plus Usual Care Polypharmacy vs. Placebo Plus Usual Care Polypharmacy for Functional Dyspepsia. *Gastroenterol* Apr 2017; 152: S306 (Ab#Sa1618).
308. **Chey WD**, Lacy BE, Cash BD, et al. Efficacy of Caraway Oil/L-Menthol Plus Usual Care vs. Placebo Plus Usual Care, in Functional Dyspepsia Patients with Post-Prandial Distress (PDS) or Epigastric Pain (EPS) Syndromes: Results from a US RCT. *Gastroenterol* Apr 2017; 152: S307 (Ab#Sa1619).
309. Eswaran SL, **Chey WD**, Jackson K, Han-Markey T. The Low Fodmap Diet is Equally Efficacious in IBS-D Patients with and without Baseline Anxiety: A Post-Hoc Analysis from a US Randomized, Controlled Trial. *Gastroenterol* Apr 2017; 152: S719 (Ab#Mo1562).
310. Eswaran SL, Merchant JL, Photenhauer A, Jackson K, Madriaga D, Selvaraj FM, Princen F, **Chey WD**. Tryptophan Hydroxylase 1 (TPH1) Promoter Genotype but not Serum Serotonin Levels Identify IBS-D Patients More Likely to Benefit from the Low FODMAP Diet. *Gastroenterol* Apr 2017; 152: S69 (Ab#262).
311. Eswaran SL, Selvaraj FM, Princen F, Tooker P, Harvie G, **Chey WD**. Serum 7C4 Levels Decrease After Low FODMAP Diet in IBS Patients: A Potential Mechanism for Benefit. *Gastroenterol* Apr 2017; 152: S160 (Ab#733).
312. Lacy BE, **Chey WD**, Cash BD, Epstein M, Shah SM. yy A Caraway Oil/Menthol Combination Improves Functional Dyspepsia (FD) Symptoms within the First 24 Hours: Results of a Randomized Controlled Trial, Which Allowed Usual FD Treatments. *Gastroenterol* Apr 2017; 152: S307 (Ab#Sa1620).
313. Lubarda J, Warters M, Chatterjee P, Cash BD, **Chey WD**. How is OIC Diagnosed and Managed? Insights from a Virtual Patient Simulation. *Gastroenterol* Apr 2017; 152: S230 (Ab#Sa1131).
314. Menees SB, Almario CV, Spiegel B, **Chey WD**. Sex Differences in Fecal Incontinence: Results from a US Population-Based Study. *Gastroenterol* Apr 2017; 152: S308-S309 (Ab#Sa1623).
315. Nojkov B, Baker J, Lee A, Eswaran SL, Menees SB, Saad RJ, **Chey WD**. Impact of Age and Gender to Severity of Constipation-Related Symptoms and Quality of Life Indices in Patients with Chronic Idiopathic Constipation. *Gastroenterol* Apr 2017; 152: S514 (Ab#Su1539).
316. Shah ED, **Chey WD**, Stidham RW. Assessing Long-Term Persistence with Pharmacotherapy for Constipation-Predominant Irritable Bowel Syndrome and Functional Constipation in Clinical Practice: A Retrospective Cohort Analysis. *Gastroenterol* Apr 2017; 152: S713 (Ab#Mo1546).

317. Shah ED, Almario CV, Spiegel B, **Chey WD**. Patients with IBS-C Report More Severe, Bothering, Frequent and Diffuse Abdominal Pain vs. IBS-D: Results of a Nationwide Population-Based Study. *Gastroenterol* Apr 2017; 152: S712-S713 (Ab#Mo1545).
318. Shah ED, Farida J, **Chey WD**. A Systematic Review and Meta-Analysis to Determine Whether Balloon Expulsion Testing Might be an Appropriate Initial Office-Based Test for Dyssynergic Defecation. *Gastroenterol* Apr 2017; 152: S315 (Ab#Sa1638).
319. Shah ED, Andraska E, Li J, Zhang S, **Chey WD**. How Cost Affects the Treatment Choice for Irritable Bowel Syndrome with Diarrhea Patients: A Cost-Effectiveness Analysis of Tricyclic Agents and Rifaximin. *Gastroenterol* Apr 2017; 152: S118 (Ab#515).
320. Brenner D, **Chey WD**, Dove LS, Andrae D, Gutman CR, Covington PS. Using Radar Plots to Display Disparate Global Effects of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. *Am J Gastroenterol* Oct 2018; 112: S255-S256 (Ab#486).
321. **Chey WD**, Lembo AJ, Korner P, Yan A, Rosenbaum DP. Efficacy and Safety of Tenapanor in Patients with Constipation Predominant Irritable Bowel Syndrome: A 12-week, Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial. *Am J Gastroenterol* Oct 2017; 112: S226-S227 (Ab#421).
322. **Chey WD**, Lacy BE, Cash BD, Epstein M, Shah SM. Rapid Relief of Functional Dyspepsia Symptoms with a Novel Formulation of Caraway Oil and L-menthol: Outcomes from a Self-Reported Patient Outcomes Study. *Am J Gastroenterol* Oct 2017; 112: S663 (Ab#1209).
323. **Chey WD**, Bochenek W, Tripp KJ, Higgins CS, Fox SM, Cronin JA, Chamberlin P. Effect of Linaclotide DR1, a Delayed-Release Formulation of Linaclotide, in IBS-C Patients: Analysis of Symptom Improvement Using Responder Radar Plots. *Am J Gastroenterol* Oct 2017; 112: S236-S237 (Ab#445).
324. Farida JP, Shah ED, Ball S, **Chey WD**, Eswaran S. Micronutrient Intake Changes with the Low FODMAP and mNICE Diets. *Am J Gastroenterol* Oct 2017; 112: S247 (Ab#468).
325. Lenhart A, Ferch C, Shaw M, **Chey WD**. Use of Dietary Management for Irritable Bowel Syndrome: Results of a Survey of Over 1,500 Members of the American College of Gastroenterology. *Am J Gastroenterol* Oct 2017; 112: S250-S251 (Ab#475).
326. Lubarda J, Chatterjee P, Muino J, **Chey WD**. Improving Diagnosis and Management of IBS-D Through Continuing Medical Education. *Am J Gastroenterol* Oct 2017; 112: S1468 (Ab#2699).
327. Menees S, Almario C, Spiegel BM, **Chey WD**. Does Obstetrical History Impact Women's FI PROMIS Severity Scores? *Am J Gastroenterol* Oct 2017; 112: S248-S249 (Ab#471).
328. Pambianco DJ, Adler DG, Cash BD, **Chey WD**, DeVault K, Karlitz JJ, Knapple W, Leavitt J, Oxentenko AS, Shah NL, et al. Gastroenterologists Attitudes about Maintenance of Certification: A Multi-Practice National Survey. *Am J Gastroenterol* Oct 2017; 112: S607-S608 (Ab#1110).
329. Quigley E, Camilleri M, Yishai R, **Chey WD**, Morliere C, Misra B, Lane P, et al. A Comparison of the Efficacy and Safety of 2 Dosing Regimens, 2 and 5 Times per Week, of an Intraluminal Vibrating Capsule in the Management of Chronic Idiopathic Constipation. *Am J Gastroenterol* Oct 2017; 112: S226 (Ab #420).
330. Shah ED, Eswaran S, **Chey WD**. How Cost-Effectiveness Impacts Treatment Choice in Irritable Bowel Syndrome: A Cost-Effectiveness Analysis of Guideline Recommended Over-the-Counter Treatments and Low FODMAP Diet from a Patient Perspective. *Am J Gastroenterol* Oct 2017; 112: S618 (Ab#1132).

331. Shah ED, Almario C, Spiegel BM, **Chey WD**. Constipation Symptoms Differ Between Individuals with Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation. *Am J Gastroenterol* Oct 2017; 112: S241-S242 (Ab#456).
332. Shah ED, Eswaran S, **Chey WD**. Understanding How Low FODMAP Diet Fits into the IBS Treatment Paradigm: A Cost-Effectiveness Analysis of Low FODMAP Diet versus Guideline-Recommended Prescription Therapy. *Am J Gastroenterol* Oct 2017; 112: S242 (Ab#457).
333. Taylor DCA, Abel JL, Doshi JA, Martin C, Hunter AG, Esoi B, Korrer S, Carson RT, Reasner DS, **Chey WD**. Impact of Stool Consistency on Bowel Movement Satisfaction in IBS-C or CIC Patients Treated with Linaclotide or Other Medications: Results from the CONTOR Study. *Am J Gastroenterol* Oct 2017; 112: S228 (Ab#425).
334. Baker J, **Chey WD**, Lee A, Amat L, Saad R, Harer K, Hasler WL. Comparative Quantitative Analysis Between the North American Consensus Positive Hydrogen Breath Test – Small Intestinal Bacterial Overgrowth Versus Traditional Thresholds. *Gastroenterol* May 2018; 154: S957 (Ab#Tu1584).
335. Baker J, Read AJ, Rubenstein J, Saini S, **Chey WD**, Kurlander JE, Chen JW. Trends in utilization of Esophageal Manometry and Ambulatory Reflux Monitoring. *Gastroenterol* May 2018; 154: S742-743 (Ab#Mo1529).
336. **Chey WD**, Lembo AJ, Yan A, Rosenbaum DP. Efficacy and Safety of Tenapanor in Patients with Constipation Predominant Irritable Bowel Syndrome: A 6-month, Double-blind, Placebo-controlled Phase 3 Trial (T3MPO-2). *Gastroenterol* May 2018; 154: S1362 (Ab#885).
337. Dionne JC, Ford AC, Yuan YH, **Chey WD**, Quigley EM, Moayyedi P. Exclusion Diets and Irritable Bowel Symptoms: A systematic Review and Meta-Analysis. *Gastroenterol* May 2018; 154: S783 (Ab#Mo1648).
338. Jou J, Suresh S, Stidham RW, **Chey WD**, Shah, ED. Mood Disorders do not Appear to Impact Discontinuation of Chronic Pharmacotherapy for IBS with Constipation and Chronic Constipation. *Gastroenterol* May 2018; 154: S976 (Ab#Tu1634).
339. Maneerattanaporn M, Boonanuwat R, Kriengsinyos W, **Chey WD**. The Impact of High vs. Low Fodmap Diet on GI Symptoms and Breath Hydrogen & Methane Excretion in Thai Healthy Volunteers and Subjects with Functional Floating. *Gastroenterol* May 2018; 154: S865 (Ab#Mo1962).
340. Menees SB, Baker J, **Chey WD**. What is the Prevalence of Dyssynergic Defecation in Patients with Fecal Incontinence Undergoing High Resolution Anorectal Manometry? *Gastroenterol* May 2018; 154: S551 (Ab#Su1620).
341. Jusufagic A, Dzibur E, Almario CV, Howard A, Martinez MB, **Chey WD**, Spiegel B. Validation and feasibility of a Food and Symptom Tracker (FAST) Score using a Mobile Health Application. *Gastroenterol* May 2018; 154: S867 (Ab#Mo1965).
342. Menees SB, Baker J, **Chey WD**. Gender Difference in Patients with Fecal Incontinence: Symptom Severit, Quality of Life, and HR Anorectal Manometry Results. *Gastroenterol* May 2018; 154: S550-S551 (Ab#Su1619).
343. Riehl ME, Stidham RW, Goldstein C, Kinnucan JA, **Chey WD**. The Impact of a GI-Specific Behavioral Intervention on Sleep Quality in Functional Bowel Disorder Patients. *Gastroenterol* May 2018; 154: S539 (Ab#Su1591).

344. Ritter AJ, **Chey WD**, Foyt HL, Sandborn WJ, Savaiano DA. Improvement of Clinical Symptoms of Lactose Intolerance with a Novel Prebiotic Galacto-Oligosaccharide, RP-G28. *Gastroenterol* May 2018; 154: S1047 (Ab#Tu1884).
345. Ritter AJ, **Chey WD**, Foyt HL, Lundy JJ, Coon CD, Savaiano DA. A Novel Tool to Assess Symptoms of Lactose Intolerance and Define Meaningful Patient Benefit. *Gastroenterol* May 2018; 154: S683 (Ab#Mo1048).
346. Simmer S, **Chey WD**, Eswaran SL, Ranagan J, Petrucelli S. Is Sucrase-Isomaltase Deficiency an Under-Recognized Cause of IBS-D Symptoms? *Gastroenterol* May 2018; 154: S867 (Ab#Mo1966).
347. Spechler SJ, Lee RH, Smith BR, Mashimo H, Sanchez V, Dunbar KB, Pham T, Murthy UK, Kim T, Jackson CS, **Chey WD**, et al. A VA Cooperative, Randomized Trial of Medical and Surgical Treatments for Patients with Heartburn that is Refractory to Proton Pump Inhibitors. *Gastroenterol* May 2018; 154: S129 (Ab#615).
348. Spechler SJ, Lee RH, Smith BR, Mashimo H, Sanchez V, Dunbar KB, Pham T, Murthy UK, Kim T, Jackson CS, **Chey WD**, et al. Characterization of Conditions Underlying Heartburn Refractory to Proton Pump Inhibitors (PPIS) in a VA Cooperative Study of Medical and Surgical Treatments for PPI-Refractory Heartburn. *Gastroenterol* May 2018; 154: S101-S102 (Ab#444).
349. Suresh S, Jou J, Stidham RW, **Chey WD**, Shah ED. Evaluating Why and When Patients Discontinue Chronic Therapy for IBS with Constipation and Chronic Constipation: A Real-World Experience. *Gastroenterol* May 2018; 154: S93 (Ab#387).
350. Taylor DCA, Abel JL, Doshi JA, Martin C, Hunter AG, Esoi B, Korrer S, Carson RT, Reasner DS, **Chey WD**. Effect of stool consistency on bowel movement satisfaction in patients with Irritable Bowel Syndrome with constipation or chronic idiopathic constipation: results from the CONTOR study. *Neurogastroenterology and Motility* Aug 2018; 30: S1 (Ab#394).
351. Baker J, Nojkov B, Saad RJ, Menees S, Eswaran S, Lee A, Harer KN, **Chey WD**: Are dyssynergic defecation and altered rectal sensation under-recognized cause of chronic constipation in patients taking opioids?, *Digestive Diseases Week, San Diego, CA, 2019*.
352. Harer K, Jagielski C, Riehl M, **Chey W**: Avoidant/restrictive food intake disorder among adult gastroenterology behavioral health patients: Demographic and clinical characteristics, *Digestive Diseases Week, San Diego, CA, Gastroenterology, 156, 6, S53, 2019*.
353. Nojkov B, Dolan R, Liu J, Appelman H, Wang T, Sturm M, **Chey WD**: Confocal laser endomicroscopy in patients with functional dyspepsia: Does "leaky gut" play a role?, *Digestive Diseases Week, San Diego, CA, 2019*.
354. Shah E, Gibson P, Muir J, Eswaran S, **Chey WD**: How cost affects treatment choice for irritable bowel syndrome with diarrhea: A cost-effectiveness analysis of guideline-recommended treatment interventions to determine appropriate order of therapy in clinical practice, *Digestive Diseases Week, San Diego, CA, Gastroenterology, 156, 6, S573-S574, 2019*.
355. Jagielski CH, Riehl ME, **Chey WD**: How often do gastroenterologist's screen for psychological trauma? Identifying the unmet need., *Digestive Diseases Week, San Diego, CA, Gastroenterology, 156, 6, S1060- S1061, 2019*.
356. Baker J, Watts L, Hasler W, Harer KN, Menees S, Eswaran S, Lee A, **Chey WD**: Understanding how differences in socioeconomic status, education, and age influence treatment choice in IBS patients, *Digestive Diseases Week, San Diego, CA, 2019*.

357. Baker J, **Chey WD**, Watts L, Armstrong M, Collins K, Thibault M, Hasler W: Agreement between tests of anorectal function for presumed dyssynergia in patients with unexplained constipation, European Society of Neurogastroenterology and Motility Meeting, Lisbon, Portugal, Neurogastroenterology and Motility, 31, S4, 2019.
358. Harer KN, Baker JR, Watts L, **Chey WD**, Lee A, Hasler WL: Small Intestinal Bacterial Overgrowth And Glucose Hydrogen Breath Test Characteristics Differ In Patients Taking Versus Not Taking Opioids, European Society of Neurogastroenterology and Motility Meeting, Lisbon, Portugal, Neurogastroenterology and Motility, 31, S4, 2019.
359. Eswaran S, Zheng T, D'Amato M, **Chey WD**: Is Sucrose the Sixth Fodmap in a Subset of Patients with Irritable Bowel Syndrome with Diarrhea and Sucrase Isomaltase Deficiency?, Gastroenterology, 156, 6, S69-S70, 2019.
360. Delshad S, Almario CV, **Chey WD**, Spiegel B: Prevalence and Predictors of Gerd and Ppi-Resistant Gerd in the United States: Results from a Population-Based Survey of Over 71,000 Americans, Gastroenterology, 156, 1, S3-S4, 2019.
361. Harer K, Jagielski C, **Chey W**, Riehl M: Avoidant/restrictive food intake disorder (ARFID) among adult gastroenterology behavioral health patients: Comparison of ARFID vs. non-ARFID patients. Presidential plenary session (category award) abstract presentation, The American Journal of Gastroenterology Annual Scientific Meeting, San Antonio, TX, The American Journal of Gastroenterology, 114, S271 - S272, 2019.
362. Lee A, Rao K, Haller E, Van Dam L, Baker J, Watts L, Eswaran S, **Chey WD**, Owyang C, Young V, Hasler W: Baseline and Longitudinal Microbial Changes Predict Response to Rifaximin and/or Diet Low in Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols in Irritable Bowel Syndrome, The American Journal of Gastroenterology Annual Scientific Meeting, San Antonio, TX, The American Journal of Gastroenterology, 114, S289, 2019.
363. Brenner DM, Sayuk GS, Elmes SJ, Saeed M, **Chey WD**: Effects of Eluxadolone on a Range of Bowel and Abdominal Symptoms in Patients With Irritable Bowel Syndrome With Diarrhea who Report Inadequate Symptom Control With Loperamide, The American Journal of Gastroenterology Annual Scientific Meeting, San Antonio, TX, The American Journal of Gastroenterology, 114, S273 - S274, 2019.
364. Xiong T, Baker J, **Chey WD**, Nojkov B: Small Intestinal Bacterial Overgrowth (SIBO) Is Common in Patients With Ehlers-Danlos Syndrome (EDS), The American Journal of Gastroenterology Annual Scientific Meeting, San Antonio, TX, The American Journal of Gastroenterology, 114, S662-S663, 2019.
365. Nojkov B, Baker J, Watts L, Lee A, **Chey WD**, Saad R: Small Intestinal Bacterial Overgrowth (SIBO) in Functional Dyspepsia (FD): Does Dyspeptic Symptom Pattern Make a Difference?, The American Journal of Gastroenterology Annual Scientific Meeting, San Antonio, TX, The American Journal of Gastroenterology, 114, S293-S294, 2019.